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Chapter 1
General Introduction
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IntRoDUCtIon
About 30,000 patients per year suffer a stroke in the netherlands. twenty five percent of 
these patients die within 4 weeks after the event and 60% are still disabled 6 months after 
the stroke. In the western world, stroke is the third cause of death, and the leading cause of 
disability. the overall risk of stroke, myocardial infarction or vascular death in patients with 
a tIA or non-disabling stroke is about 7% per year.1 the most well known risk factors for 
these vascular complications are age, male sex, diabetes, hypertension, hyperlipidemia, and 
smoking, but there are many others such as cerebral infarction or white matter lesions on Ct 
scan of the brain, severe stenosis of carotid or vertebral arteries, and cardiac arrhythmia or 
other abnormalities on eCG and echocardiography. with this large number of risk factors, the 
occurrence of a vascular event can be predicted by means of multiple regression models based 
on data from large studies.2-4 However, these prognostic factors are not clustered, and rather 
weak. Furthermore, especially among the younger patients, often no risk factors are detected 
at all.5 this is why patients with a high risk cannot be adequately identified.6 It is therefore 
important to try and identify new risk factors for the occurrence of stroke and major vascular 
events. In this respect, genetically determined coagulation disorders are of particular interest. 
In the past decade, several of these disorders have been identified and linked to thrombotic 
complications, especially to venous thrombosis.7-9 their role in arterial thrombosis, including 
ischemic stroke, is less clear.
the aim of the research described in this thesis was to investigate the role of genetically 
determined coagulation disorders in ischemic stroke. we therefore performed several 
retrospective studies and one prospective case-control study of patients with recent ischemic 
stroke (the CoCoS study). we studied the relationship between ischemic stroke and various 
coagulation disorders as well as their phenotypic expressions.
ContentS oF tHIS tHeSIS 
Chapter 2 describes the results of a retrospective case-control study among young patients 
with ischemic stroke and healthy controls. In chapter 2.1 the association between the G20210A 
prothrombin gene variant, prothrombin level and the occurrence of ischemic stroke is 
described. In chapter 2.2, we studied the same association for glycoprotein receptor IIb/IIIa gene 
polymorphism. Chapter 3 covers the rationale, background and design of the Controlled study 
of genetically determined Coagulation disorders in patients with a recent tIA or ischemic Stroke 
(CoCoS). Chapter 4 contains the association between prothrombotic coagulation disorders 
and ischemic stroke in the CoCoS population. Chapter 4.1 provides a review of the literature 
concerning the Factor V Leiden (FVL) mutation and the G20210A prothrombin gene variant 
as risk factors for ischemic stroke combined with the results of these coagulation disorders 
within the CoCoS study. Chapter 4.2 and 4.3 describe the role of the -148C/t fibrinogen gene 
polymorphism and the protein Z G79A gene polymorphism and their phenotypic expressions 
in ischemic stroke. Chapter 5 focuses on the association between fibrinolysis related genetically 
determined coagulation disorders in the CoCoS population. In chapter 5.1 the association 
between 4G/5G PAI-1 gene polymorphism and PAI-1 levels and ischemic stroke is studied. Chapter 
5.2 describes the association between the annexin A5 kozak sequence (-1C/t) polymorphism 
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and ischemic stroke. Chapter 5.3 addresses the recently identified polymorphisms of the tAFI 
gene and their phenotypic expression in relation to ischemic stroke. In Chapter 6 all genetically 
determined coagulation disorders of the CoCoS study are combined to assess whether the 
risk of ischemic stroke changes with the presence of more than one coagulation disorder in 
comparison with an isolated mutation. Finally, chapter 7 and 8 provide a general discussion and 
summary of the results of the studies presented in this thesis.
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Chapter 2.1
elevated prothrombin is a risk factor for cerebral 
arterial ischemia in young adults
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ABStRACt
Background: the prevalence of elevated prothrombin in the absence of the G20210A 
prothrombin gene mutation has not been studied in patients with cerebral ischemia. 
Methods: we carried out a case-control study of the G20210A prothrombin gene variant and 
prothrombin activity in 49 adult patients aged 45 years or less, with tIA or ischemic stroke 
without cardiac embolism or large vessel disease, and 87 controls from a group of blood 
donors. 
Results: Five patients were heterozygous for the A-allele (oR = 2.3, 95% CI: 0.6 to 8.0). even 
after exclusion of individuals with the prothrombin gene variant, the prothrombin activity 
was significantly higher in patients than in controls (1.11 vs 0.97, p=0.0003). the relative risk 
of cerebral ischemia in patients within the fourth quartile of prothrombin activity (1.10 U/ml or 
higher), was 3.2 fold (95% CI: 1.03 to 9.96), than in patients whose level of prothrombin activity 
was in the second or third quartile. 
Conclusion: we conclude that, although the G20210A prothrombin gene variant may be a 
weak risk factor for tIA and ischemic stroke in young patients, increased prothrombin activity, 
which is more frequent than the mutation, appears to be more strongly related to cerebral 
ischemia.
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IntRoDUCtIon
Although cerebral ischemia occurs predominantly at older age, about 10% of the cases appear in 
individuals under 45 years of age. Unlike their older counterparts in whom it is mostly attributed 
to atherosclerosis and cardioembolism, the etiology of cerebral ischemia in the young remains 
unknown in a large proportion of patients. In 1996, Poort et al.1 reported that a G to A transition 
in the 3’- untranslated region of the prothrombin (Pt) gene confers an enhanced risk of venous 
thromboembolism (Vte). this mutation is associated with high Pt levels. More recently, it has 
also been shown that the prothrombin gene variant is frequently associated with cerebral 
venous thrombosis, especially in women who take oral contraceptives.2,3 whether this 20210A 
Pt variant is also a relevant genetic risk factor for arterial thrombosis and for cerebral ischemia 
in particular, remains controversial.4-8 High Pt activity is much more frequent than the mutation 
1,4,9, and has been shown to be an independent risk factor in patients with Vte.1 the cause of 
elevated Pt in the absence of the 20210A allele is unknown. none of the studies performed in 
patients with cerebral ischemia have reported on the Pt levels. 
the aim of the study reported here was to estimate the relative risk of focal cerebral ischemia, 
related to the Pt 20210A allele and to elevated Pt activity, in a series of adult patients aged 45 
years or less who had had a tIA or ischemic stroke of unknown cause.
PAtIentS AnD MetHoDS
Patients 
Adult patients, aged 45 years or less, with ischemic stroke or a tIA who were diagnosed and 
treated at the Department of neurology of the University Hospital Rotterdam, were enrolled. 
Ischemic stroke was defined as the acute onset of focal cerebral dysfunction due to cerebral 
ischemia with symptoms lasting more than 24 hours. Symptoms lasting less than 24 hours and 
without persistent deficit were classified as tIA. Diagnosis was confirmed with Ct-scan. Clinical 
stroke types were classified according to Bamford et al10, and etiologic classification was based 
on the toASt-criteria.11 Patients with a known cause according to the toASt classification, 
i.e. large-artery atherosclerosis, cardioembolism or vasculopathy were excluded. All patients 
were thoroughly evaluated for cardiovascular and metabolic risk factors. A total of 54 patients 
fulfilled the initial entry criteria, i.e. adult patients between 18 and 45 years, with focal cerebral 
ischemia and without a known cause according to the toASt criteria. twenty seven patients 
had a lacunar stroke and the same number a stroke of undetermined cause. of these 54 
patients, 22 had had a tIA and 32 an ischemic stroke. the patients’ mean age was 36 years, and 
31 (57%) were female. Seven (13%) of the patients had a history of angina pectoris, myocardial 
infarction, stroke or peripheral arterial disease and 4 (8%) of venous thrombosis. A family history 
of either arterial or venous thrombosis was present in 17 (46%) and 3 (7%) patients, respectively. 
Smoking was de most frequent risk factor (29 patients, 54%), followed by oral contraceptive 
use (14 patients, 52% of the women). Almost half of them had hyperlipidemia (n=21) and eight 
(15%) suffered from hypertension. Five out of the 54 patients were excluded from this study 
due to unavailability of DnA and plasma.
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Control subjects
A group of 87 controls with a similar age and sex distribution (mean age: 37, 51% female) and 
without a history of cerebral ischemia were recruited from a pool of blood donors at the blood 
bank in Rotterdam. Due to privacy regulations, no detailed clinical information regarding the 
blood donors is available.
Ethical considerations
Informed consent was given by patients and by blood donors (control group) for drawing of 
blood for the measurement of the coagulation parameters necessary for this study. 
MetHoDS
Laboratory assays
the Pt 20210G/A alleles and Factor V Leiden mutation were identified simultaneously, using 
a multiplex PCR method previously described.12 DnA sample was available from 49 patients. 
Prothrombin activity was evaluated from blood samples collected within 1 year after the event. 
the activity was measured by a chromogenic assay performed on an ACL-300R (Instrumentation 
Laboratory, IJsselstein, the netherlands) automated coagulometer. the assay was performed 
according to the manufacturers’ instructions, modification of the original technique13, and 
includes the use of echis carinatus venom (Sigma, Zwijndrecht, the netherlands) as activator and 
S-2238 (Chromogenix, nodia, Amsterdam, the netherlands) as substrate. Prothrombin activity 
was measured in 39 of the 49 patients. the remaining 10 patients were excluded because they 
were either on oral anticoagulant treatment, the value of the thrombotest was below normal or 
no plasma was available for assessment of Pt activity.
Statistical methods
we estimated the relative risk of cerebral ischemia according to the Pt levels and in the presence 
of Pt variant. the study population was divided into four quartiles according to the distribution 
of the Pt activity. the relative risk of stroke in each quartile was then estimated. odds ratios 
with 95% confidence interval (CI), χ2, Fisher’s exact test and Student’s t were used to compare 
subgroups, where appropriate.
ReSULtS
A total of 49 patients were selected, i.e. adult patients between 18 and 45 years, without a known 
cause for the focal cerebral ischemia according to toASt criteria and from whom material was 
available for laboratory studies.
Prothrombin gene variant
Five (10.2%) patients, of whom two had a tIA and three an ischemic stroke, and four (4.7%) 
controls were heterozygous for Pt 20210A. the relative risk (oR) of cerebral ischemia in these 
patients is 2.3 (95% CI: 0.6-8.3). no homozygotes for the 20210A variant were identified. the 
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clinical features of the five patients who were heterozygous for Pt 20210A did not differ from 
the others. All but one had at least one other vascular risk factor (data not shown). 
Prothrombin activity
the mean Pt activity, measured in three of the heterozygous patients, was significantly higher 
than in the patients without the variant: 1.49 ± 0.18 vs. 1.11 ± 0.19 U/ml, respectively (Student’s 
t, p=0.002). the mean Pt activity in the patient group as a whole was 1.14 ± 0.21 U/ml, and in 
the controls it was 0.98 ± 0.14 U/ml (p=0.0001). even after exclusion of all individuals with the 
Pt gene variant, the Pt activity was significantly higher in the patients than in the controls (1.11 
±.19 vs. 0.97 ± 0.14 U/ml, p=0.0003). Figure 1 shows how the risk of cerebral ischemia is related 
with the Pt activity in a dose-dependent manner. the relative risk of stroke (odds ratio) in the 
fourth quartile of Pt activity (mean Pt level: 1.19 U/ml) was 3.2 times higher (95% CI: 1.03 to 
9.96) than in the second and third quartile, where the relative risk was approximately 1 (95% CI: 
0.3 to 3.0).
Figure 1: Prothrombin activity and risk of cerebral ischemia. Relative risk (odds ratios) for cerebral ischemia according to PT activity . Patients 
and controls were stratified according to PT level: first quartile <0.91, second quartile 0.91 to 1.00, third quartile 1.00 to 1.10 and fourth 
quartile 1.10 U/ml or higher. Mean PT values in each quartile are indicated on the X-axis. Odds ratios were computed for patients in the first, 
third and fourth quartile, as compared to the second quartile. The 95% confidence interval of the odds ratio for the first quartile was .01 to .97, 
for the third quartile .31 to 3.04, and for the fourth quartile 1.03 to 9.96. 
we investigated whether other clinical features could influence Pt activity (table 1). Female 
patients had a significantly higher Pt level than males (1.20 U/ml vs. 1.06 U/ml, p=0.04). Among 
controls, the Pt level in women did not differ from the Pt level in men (0.99 vs. 0.97 U/ml, p=0.9). 
Age, type of ischemic event (tIA vs. ischemic stroke; lacunar stroke vs. stroke of unknown cause) 
and a positive history of arterial or venous thrombosis did not influence Pt activity. 
H 2.1 figure 1 
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Table 1: Relationship of prothrombin level with clinical characteristics in the patients 
Risk factor or clinical characteristic YeS no p ( t test)
Demographics
 Male sex
 Age over 37 yrs
1.06
1.12
1.20
1.16
0.04
n.S.
type of event
 Ischemic stroke
 Small vessel disease
1.14
1.13
1.14
1.15
n.S.
n.S.
Previous event
 AP, MI, stroke or PAD 1.26 1.13 n.S.
Family history
 MI stroke or PAD
 Venous thrombosis*
1.13
1.00
1.06
1.15
n.S.
n.S.
*Venous thrombosis includes deep venous thrombosis and pulmonary embolism AP= angina pectoris, MI=myocardial infarction, 
PAD=peripheral arterial disease.
Results expressed as mean PT activity (U/ml).
DISCUSSIon
this study shows that Pt levels in patients with focal cerebral ischemia are often high, and that 
high Pt levels by themselves are associated with an increased stroke risk, even in the absence of 
the Pt G20210A mutation. the association with ischemic stroke has not been described before. 
the etiology of increased Pt activity in the majority of our cases remains unclear. our results 
show that Pt is not an acute-phase reactant protein, as shown by the fact that it is found elevated 
long after the thrombotic episode, as well as in control individuals, a finding also reported by 
Poort et al.1 the Pt levels in these cases might be elevated due to either other genetic variations 
in the Pt or other (coagulation) genes and/or to acquired, metabolic or exogenous, factors. 
In order to gain insight into the pathogenesis of increased Pt activity, we correlated the Pt 
level with the clinical features of the patients. Prothrombin activity was not influenced by age, 
neither did it correlate with the type of ischemic event or with a personal or familial history of 
arterial or venous thrombosis. Gender appeared as the only variable which correlated with Pt 
activity, being higher in women than in men. oral contraceptives have been reported to cause 
changes in several proteins involved in blood coagulation and fibrinolysis, with increased levels 
of Pt among them.14 However, among our female patients oral contraceptives were already 
stopped at the time blood was drawn for Pt analysis. In addition, there was no difference in the 
Pt activity between women who at the time of event were using oC and those who did not 
(1.24 vs. 1.10 U/ml, p= 0.7, data not shown). Finally, another argument against a relevant effect 
of oC in Pt activity is that among controls no difference was found between men and women 
and, although we do not have information about the percentage of female blood donors who 
used oC we can assume based on their age that at least some were using them. 
other metabolic or acquired risk factors (smoking, hypertension, hyperlipidemia), probably 
did not influence Pt levels either for the same reason, since they were already being treated at 
the time blood was drawn for Pt analysis. 
In conclusion, our results suggest that increased Pt activity is a risk factor in young patients with 
cerebral ischemia of unknown cause. Large (nested) case-control studies are needed before a 
definitive conclusion can be reached about the role of elevated Pt, and its interactions with 
other risk factors.
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Chapter 2.2
PLA1/A2 polymorphism of the platelet glycoprotein 
receptor IIb/IIIa in young patients with cryptogenic 
tIA or ischemic stroke.
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ABStRACt
Background: the relationship between the PLA2 allele of the Leu33Pro polymorphism of 
glycoprotein IIb/IIIa receptor (GPIIb/IIIa) and ischemic stroke is uncertain. the purpose of this 
study was to investigate a possible association between the GPIIb/IIIa PLA1/A2 polymorphism 
and the occurrence of cryptogenic stroke in young patients. 
Methods: From a consecutive series of 80 patients aged 45 or less with a recent ischemic 
stroke or tIA, we selected 45 patients with stroke due to small vessel occlusion or stroke of 
undetermined etiology (according to the toASt criteria). Controls were 60 healthy blood 
donors with a similar age distribution. All patients underwent Ct of the brain and were screened 
for cardiovascular risk factors, cardiac disorders and large vessel disease. the frequency of the 
PLA2 allele was determined by PCR and Msp1 restriction analysis. 
Results: eight patients (16%) and 16 controls (27%) were heterozygous for PLA2 allele. two 
patients (4%) were homozygous for PLA2.the relative risk of ischemic stroke associated with 
PLA2 allele was estimated at 0.8 (95% CI: 0.3-1.9). 
Conclusion: this study does not support the association between the PLA1/A2 polymorphism 
and cryptogenic stroke or tIA in patients aged 45 or less. 
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IntRoDUCtIon
Although acute ischemic stroke is more common among elderly persons, 10 percent of all 
cerebral infarctions occur among patients aged 45 years or less. Several conditions may 
contribute to the occurrence of ischemic stroke in this age-group, including abnormalities of 
hemostasis.1
Platelet membrane glycoprotein IIb/IIIa is a platelet membrane receptor and member of 
the integrin family of adhesive molecules that, by binding fibrinogen and von willebrand 
factor, promotes platelet aggregation and thrombosis.2 the gene encoding this glycoprotein 
is polymorphic at exon 2. the more common allele encodes a leucine (PLA1) and the less 
common allele encodes a proline (PLA2).3 the wild type leucine is found in approximately 85% 
of the white population, whereas the proline is present in 15%.4 
Recent studies have unravelled the mechanism by which the PlA2 polymorphism could 
contribute to arterial thrombosis. the polymorphism has been shown to increase binding to 
immobilized fibrinogen, a greater extent of polymerized actin and cell spreading and greater 
fibrin clot retraction. In platelets this may result in a difference in platelet function, which 
strengthens the putative role of the polymorphism in cardiovascular disease.5 
the PlA2 allele of glycoprotein IIb/IIIa receptor has been associated in some case-control 
studies with coronary heart disease6, especially among young white patients.7-9 However, a meta-
analysis of published studies between 1996 and 1999 showed no evidence of a relationship 
between the PlA1/A2 polymorphism and myocardial infarction.10
Studies in stroke patients have also reported contradictory results. Five case-control studies 
in patients of all ages11-15 failed to show a relationship between PlA1/A2 polymorphism and the 
occurrence of ischemic stroke. three studies described a weak association in specific subgroups, 
like in young women with a clinically identified probable cause of their stroke16 or with several 
cardiovascular risk factors17, and in non smokers who were younger than 50 years.18 
the purpose of our study was to further investigate the evidence on the association between 
GPIIIa PlA1/A2 polymorphism and the occurrence of cryptogenic stroke in young patients. we 
focused on young patients with cryptogenic stroke, because we expected that specific etiologic 
factors such as a hypercoagulable state as a result of a genetically determined disorder like 
PlA1/A2 polymorphism would be more common in this group. 
MAteRIALS AnD MetHoDS
Patients with a stroke due to small vessel occlusion, and patients with a stroke of undetermined 
origin and with a negative diagnostic evaluation, were considered to have had cryptogenic 
stroke, and could be included in this study. this etiological classification was based on the 
toASt criteria.19 All patients were admitted to the department of neurology of the erasmus 
Medical Center Rotterdam between June 1997 and october 1998 and they were selected from 
a consecutive series of 80 patients aged 45 or less with a recent ischemic stroke. Ischemic 
stroke was defined as the acute onset of focal cerebral dysfunction due to cerebral ischemia, 
with symptoms lasting more than 24 hours. Symptoms lasting less than 24 hours and leaving 
no persistent deficit were classified as tIA. we used Ct or MRI to rule out hemorrhage and 
uncommon causes of stroke-like syndromes. All patients were screened for cardiovascular risk 
GP IIb/IIIa polymorphism in ischemic stroke 29
factors, such as previous (cardio)-vascular events, smoking habit, hyperlipidemia, use of oral 
contraceptives, history of hypertension, diabetes mellitus or venous thrombosis and family 
history of cardiovascular risk factors and venous thrombosis.
All patients were also screened for cardiac abnormalities by a cardiologist who routinely 
ordered 24 hours eCG monitoring and transthoracic and/or transoesophageal echocardiography. 
Screening for large vessel disease included duplex ultrasound and, if indicated, angiography of 
the carotid or vertebral arteries. occlusion or stenosis in the extracranial part of > 50% of a 
symptomatic artery were considered to be indicative of large vessel disease. 
In the patients with cryptogenic stroke, venous blood samples were collected for routine 
laboratory measurements, including platelet count, hemoglobin, hematocrit, lipid profile, renal 
and liver function tests. the frequency of the PLA2 allele was determined by PCR and Msp1 
restriction analysis. 
Sixty healthy blood donors served as controls. only the frequency of the PlA2 allele was 
determined in these patients. Risk factors and other clinical data apart from age and sex were 
not assessed, because of privacy regulations. 
Informed consent was given by patients and controls for drawing of blood for measurements 
of coagulation parameters necessary for this study.
we estimated the relative risk of stroke (odds ratio with 95% confidence interval) in the 
presence of PlA2 allele by comparing the prevalence of the PlA2 allele in both groups. 
Assuming a prevalence of the PlA2 allele of 15%, we estimated that in a study with 45 cases 
and 60 controls a minimal odds ratio of 4.0 could be detected with a significance level of 0.05 
and a power of 80%. 
ReSULtS
Forty-five patients with stroke due to small vessel occlusion (n=24, 53%) or stroke of 
undetermined etiology (n=21, 47%) were selected from a consecutive cohort of 80 young 
stroke patients. Patients had a mean age of 36 years (range 20-45 years) and controls of 37 
years (range 21-45 years). twenty-three patients (51%) were women, 22 (49%) were men. 
Sixteen patients (36%) had a tIA, 29 (64%) had an ischemic stroke, all confirmed by Ct-scan. 
twenty-seven patients (60%) smoked, 7 (16%) had hypertension and 16 patients (38%) had 
hyperlipidemia. three patients (7%) had a history of venous thrombosis and 3 others had a 
family history of venous thrombosis. oral contraceptives were used by 10 (43%) of the women. 
none had the ischemic event during pregnancy or puerperium.
eight patients (16%) and 16 controls (27%) were heterozygous for PlA2 allele. From these, 
3 had small vessel occlusion and 5 had a stroke of undetermined etiology. two patients (4%) 
were homozygous for PlA2, but none of the controls. Among the homozygous patients one 
had small vessel occlusion, the other a stroke of undetermined etiology. For the purpose of this 
analysis they were both included with the heterozygotes. 
the relative risk of ischemic stroke in the presence of PlA2 allele was estimated at 0.8 (95% 
CI:0.3-1.9). there were no clinically or statistically significant differences in the distribution of 
the cardiovascular risk factors mentioned above, between patients with and without the PlA1/
A2 polymorphism. 
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DISCUSSIon
the cause of a stroke in young patient remains often unclarified. especially in this age-group, 
in which atherosclerosis is less frequent1,20, genetically determined coagulation disorders could 
provide an additional explanation for the occurrence of the stroke. However, in the present 
study the PlA1/A2 polymorphism of the GPIIIa receptor was not associated with the occurrence 
of cryptogenic stroke at young age. 
Before our results can be accepted, some methodological issues should be discussed. First, a 
limitation of our study is the small sample size and hence, a low power in detecting a weak risk 
factor, with odds ratios typically around 1.5 to 2.5. nevertheless, due to a higher prevalence of 
the GPIIIa PlA2 polymorphism in our study than we initially expected, the confidence interval 
surrounding our estimate of the relative risk is rather tight. Second, the GPIIIA PlA2 polymorphism 
may interact with determinants of atherosclerosis rather than be the single cause of stroke in 
some young stroke victims. For example, one study17 described an almost 5-fold increased risk 
of ischemic stroke in women with diabetes, hypertension or elevated plasma homocysteine 
levels and the PlA1/A2 polymorphism. In another study16, the PlA2 allele appeared to be 
associated with stroke in a subgroup of young female patients with an underlying cause of the 
stroke, such as cardiac embolism or ipsilateral carotid stenosis. However, both reports applied 
post-hoc sub-group analyses among a small number of patients. Furthermore, no consistent 
pattern of risk factors was emerged. 
Finally, ethnic differences in the prevalence of genetically determined disorders exist.21 we 
could however, not adjust for ethnic origin because we didn’t have these data on the control 
subjects at our disposal.
we conclude that the GPIIIA PlA2 polymorphism does not appear to be a strong risk factor 
for cryptogenic stroke in young patients. the results of our study, taken together with previous 
case-control studies22 suggest that an association between the GPIIIa PlA2 polymorphism and 
ischemic stroke is not likely at all.
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IntRoDUCtIon
Before discussing the background and design of the Controlled study of genetically determined 
coagulation disorders in patients with tIA or ischemic stroke (CoCoS), I will first briefly review 
the basic principles of hemostasis and the clotting cascade.
HeMoStASIS
the adequate control of flow and viscosity of the blood requires a precise balance between 
activation and inhibition of coagulation factors, fibrinolytic factors, platelets and tissue factors. 
Hemostasis involves the process of blood clotting and subsequent dissolution of the clot. Any 
disturbance of the balance between procoagulant and anticoagulant factors may lead to an 
increased risk of thrombosis or an increased bleeding risk. the following figure provides a 
simple representation of hemostasis.
In the process of hemostasis three stages can be distinguised: 1) primary hemostasis, 2) formation 
of fibrin clot and 3) after some time the breakdown of the fibrin clot, called fibrinolysis.
Primary hemostasis
Primary hemostasis starts when subendothelial structures, especially collagen, come into direct 
contact with the blood as a result of a defect in the blood vessel wall. Collagen activates platelets 
by binding to the platelet receptors Ia/IIa and IV on the surface. Adhesion of activated platelets 
to the vessel wall is achieved by binding of another platelet receptor, the glycoprotein receptor 
Ib, to the Von willebrand factor, that in its turn binds to collagen in the vessel wall. this results in 
a direct connection between the vessel wall and the platelet, with the Von willebrand factor as 
linkage (Figure 2a). As a consequence of the adhesion, platelets are further activated and express 
the glycoprotein IIb/IIIa receptor on their surface. Fibrinogen binds to these receptors and 
provides connections between individual platelets, a process called platelet aggregation (figure 
2b). During the platelet activation several biochemical reactions in the platelets take place. An 
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Figure 1: Schematic presentation of hemostasis
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example is the formation of thromboxane-A2 from arachidonic acid. thromboxane-A2 activates 
other platelets contributing to the formation of the platelet clot. the enzyme cyclo-oxygenase 
(CoX), which is responsible for the formation of thromboxane, is completely inhibited by aspirin. 
there are 2 isoforms of cyclo-oxygenase, CoX-1 and CoX-2. CoX-1 is considered the constitutive 
isoform and is responsible for basal prostaglandin production for tissue homeostasis. It is found 
in many tissues, including the stomach, kidney and platelets, where it catalyzes the synthesis 
of prostaglandins involved in gastric cytoprotection, renal blood flow regulation and platelet 
function. CoX-2 is the inducible isoform. It is not present at baseline but increases in response 
to inflammation. Aspirin acts as an almost selective CoX-1 inhibitor at low dosis. At higher doses 
it also inhibits CoX-2 activity. It needs further investigation if simultaneously inihibition of CoX-
1 and CoX-2 provides better secondary prevention for ischemic stroke than CoX-1 inhibition 
alone.
 
Figure 2a and 2b: Platelet activation and adhesionH 3 figure 2a 
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Formation of fibrin clot
During this phase the clotting factors become activated resulting in the formation of the fibrin 
clot. traditionally, the conversion of prothrombin into thrombin was regarded as the result of 
two different clotting pathways, i.e. the intrinsic- and extrinsic pathway. Recently, however, it 
was shown that this view merely represents the clotting in vitro. the in vivo clotting process 
is much simpler. Coagulation starts at a site of injury with the release of tissue factor, which 
activates factor VII. Subsequently, the clotting cascade sets off which means that each clotting 
factor is activated by a former clotting factor in the cascade. the process of activation requires 
enzymatic cleavage of the factor into a peptide and an active clotting factor, which can then 
activate the following clotting factor. each step takes place on a negatively charged surface of 
phospholipids provided by activated platelets. the tissue factor/factor VIIa complex cleaves 
factor X into factor Xa and forms the tissuefactor/factor VIIa/factor Xa complex. the latter 
complex is also called “tenase complex”. the tenase complex activates, with assistance of factor 
V, prothrombin (factor II) into thrombin (factor IIa). thrombin, in turn, converts fibrinogen into 
fibrin and at that moment the blood starts to clot (figure 3). Apart from this main pathway in 
the clotting cascade, two other loops can enhance coagulation. the tissue factor/factor VIIa 
complex can indirectly activate factor X by activation of factor IX to factor IXa. together with 
factor VIII, factor IXa can activate factor X to Xa. A second enhancing loop involves activation 
of factor XI by thrombin. Factor XIa can activate factor IX which results in further activation 
of factor X by the first loop. In that way thrombin can stimulate its own formation. Almost all 
clotting factors are synthesized by the liver. Factor II, VII, IX and X are vitamin k-dependent.
Figure 3. The clotting cascade. The black  arrows represent stimulating steps, the dotted arrows represent inhibitory steps. 
For further details see text.
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Inhibitors of coagulation
In order to prevent hypercoagulation, there are 3 physiologically inhibitory mechanisms of the 
clotting cascade. the first and most powerful inhibitor is antithrombin III. this protein inhibits 
factor Xa and factor IIa almost completely. Another is activated protein C that degrades, in the 
presence of protein S, factor Va and factor VIIIa, thereby limiting the activity of these factors 
in the clotting cascade. the tissue factor pathway inhibitor (tFPI) inhibits the influence of the 
tissue factor/factor VIIa complex.
Fibrinolysis
Another way of controlling the amount of fibrin is the degradation of fibrin clots by plasmin, 
a process called fibrinolysis (figure 4). tissue plasminogen activator (t-PA) and urokinase 
plasminogen activator (u-PA) convert plasminogen to plasmin that consecutively degrades the 
fibrin to fibrin degradations products (FDP). the fibrinolysis has just as the coagulation system 
regulatory loops. the release of plasminogen and plasmin is followed by rapid inactivation by 
their respective inhibitors, plasminogen- activator-inhibitors type 1 (PAI-1) and type 2 (PAI-2). At 
last, any free circulating plasmin is inhibited by α2-antiplasmin.
Figure 4: schematic presentation of the fibrinolysis.
BACkGRoUnD oF tHe CoCoS StUDY
As discussed above the continuous in vivo process of clotting and subsequent dissolution of 
the clot leads to a certain viscosity of the blood. Changes in function or in the plasma level of 
a clotting factor immediately lead to a disturbance of the fine balance in the clotting cascade. 
this results in an increased risk of thrombosis or in an increased bleeding risk, depending on 
whether the factor concerning has procoagulant or anticoagulant features. the function and 
the plasma level of a clotting factor are genetically determined. Mutations or polymorphisms 
in the clotting genes can give rise to changes in function of clotting factors or to modified 
plasma levels of the proteins. Both changes lead to a hypercoagulable state which might result 
in ischemic stroke, either as a result of increased thrombus formation or as a result of increased 
blood viscosity. Furthermore, damage of the vessel wall by atherosclerosis may lead to an 
increased activation of the clotting cascade resulting in an increased thrombosis risk. 
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In the past decade several specific genetically determined disorders of coagulation that 
increase the risk of venous thrombo-embolic complications, have been identified. In case-
control and family studies it has been demonstrated that deficiencies of antithrombin, protein 
C and protein S, and –more recently- Factor V Leiden and G20210A prothrombin gene variant 
predispose to venous thrombosis.1-3 whether these genetically determined coagulation 
disorders are also associated with an increased risk of arterial thrombosis, especially ischemic 
stroke, is less clear. within the group of genetically determined coagulation disorders, factor V 
Leiden and prothrombin gene variant have been studied most extensively in stroke. However, 
the majority of the studies was small and therefore underpowered. Moreover, some studies also 
included hemorrhagic stroke4,5 or did not determine stroke subtype reliably.6-9 Furthermore, 
there were many differences in ethnic origin of the participants of the studies. Before starting 
CoCoS, we performed a systematic review of the literature concerning the association between 
FVL mutation, prothrombin gene variant and ischemic stroke, that is further described in 
chapter 4. 
In the general population a correlation has been found between 4G/5G polymorphism and 
PAI-1 level and the fibrinogen polymorphism and the level of this protein.10,11 Studies in patients 
with arterial thrombosis have yielded contradictory results on whether there is an association12-
14or not.15-18 Increased levels of fibrinogen and of plasminogen activator inhibitor-1 (PAI-1) have 
been reported in patients with myocardial infarction or stroke. Most of these factors are acute 
phase reactants. It is not clear whether some of these increased levels of coagulation factors are 
in fact genetically determined. It is also unknown whether these elevated levels are linked to 
polymorphisms or are regulated by other genetic or environmental mechanisms.19-21
Recently, polymorphisms in the protein Z gene, tAFI (thrombin activatable fibrinolysis 
inhibitor) gene and AnxA5 (Annexine V) gene have been reported.22-25 their role in ischemic stroke, 
together with that of their phenotypic expressions in plasma, needs further investigation.
In the following figure of the clotting cascade the possible genetic mutations that are studied 
within CoCoS are indicated with arrows. 
Figure 5. PM=polymorphism, AnxA5=Annexine V, vWF=von Willenbrand factor, FVL=factor V Leiden, PTII=prothrombin, PZ=protein Z, 
TAFI=thrombin activatable fibrinolysis inhibitor, PAI-1=plasminogen activator inhibitor-1
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AIM oF tHe StUDY
the aim of the CoCoS-study is to answer the question whether genetically determined 
coagulation disorders are associated with the occurrence of ischemic stroke. this leads to the 
following more detailed sub-questions:
1. Are the most common genetically determined hemostatic risk factors for venous 
thrombosis, i.e. FV-L mutation and the G20210A prothrombin gene variant and their 
phenotypic expressions associated with the occurrence of ischemic stroke?
2. Are reported polymorphisms of fibrinogen, vwF and PAI-1 and their phenotypic expression 
associated with the occurrence of ischemic stroke?
3. Are there new polymorphisms that are associated with the occurrence of ischemic 
stroke?
DeSIGn oF tHe StUDY
CoCoS is a case-control study with prospective inclusion of the participants. A case-control 
study aims, just like a prospective follow-up study, to identify features that influence the 
frequency of an illness. In a follow-up study, individuals exposed or not to a risk factor are 
followed and continuously screened for the development of relevant diseases, wheras in a case-
control study individuals that have developed the disease (cases) are compared with individuals 
who are free of the disease (controls) at a certain time regarding the presence of potential risk 
factors. Consequently, a follow-up study measures and compares frequencies of illness and a 
case-control study measures and compares frequencies of exposure. From the incidences in 
a follow-up study the relative risk can be calculated. In 1951 Cornfield introduced the theory 
that the ratio from the incidences of which the relative risk is estimated, can be estimated also 
from a case-control study. this theory, “the rare disease assumption”, was further described by 
Mantel and Haenszel in 1959, by Miettinen in 1976 and finally by thomas and Greenland in 
1982.26-29 It implies that if the disease is rare enough, the odds ratio of a case-control study can 
be interpreted as a relative risk.
 A case-control study can be summarized as follows:
Cases (disease +) Controls (disease -)
Determinant + a b 
Determinant - c d 
and the odds ratio (oR) can be calculated as:
oR = ad/bc
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An advantage of the case-control design with prospective inclusion is that detailed information 
of the participants concerning for instance the neurological complaints, medical history, 
medication use, family history, can be gathered. Another advantage is the relatively fast inclusion 
within a few years. However, an important disadvantage is the lack of the determination of the 
variable beforehand. For this, a nested case-control study is needed.
Probably the most discussed and controversial principle of the case-control study is the 
choice of the controls. In an ideal world, the controls must reflect the same population and the 
same exposure category as where the cases stem from. Frequently chosen control populations 
are hospital controls, i.e. patients with another disease than the cases, healthy blood donors or 
population controls from the same geographical area as the cases. An advantage of hospital 
donors is that they are easy to find and quality of medical information is usually high. A 
disadvantage is that it cannot be excluded that the exposure has some relation to the illness. 
Furthermore, especially in case of participants of specialized hospitals, hospital controls do not 
well reflect the geographical aspects of the cases and other variables such as social economic 
status. Using healthy blood donors carries the advantage of the easy and speed of composing 
a control group. A disadvantage is the lack of sufficient medical information and the relatively 
healthy character of the controls. Population based controls from the same geographical area 
are the most valid choice, as they are the best representatives of the population at risk from 
which the cases originate. A relative disadvantage is that it is time consuming to find them. 
In CoCoS we have chosen for population controls matched for sex and age, with a range of 5 
years.
Confounding is a main problem of epidemiological research and means that the effect of a 
determinant is partly or completely determined by another variable. this problem can be partly 
overcome by matching cases and controls for possible confounding variables, such as age and 
sex. Another way of dealing with this problem is adjustment for confounding variables during 
the statistical analysis.
essential in epidemiology is the matter of causation and causal interference. Since almost 
all diseases are multifactorially induced various attempts have been made to organize this 
complex process in order to gain a better understanding of the occurrence of diseases. A rather 
simple example is the host-agent-environment theory in which the occurrence of a disease is 
the result of the presence of an agent which causes the disease in a susceptible person, given 
certain environmental circumstances. A probably more realistic but more complex view of 
disease etiology is the web of causation. In this concept all predisposing factors for a disease 
and their complex relations both with each other and with the disease are considered. Hill has 
suggested that the following aspects of an association must be considered when attempting 
to distinguish causal from noncausal associations: (1) strength, (2) consistency, (3) specificity, 
(4) temporality, (5) biologic gradient, (6) plausibility, (7) coherence, (8) experimental evidence 
and (9) analogy. Rothman proposed the concept of sufficient cause and component causes.30 
A sufficient cause is defined as a set of minimal conditions and events (component causes) 
that inevitably produce disease. Minimal implies that none of the conditions or events is 
superfluous. A given disease is considered to have a fixed number of sufficient causes. If a 
component cause is member of all sufficient causes it becomes a necessary cause. In disease 
etiology, the completion of a sufficient cause may be considered equivalent to the onset of 
disease. In CoCoS, we tried to reduce the occurrence of the stroke to one sufficient cause, i.e. 
the coagulation disorder, by adjusting for other possible component causes such as smoking. 
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Inclusion and exclusion criteria
Cases were consecutively recruited patients with first-ever ischemic stroke, admitted to the 
department of neurology of the erasmus MC between January 1999 and December 2001. we 
used population controls, i.e. partners, friends or neighbours of the patients. they were age-en 
sex-matched (range 5 years), did not have a history of stroke and were not related to the patient. 
Patients, controls and their parents should be born in northern europe and be of the Caucasian 
race, because substantial differences in the prevalence of genetically determined coagulation 
disorders have been reported between people from different geographical regions or race.31 
Patients with a definite non-atherosclerotic cause for the stroke such as a mechanical heart 
valve, endocarditis, DIC or carotid dissection were excluded, because we considered these 
conditions as a likely and sufficient cause of the stroke. other exclusion criteria were age over 
75 years, the use of oral anticoagulants and the absence of written informed consent. 
Definitions and measurements
Ischemic stroke was defined as the acute onset of focal cerebral dysfunction due to cerebral 
ischemia with symptoms lasting more than 24 hours. Patients with tIA (symptoms lasting less 
than 24 hours) were included only if the neurological deficit in the acute phase was observed 
by a neurologist. In all patients, a Ct of the brain was made within three days from the onset 
of symptoms to confirm the diagnosis of ischemic stroke and to rule out hemorrhagic stroke 
or uncommon causes. Clinical stroke subtypes were classified according to the oCSP criteria, 
modified by the results of Ct.32 etiologic stroke types were classified according to the toASt 
criteria.33 Stroke severity was assessed with the nIH scale and Barthel scale.34,35 
In patients as well as controls, we collected detailed information about cardiovascular 
risk factors, such as previous cardiovascular events, smoking habit, hyperlipidemia, use of 
oral contraceptives, history of hypertension, diabetes mellitus, and venous thrombosis. 
Hypertension was defined as a systolic blood pressure above 160 mmHg and a diastolic 
blood pressure above 90 mm Hg 5 days after the event, or the use of medication because of 
hypertension at inclusion. Hyperlipidemia was defined as fasting cholesterol level above 5.0 
mmol/l or the use of medication because of hyperlipidemia at inclusion. Diabetes mellitus 
was defined as the use of antidiabetic medication at assessment or glyco-Hb > 6.5 %. Ischemic 
changes on eCG or a history of angina pectoris combined with an increasing level of Ck was 
scored as myocardial infarction. Deep venous thrombosis was scored as “definite” when there 
was evidence of a venous thrombosis on phlebographic or duplex investigation. In case of 
clinical signs of deep venous thrombosis without support from the ancillary investigations, 
this was scored as “possible” deep venous thrombosis. In the same way, pulmonary embolism 
was defined as “definite” in case of positive findings on a VP-scan, Ct-thorax or arteriography 
and as “possible” when there were only clinical signs of pulmonary embolism. Intermittent 
claudication was scored “positive” in case of clinical symptoms or signs of arterial vascular 
insufficiency in the legs. Peripheral arterial disease was defined as the presence of a bifemoral 
bypass, a documented arterial occlusion in the past, amputation of a leg above the ankle or a 
known arterial stenosis (femoral, brachial). 
Blood samples and procedures
one week after the ischemic stroke, venous blood samples were taken under strictly standardized 
conditions. this standardization ensured that differences between participants were real and 
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not the result of circadian rhythm, physical exercise or different food intake. the participant 
was in fasting condition, with no exposure to tobacco or alcohol for at least 8 hours and the 
drawing of blood took place after 15 minutes of rest. the blood extraction was performed at one 
week after the stroke as we want to bypass the first acute phase response. In the venous blood 
samples routine laboratory measurements such as platelet count, hemoglobin and hematocrit, 
lipid profile, renal and liver function tests were carried out. Secondly, the specific DnA 
analysis and protein assays for the genetic mutations or polymorphisms and their phenotypic 
expression were performed. the exact procedures of the specific tests will be described in the 
corresponding chapters of this thesis.
All patients were screened for cardiac abnormalities by means of standard twelve lead eCG 
examination in order to find a possible cardiac cause for the ischemic stroke. A cardiologist was 
consulted in female patients aged 55 years or less, in male patients aged 45 years or less and 
in patients with eCG abnormalities or a clinical suspicion of cardiac disease. In these patients, 
24 hours eCG monitoring, transthoracic and/or transesophageal echocardiography was carried 
out. we did not perform complete cardiac work-up in the older patients, because in this patient 
group the chance of finding a relevant cardiac cause for the stroke is very low, given a normal 
eCG and the absence of clinical cardiac symptoms.36 Screening for large vessel disease included 
duplex ultrasound or, if indicated, angiography of the carotid or vertebral arteries. 
Sample size estimation
Assuming a prevalence of the factor V Leiden mutation of 5% in the control group37, inclusion 
of 116 cases and 116 controls would allow us to estimate an odds-ratio of 4.0 with a power of 
80% at a significance level of 5%. the number of patients and controls was rounded to 125.38,39 
For the studied polymorphisms the prevalence in the general population is higher than 5%, so 
the minimally detectable odds ratio would be lower. 
Statistical analysis
the relationship between each hemostatic risk factor and ischemic stroke was expressed by 
odds-ratios with a 95% confidence interval. Multiple logistic regression analysis will be used to 
adjust for possible confounders. Adjustments were made for known risk factors for ischemic 
stroke, such as hypertension, smoking, diabetes mellitus.
Follow-up
If possible the patient was seen at more than three months after the onset of symptoms to 
assess stroke outcome according to modified Rankin and Barthel score. A new venous blood 
sample was gathered at that time and the measurements of fibrinogen, prothrombin, CRP, 
cholesterol and glyco-Hb were repeated. the blood extraction took place under the same 
standardized conditions as during the first blood sample.
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ABStRACt
Background: whether carriership of the factor V Leiden mutation or the prothrombin 20210A 
gene variant predispose to arterial thrombosis, and in particular to stroke, is unclear. 
Methods: we performed a Medline search of case-control studies of the prothrombin (Pt) 
20210A gene variant or factor V Leiden (FVL) mutation as a risk factor for ischemic stroke, 
published between 1995 and 2000. we used predefined criteria for inclusion of the studies and 
selected patients with ischemic stroke as a subgroup, if possible. we made a summary estimate 
of the relative risk of ischemic stroke, in relation to either FVL mutation or the prothrombin 
gene variant by computing the Mantel-Haenszel (M-H) odds ratio. In addition, we performed a 
case-control study in a well defined ischemic stroke population and population based controls 
of the same ethnic origin to further establish a possible association between ischemic stroke 
and FVL mutation or Pt gene variant. Furthermore, the association between prothrombin levels 
and ischemic stroke was studied.
Results: the M-H odds ratio associated with ischemic stroke in the presence of FVL mutation 
was 1.35 (95% CI: 1.11-1.65), and of prothrombin gene variant 1.32 (95% CI: 0.95-1.84). when 
only studies were considered in which brain imaging was performed in more than 95% of 
the patients, the M-H odds ratio changed to 1.52 (95% CI: 1.22-1.90) for FVL mutation, and to 
1.36 (95% CI: 0.96-1.93) for prothrombin gene variant. However, when the studies that also 
included children were excluded, the M-H odds ratio dropped to 0.89 (95% CI: 0.67-1.19) for FVL 
mutation, and to 1.05 (95% CI: 0.63-1.74) for prothrombin gene variant. our own case-control 
study also provided no evidence for an increased risk of ischemic stroke in the presence of the 
FVL mutation or G20210A prothrombin gene variant. In contrast to the genotype, prothrombin 
level was associated with ischemic stroke. the adjusted oR associated with ischemic stroke in 
the highest quartile of prothrombin was 2.2 (95% CI: 0.96-4.90)
Conclusion: An association between ischemic stroke and the FVL mutation or the prothrombin 
20210A gene variant is not likely. However, elevated prothrombin levels in the absence of the 
G20210A prothrombin gene variant may be associated with an increased risk of ischemic 
stroke.
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IntRoDUCtIon 
Several case-control studies have been performed concerning the relationship between 
prothrombotic conditions, such as carriership of the factor V Leiden (FVL) mutation or the 
prothrombin 20210A gene variant, and thrombotic events. FVL mutation results in resistance of 
FVa to activated protein C which is known to be associated with a prothrombotic phenotype.1 
Prothrombin gene (Pt) variant is characterized by G to A mutation at position 20210 at the 3’ 
end of the prothrombin gene and is associated with increased prothrombin levels in plasma.2 
It has been well established that both FVL mutation and prothrombin gene variant predispose 
to venous thrombosis.1, 3-5 whether these genetically determined disorders of hemostasis also 
predispose to arterial thrombosis, and in particular to stroke, is still unclear. the majority of 
studies was small and therefore underpowered. Moreover, in some studies stroke type was not 
reliably determined in all patients. Hemorrhagic strokes are relatively common among young 
patients. Since it is unlikely that FVL mutation or the prothrombin gene variant are associated 
with hemorrhage, this may have further decreased the power of these studies.
to make a more reliable and precise estimate of the association between either the FVL 
mutation or the prothrombin 20210A gene variant and the occurrence of ischemic stroke, we 
combined the evidence from all published case-control studies in a systematic review. Special 
attention was paid to critical aspects of study-design, such as verification of stroke type, choice 
of control subjects and age of participants. 
In addition, we studied the association between ischemic stroke and FVL mutation and 
prothrombin gene variant within a well defined case-control population of Caucasian 
participants (CoCoS study). In case of the prothrombin gene variant, we investigated to 
what extent a possible association could be explained by the phenotypic expression, i.e. the 
prothrombin level.
MetHoDS
Systematic review
we performed a Medline search of published case-control studies between 1995 and 2000 of 
the prothrombin gene variant or FVL mutation as a risk factor for ischemic stroke, using the key 
words prothrombin gene mutation, G20210A, factor V Leiden, stroke or arterial thrombosis. the 
design of each case-control study was further characterized as prospective or retrospective, 
depending on whether the data were collected according to a predefined protocol, and as 
“nested” or not. In a nested case-control study both cases and controls are derived from the 
same longitudinal population-based cohort and therefore the exposure distribution is the same 
for both groups. In such a design, exposure, i.e. the coagulation disorder, may be determined 
at the start of the cohort-study, and will not be affected by the event under study, i.e. stroke, 
which may not necessarily be a problem in genetic studies. Cases had to be patients with acute 
ischemic stroke, preferably confirmed by brain imaging study (Ct or MRI) and by a neurologist. 
Controls and cases had to stem from a well-defined dynamic population.6 Controls were defined 
as population based, when some method of aselective population sampling was carried out, for 
example by random digit dialling. Hospital-based controls were patients who were admitted 
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for a condition that was presumably not related to a prothrombotic condition or stroke, such as 
head injury or multiple sclerosis. If studies included cases of cerebral venous sinus thrombosis 
or either hemorrhagic or ischemic stroke, we extracted the latter subgroup if possible, and 
computed the odds-ratio on the basis of these figures. we estimated the relative risk of stroke 
in relation to FVL mutation and prothrombin gene variant in each study by computing the odds 
ratio oR= (IS,e/Co,e) / (IS,ne/Co,ne), IS=patients with ischemic stroke, e=exposed, i.e. presence 
of a coagulation disorder, Co=controls, ne=not exposed, i.e. absence of a coagulation disorder. 
the odds ratio gives an estimate of the relative risk of stroke in relation to the presence of 
a genetically determined coagulation disorder. A mean odds-ratio was computed with the 
Mantel-Haenszel technique by weighing the odds ratio of each study with the inverse of its 
variance. the meta-analysis was done in StAtA version 6.0 with the metan command.7 
COCOS study 
the design of the study has been described extensively in chapter 3 of this thesis. In short, 
CoCoS is a case-control study with prospective inclusion of Caucasian participants with first 
ever ischemic stroke, confirmed by Ct. Controls are population based, age-and sex-matched and 
of the Caucasian race. Blood samples for genotype and phenotype were drawn under strictly 
standardized conditions one week after the event and in almost half of the patients also after 
three months. For the determination of FVL mutation and prothrombin G20210A gene variant 
high molecular weight genomic DnA was isolated from the white cell fraction of citrated blood 
according to the high-salt concentration standard procedure.8 Simultaneous screening of FVL 
mutation and prothrombin 20210A gene variant was performed by PCR amplification followed 
by digestion with restriction enzymes Mnl-I and Hind-III9 and visualization on an agarose 
electrophoresis gel. Prothrombin activity was measured with a chromogenic method which 
uses echis carinatus venom as activator and S-2238 as substrate, according to a previously 
described protocol.10 
the relationship between either the FVL mutation or the prothrombin gene variant and 
ischemic stroke was analysed using logistic regression analysis and expressed as an odds ratio 
with a 95% confidence interval (95% CI). the prothrombin levels were divided into quartiles 
and the relationship between prothrombin level and ischemic stroke was estimated as odds 
ratio of each quartile against the lowest quartile, and for the lowest quartile versus the higher 
three quartiles. we used logistic regression analysis to adjust for possible confounders, such as 
oral contraceptive use, as this vascular risk-factor is known to affect prothrombin level.
ReSULtS
Systematic review
twenty-six studies were identified. three studies were excluded from this review. these 
excluded studies are discussed below. 
In de Lucia et al.11 the FVL mutation was found in 19 cases (38%!) and in none of the controls. 
the authors suggest that they had selected young patients with familial defects in the protein 
C pathway. this study was not included in our systematic review because of obvious selection 
bias. In the study of Bentolila et al.12 three patients had venous sinus thrombosis. It is not clear 
whether these patients had the prothrombin 20210A gene variant or the FVL mutation. If so, 
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they account for almost half of the cases with the prothrombin gene variant. Since venous sinus 
thrombosis is frequently associated with prothrombin gene variant4, this study was excluded 
from this review. In Ferraresi et al.13 the inclusion criteria for 65 of 105 cases were not mentioned, 
they probably had asymptomatic carotid stenosis. the data from this study are therefore not 
included in our review. 
the remaining 23 studies were case-control studies. three studies concerned the prothrombin 
gene variant only, 13 studied the FVL mutation, and 7 both prothrombotic conditions. In table 1 
the main characteristics of each study are shown. In table 2 and 3 the results of each individual 
study with regard to the presence of FVL mutation and prothrombin gene variant are listed.
Table 2. Results: Factor V Leiden mutation 
Author (refno.) IS,e IS,ne Co,e Co,ne oR 95% CI
Ridker 31 9 200 42 662 0.7 0.3-1.5
Catto 26 15 333 14 233 0.8 0.4-1.6
kontula 14 9 227 1 86 7.4* 0.9-58.7
Press 27 4 157 4 166 1.1 0.3-4.3
Markus 35 15 165 5 65 1.2 0.4-3.4
Van der Bom 28 6 101 11 211 1.1 0.4-3.2
Albucher 29 3 27 1 74 8.2 0.8-82.5
Landi 15 4 91 3 187 2.7 0.6-12.5
Martinelli 16 5 150 2 153 2.6 0.5-13.3
Sanchez 18 3 63 3 63 1.0 0.2-5.1
Halbmayer 30 8 104 6 65 0.8 0.3-2.5
Longstreth 19 0 40 16 372 0.3 0.2-4.7
de Stefano 20 5 67 6 192 2.4 0.7-8.1
Cushman 36 13 192 35 460 0.9 0.5-1.7
nabavi 22 19 206 12 188 1.4 0.7-3.1
Lalouschek 34 5 91 8 88 1.7 0.5-5.3
Lalouschek 23 10 71 4 77 2.7 0.8-9.0
Margaglione 24 30 172 43 993 4.0 2.5-6.6
Gaustadnes 25 23 184 276 3912 1.8 1.1-2.8
Voetsch 33 5 109 7 112 0.7 0.2-2.3
IS=ischemic stroke, E=exposed/FVL mutation, NE=non-exposed/ FVL mutation negative, CO=controls, OR=odds ratio, 95% CI=95% 
confidence interval; *odds ratio calculated with control group of same area as cases, odds ratio with all controls in study 1.32 (95% CI: 0.4-4.36)
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Table 3. Results: Prothrombin 20210A gene variant 
Author (refno.) IS,e IS,ne Co,e Co,ne oR 95% CI
Martinelli 16 6 149 5 150 1.2 0.4-4.0
Corral 17 1 103 2 102 0.5 0.1–5.6
Longstreth 19 1 39 6 376 1.6 0.2-13.7
De Stefano 20 9 63 5 193 5.5 1.8-17.1
Reuner 21 3 128 8 346 1 0.3-3.9
Lalouschek 34 5 91 5 91 1.0 0.3-3.6
Ridker 32 11 248 69 1705 1.1 0.6-2.1
Margaglione 24 10 192 43 993 1.2 0.6-2.4
Gaustadnes 25 4 203 10 490 1.0 0.3-3.1
Voetsch 33 6 108 3 116 2.2 0.5-8.8
IS=ischemic stroke, E=exposed/prothrombin gene variant, NE=non-exposed/ normal prothrombin gene, CO=controls, OR=odds ratio, 95% 
CI= 95% confidence interval
twelve studies had a retrospective design14-25 seven studies were prospective.26-32 three studies 
did not mention whether the data were collected prospectively or retrospectively.33-35
the estimated M-H odds ratio, based on the results of all 23 included studies of FVL mutation 
was 1.35 (95% CI: 1.11-1.65) and of prothrombin gene variant 1.32 (95% CI: 0.95-1.84), (Figure 
1).
Figure 1: Graphical representation of a meta-analysis of case-control studies of factor V Leiden (left) and Prothrombin 20210A gene variant 
(right) as a possible risk factor for stroke.
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In six studies, however, no brain imaging studies were performed and hence, no certain 
distinction between hemorrhagic and ischemic stroke was made.14, 16, 17, 27, 28, 36 In two studies Ct 
or MRI showed hemorrhagic stroke19, 26 or even venous stroke19, but we considered the ischemic 
stroke cases only. taking into account only those studies in which brain imaging was performed 
in more than 95% of the patients, the M-H odds ratio changed from 1.35 to 1.52 (95% CI: 1.22-
1.90) for FVL mutation and from 1.32 to 1.36 (95% CI: 0.96-1.93) for prothrombin gene variant 
respectively (table 4). 
Table 4. Results of the meta-analysis: Odds ratio and 95% confidence interval for factor V Leiden mutation and Prothrombin 20210A gene 
variant in subgroups 
Factor V Leiden mutation Prothrombin gene variant 
Subgroup n of studies oR (95% CI) n of studies oR (95% CI)
Brain imaging in > 95% of patients 14 1.51 (1.22-1.90) 7 1.36 (0.96-1.93)
Age > 17 years 12 0.89 (0.67-1.19) 5 1.05 (0.63-1.74)
Use of population controls 12 1.15 (0.84-1.57) 4 1.05 (0.49-2.27)
OR=odds ratio, 95% CI=95% confidence interval
Most studies included adults only, seven also included children.15, 18, 20, 22, 24, 25, 33 Considering only 
the studies with patients aged 18 years or more, the M-H odds ratio was 0.89 (95% CI: 0.67-1.19) 
for FVL mutation and 1.05 (95% CI: 0.63-1.74) for prothrombin gene variant (table 4).
All studies used different criteria for the selection of controls, and in some they were poorly 
defined.20 Most studies used population based controls14-19, 22, 23, 27-29, 34-36 others used blood bank 
donors18, 21, 26, 30 or healthy physicians26, 31, 32 and other hospital workers24, 33 as control subjects. 
one study used a cohort of new-born babies as control group.25 A subanalysis of the studies 
in which only population-based control subjects were used, showed a change in M-H odds 
ratio for FVL from 1.35 to 1.15 (95% CI: 0.84-1.57) and from 1.32 to 1.05 (95% CI: 0.49-2.27) for 
prothrombin gene variant (table 4). 
Although ethnic origin can be an important confounder when studying genetically determined 
coagulation disorders, it was mentioned in only six studies.19, 25, 31-33, 35 Because of this small sample 
size, we did not perform a subgroup analysis of the relationship between ischemic stroke and 
ethnic origin.
COCOS study
Five patients (4%) and 4 controls (3%) were heterozygous for the FVL mutation. none of the 
participants were homozygous for the FVL mutation. the oR of ischemic stroke associated 
with the FVL mutation was 1.3 (95%CI: 0.27-6.6). two patients (2%) and 5 controls (4%) had 
the G20210A prothrombin gene variant. Again no homozygous mutations were found in 
cases or controls. the oR of ischemic stroke associated with the prothrombin 20210A gene 
variant was 0.4 (95% CI: 0.04-2.49). the oR did not change after adjustment for smoking, use of 
contraceptives, hypertension or diabetes for both coagulation disorders. 
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the mean prothrombin activity was significantly higher in participants with the G20210A 
prothrombin gene variant than in participants without the mutation (1.08 U/ml versus 1.32 
U/ml, p<0.0001, student’s t). the mean prothrombin activity in patient group as a whole was 
1.09 ± 0.16 U/ml and in controls it was 1.10 ± 0.16 U/ml, (p=0.6). After exclusion of all individuals 
with the prothrombin gene variant, the mean prothrombin activity in controls slightly changed 
to 1.09 ±0.15 U/ml. In the convalescent phase, the mean prothrombin activity in patients 
was 1.11 ± 0.19 U/ml compared with 1.10 ± 0.16 U/ml in controls. Females had significantly 
higher prothrombin levels than males 1.12± 0.15 U/ml versus 1.06 ± 0.12 (p=0.0007). the 
prothrombin activity was also significantly higher in participants with hypercholesterolemia. 
Age, hypertension, smoking and type of stroke did not influence the prothrombin level. the 
oR of ischemic stroke in the fourth quartile of prothrombin activity was 1.03 (95%CI: 0.58-1.85) 
during the first blood examination. three months later the oR in the highest quartile versus 
the lower was 2.0 (95 % CI: 0.90-4.37). After adjustment for oral contraceptives the oR slightly 
increased to 2.2 (95% CI: 0.96-4.90) (Figure 2a and 2b). 
Figure 2a: Relative risk (odds ratios) for ischemic stroke according to prothrombin (PT) level during the first blood sample in the acute phase. 
Patients and controls were stratified according to PT level: first quartile <0.98, second quartile 0.98-1.08, third quartile 1.08-1.20, fourth 
quartile 1.20 U/ml or higher. Mean PT level in each quartile are indicated on the x-axis. Odds ratios (OR) were computed for patients in the 
second, third and fourth quartile as compared with the first quartile. The 95% confidence interval of the odds ratio for the second quartile was 
0.45-1.85, for the third quartile 0.37-1.51, for the fourth quartile 0.45-1.86.
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Figure 2b: Relative risk (odds ratios) for ischemic stroke according to prothrombin (PT) level during the second blood sample in the convalescent 
phase. Patients and controls were stratified according to PT level: first quartile <0.99, second quartile 0.99-1.18, third quartile 1.18-1.23, fourth 
quartile 1.23 U/ml or higher. Mean PT level in each quartile are indicated on the x-axis. Odds ratios (OR) were computed for patients in the 
second, third and fourth quartile as compared with the first quartile. The 95% confidence interval of the odds ratio for the second quartile was 
0.59-4.36, for the third quartile 0.19-1.97, for the fourth quartile 0.76-5.67.
DISCUSSIon
Systematic review
In this study, we systematically reviewed case-control studies that addressed the association 
between prothrombin 20210A gene variant or FVL mutation and the occurrence of ischemic 
stroke. the M-H odds ratio for the association with ischemic stroke was 1.35 (95% CI: 1.11-1.65) 
for FVL mutation and 1.32 (95% CI: 0.95-1.84) for prothrombin gene variant. the results of this 
meta-analysis, based on studies published between 1995 and 2000, suggest that FVL is a weak 
risk factor for stroke. Although the effect of the prothrombin gene variant is probably of similar 
direction and magnitude, it was just not statistically significant. 
Some studies included patients with hemorrhagic stroke although the aim was to investigate 
the relationship between ischemic stroke and genetically determined coagulation disorders.19,26 
Hemorrhagic events are unlikely to be caused by FVL mutation or prothrombin gene variant. 
Furthermore, in some studies, the diagnosis of ischemic stroke was not reliable because no 
imaging studies were done at all16,17,36 or only in a proportion of the patients.13 Both for FVL 
mutation and the prothrombin gene variant the relative risk of stroke seemed to increase when 
we excluded the studies without a high stroke-type verification rate through brain imaging. 
this finding emphasizes the importance of valid inclusion criteria.37-39 
Some studies included children with stroke.15, 18, 20, 24 In children, FVL may be a stronger risk factor 
than in adults.40-42 we could not assess the effect of age on the possible relationship between 
prothrombotic conditions and ischemic stroke, as we could not re-analyse the data from each 
study. therefore, we could assess the influence of age only on study level. After excluding those 
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studies with at least one patient who was younger than 18 years, the possible relationship 
between ischemic stroke and FVL mutation or prothrombin gene variant disappeared. this 
suggests that these genetically determined prothrombotic conditions may be especially 
important at a relatively young age. However, these prothrombotic conditions may also interact 
with the atherosclerotic process, especially in high risk patients. this interaction will be missed 
if not specifically sought for, in particular if the study is restricted to young patients with stroke 
of undetermined (i.e. non-atherosclerotic) origin.
ethnic origin was not mentioned in the majority of studies.11,13,15-21, 23, 24, 26, 27, 29, 34, 36 Geographic 
and demographic differences in prevalence of FVL mutation and prothrombin gene variant are 
well know.38,43 we did not analyze the studies in which ethnic origin was mentioned separately 
because of their small number. Although an unequivocal definition of race is difficult to give44, 
future studies should control for ethnicity either by matching, or by modifying their inclusion 
criteria for patients as well as for controls. 
none of the studies assessed the relative risk that was associated with the phenotype that 
corresponds to the genetic defect, in this case resistance to activated protein C, or prothrombin 
level in plasma. this could be of importance, as more than one genetic defect could cause 
the phenotype, which means that the association between the occurrence of stroke and the 
phenotype could be stronger. on the other hand, assessment of phenotype could make the 
associations more plausible. 
Publication bias may severely distort the results of a meta-analysis. In general, papers with 
positive results are more likely to become published. we performed a funnel plot in StAtA with 
the funnel command45 to qualitatively assess the effect of bias in these analyses. In a funnel 
plot the trials’ effect estimates are plotted against the sample size. the funnel plot is based on 
the fact that precision in estimating the underlying association will increase as the sample size 
of the studies increases. our funnel plot did not suggest bias, because the plot resembles a 
symmetrical inverted funnel (Figure 3).46 
It has been suggested that, as the randomized clinical trial is the paradigm of occurrence 
research, it would be wise to use similar criteria of inclusion for case-control studies as would 
have been used to include patients for a large (population-based) cohort study.47 In this light, 
the choice of population controls is easier to defend than that of hospital controls.  Interestingly, 
both the association of FVL mutation and prothrombin gene variant with stroke disappeared 
when only studies with population-based controls were considered. However, these large 
studies concerned mostly elderly subjects without confirmation of the ischemic stroke by 
means of Ct. In this meta-analysis, Ct confirmation, age and type of controls were important 
confounding factors. In our opinion, future studies of FVL mutation, prothrombin 20210A gene 
variant or similar potential risk factors for ischemic stroke should include young stroke patients, 
confirm the ischemic nature of the stroke by brain imaging, use population based controls, and 
assess the corresponding phenotypes.
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Figure 3a and 3b: Funnel plot of effect size (x-axis) versus sample size (y-axis) in case-control studies of factor V Leiden mutation (3a, upper) and 
Prothrombin 20210A gene variant (3b, lower) as a possible risk factor for stroke.
COCOS study
Although our systematic review of the literature suggested a weak association between ischemic 
stroke and FVL mutation and G20210A prothrombin gene variant, we cannot corroborate an 
association by means of the results of the CoCoS study. However, high prothrombin levels 
in the absence of the G20210A prothrombin gene variant seemed to be a risk factor for the 
occurrence of ischemic stroke. 
A strength of this study is that cases were prospectively and consecutively included and 
that all patients underwent neuro-imaging to rule out hemorrhage. we were able to include 
population controls, thus avoiding the biases induced by “hospital controls”. we collected 
detailed information about cardiovascular risk factors, medical history and family history from 
patients as well as controls. All participating subjects were of the Caucasian race and the allele 
frequencies of the polymorphism in the control group were in Hardy-weinberg equilibrium, 
indicating that we studied an unselected group. 
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our findings are in agreement with several larger population studies and case-control studies, 
which were performed after the year 2000.48-52 these studies all reported a relative risk of around 
1.0 with a narrow 95% confidence interval excluding a strong association between both of the 
mutations with the occurrence of ischemic stroke. 
Some authors suggested that FVL mutation or G202120A prothrombin gene variant might 
be a risk factor in subgroups of patients, for example patients with patent foramen ovale53-55, 
with cryptogenic stroke56 or stroke at young age20 whereas others could not support these 
findings.36,48, 49, 58, 59 we cannot comment on subgroups, as subgroup analysis in our population 
was not possible because of the low prevalence of both mutations and the sample size of the 
study. 
In our study, elevated prothrombin levels were associated with an increased stroke risk. 
this finding is in agreement with that of one other retrospective case-control study in young 
ischemic stroke patients described in chapter 2.1.60 It is unlikely that prothrombin merely acted 
as an acute phase reactant since it was elevated long after the acute event as well as in controls, 
a finding that was also reported by Poort et al.2 the association between prothrombin levels in 
the absence of the G20210A prothrombin gene variant and the occurrence of ischemic stroke 
has not been reported before. Prothrombin may be elevated due to other genetic variations 
within the prothrombin gene or due to metabolic or endogenous factors. Gender was correlated 
with prothrombin activity that was higher in women than in men. As the patients and controls 
were sex-matched, gender is not a possible confounder in our study. Higher prothrombin 
levels were measured in participants with hypercholesterolemia. However, the frequency 
of hypercholesterolemia was not significantly different between patients and controls. High 
prothrombin levels are reported in combination with the use of oral contraceptives.61 After 
adjustment for this factor, our results did not change essentially.
In conclusion, an association between the FVL mutation and G20210A prothrombin gene 
variant and the occurrence of ischemic stroke in the Caucasian is highly unlikely. Consequently, 
there is no indication for routinely screening of these genetic coagulation disorders in these 
patients. Future studies should focus on carefully selected subgroups of patients such as 
ischemic stroke patients with patent foramen ovale or patients of specific geographic area or 
race, for instance the Mediterranean origin. Furthermore, elevated prothrombin levels seem to 
be associated with an increased risk of ischemic stroke. this association as well as its underlying 
pathophysiological mechanism, needs to be further investigated in larger studies.
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ABStRACt
Background: Increased fibrinogen level is a risk factor for ischemic stroke. Fibrinogen 
promoter gene polymorphisms are associated with fibrinogen levels. the aim of this study was 
to study whether the –148C/t fibrinogen gene promoter polymorphism increases stroke risk 
by modifying fibrinogen level. 
Methods: we performed a case-control study among patients with first ever ischemic stroke, 
confirmed by Ct. All patients were screened for cardiovascular risk factors, cardiac disorders 
and large vessel disease. Patients with a definite non-atherosclerotic cause of the stroke, oral 
anticoagulants or age over 75 years were excluded. Venous blood samples were collected for 
fibrinogen level and routine coagulation tests one week after the stroke. the measurements 
could be repeated after 3 months in about half of the patients. Population controls were age 
-and sex-matched, and did not have a history of stroke. the -148C/t fibrinogen polymorphism 
was determined by PCR followed by digestion with restriction enzymes HindIII/AluI. 
Results: we included 124 patients and 125 controls. the mean age was 56 years (range 18 
to 75). thirty four patients (27%) and 41 (33%) controls were heterozygous for the -148 C/t 
fibrinogen polymorphism and 6 (5%) patients and 5 (4%) controls had the t/t genotype. the 
odds ratio of ischemic stroke associated with CC -homozygotes versus t-carriers was 0.8 (95% 
CI: 0.5 to 1.4). the relative risk of ischemic stroke associated with fibrinogen levels in the highest 
quartile was 3.9 (95% CI: 1.9 to 8.4) at one week, but it decreased to 1.4 (95% CI: 0.6 to 3.3) at 3 
months after the stroke.
Conclusion: Fibrinogen levels are associated with stroke, but the -148 C/t fibrinogen gene 
polymorphism is not a strong risk factor for ischemic stroke. High fibrinogen levels most likely 
represent an acute phase response.
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IntRoDUCtIon 
Fibrinogen is a well-known risk factor for myocardial infarction and stroke. Several meta-analyses 
of (nested) case-control studies have confirmed that high fibrinogen levels are associated with 
an increased risk of cardiovascular disease and stroke.1-4 whether this relationship between 
fibrinogen level and stroke marks the inflammatory status of the vessel wall or causally 
contributes to the occurrence of ischemic stroke, is a much debated question.5-11 
Higher fibrinogen levels have been reported in individuals carrying the rare allele of the 
fibrinogen β-promoter gene polymorphisms in the general population.12-16 these genetic 
features could therefore increase stroke risk. An alternative view is that fibrinogen is merely a 
marker of acute phase reactions, and hence an innocent bystander rather than causative agent 
in stroke. However, a combination of both hypothesis is also possible, i.e. that the presence of 
the allele of the promoter gene polymorphism which causes higher levels, could also mediate 
the fibrinogen increase as part of the acute phase response after stroke. 
Fibrinogen is a 340 kDa glycoprotein consisting of 2 sets of 3 polypeptide chains, known as α-
, β-, γ-chains, linked by disulfide bonds. the 3 polypeptide chains are encoded by three different 
genes clustered on chromosome 4 in region q28.17 the β-chain gene has been most extensively 
been studied because the β-chain synthesis is the limiting step in the production of fibrinogen. 
Several promoter polymorphisms of the β-chain gene are described, such as –455G/A, –148 C/t 
and –854 G/A. these polymorphisms are in almost complete linkage disequilibrium.18 the –148 
C/t polymorphism is located close to the consensus sequence of the IL-6 responsive element 
and expression studies show that this polymorphism is functional and determines the response 
to an IL-6 stimulation.19 
A few case-control studies focused on the possible association between the fibrinogen 
promoter gene polymorphisms and stroke. the published results are not in agreement.20-23the 
–455G/A polymorphism, has been reported to be a risk factor for stroke in subgroups only, 
such as patients with lacunar stroke22, with large vessel disease21 or in the japanese race.23 
However, in a prospective cohort study the -148 C/t fibrinogen gene polymorphism was not 
associated with an increased risk of stroke.20 In this study only genotype and not phenotype 
was described. Because the -455 G/A and -148 C/t fibrinogen polymorphisms are in complete 
allelic association18, the results of these studies are contradictory. 
to better understand to what extent the higher risk of stroke as a result of elevated fibrinogen 
levels is genetically determined or an acute phase response, it would be necessary to study the 
polymorphism and fibrinogen levels simultaneously, as well as a sequential measurement of 
the levels of fibrinogen. 
we therefore designed a case-control study, firstly to investigate the possible association 
between the –148 C/t fibrinogen polymorphism and ischemic stroke and secondly, the extent 
to which this association could be explained by the fibrinogen level.
MetHoDS
Study design 
the design of the study has been described extensively in chapter 3 of this thesis. In short, 
CoCoS is a case-control study with prospective inclusion of Caucasian participants with first 
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ever ischemic stroke, confirmed by Ct. Controls are population based, age-and sex-matched, of 
the Caucasian race and not related to the patients. Blood samples for genotype and phenotype 
were drawn under strictly standardised conditions one week after the event and in almost half 
of the patients also after three months. 
Blood samples and procedures
Fibrinogen levels, cholesterol, glyco-Hb, and CRP levels were determined in the blood samples. 
CRP was used as a control parameter of the acute phase response. Fibrinogen was measured 
as described by von Clauss.24 Genomic DnA was isolated from the white cell fraction of citrated 
blood, according to the high-salt concentration standard procedure.25 the –148 C/t fibrinogen 
polymorphism was detected by PCR followed by digestion with restriction enzymes HindIII/
AluI.18 
In patients as well as in controls, we collected detailed information about cardiovascular 
risk factors, such as smoking habit, hyperlipidemia, hypertension, diabetes, use of oral 
contraceptives, and about medical history and family medical history. Patients were screened 
for cardiac abnormalities by means of standard twelve lead eCG examination. A cardiologist 
was consulted in female patients aged 55 years or less, in male patients aged 45 years or less 
and in patients with eCG abnormalities or a history of cardiac disease. In these patients, 24 
hours eCG monitoring, transthoracic and/or transesophageal echocardiography was carried 
out. we did not perform complete cardiac work-up in the older patients, because in this patient 
group, the chance of finding a relevant cardiac cause for the stroke is very low, given a normal 
eeG and the absence of cardiac symptom. Screening for large vessel disease included duplex 
ultrasound or, if indicated, angiography of the carotid or vertebral arteries. 
Statistical aspects
For the -148 C/t mutation with an expected prevalence of the t allele of about 20% in the 
controlgroup26, the minimal detectable odds ratio would be 2 to 3. 
the relationship between the –148 C/t fibrinogen polymorphism and ischemic stroke was 
expressed as an odds ratio with a 95% confidence interval. the fibrinogen levels were divided 
into quartiles and the relationship between fibrinogen level and ischemic stroke was estimated 
by odds ratio per quartile, and for the highest quartile versus the lower three quartiles. Multiple 
logistic regression analysis was used to adjust for possible confounders, such as smoking, 
hypertension, as these vascular risk-factors are known to affect fibrinogen level as well. 
Furthermore, the relationship between genotype and stroke severity was explored by relating 
genotype to a dichotomized Barthel score.
ReSULtS
During the study period 1034 patients with acute stroke were admitted to our hospital. twenty 
percent of the patients had an intracerebral hemorrhage, 13% died within a few days as a result 
of the stroke, 28% had a recurrent ischemic stroke. of the remaining patients, 38% were of 
Caribbean or Mediterranean origin and were therefore not included. one patient was excluded 
later, after she was found to have DIC, induced by a pancreatic malignancy. the final study 
population consisted of 124 patients and 125 controls. In 123 patients and 123 controls, blood 
samples were available for detection of the fibrinogen polymorphism and fibrinogen level. 
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table 1 shows the baseline demographics and vascular risk factors in patients and controls. 
Patients were more often smokers and more often had hypertension, diabetes or were known 
to have cardiovascular disease compared with controls. 
In half of the cases no cause for the ischemic stroke was found according to the toASt 
classification (table 2). In 2 young patients the evaluation was not complete because both 
refused echocardiography. one patient was excluded later on, because she appeared to have 
suffered from DIC, resulting from a pancreatic malignancy. 
Table 1. Baseline characteristics
Cases (n=124) Controls (n=125)
Demographics
Age, yr (sd) 56 (±12) 56 (±12)
Female sex 58 (47%) 59 (47%)
Index event
Stroke: tIA 115: 9 nA
Risk factors
Smoking 61 (49%) 37 (30%)
Hypertension 60 (48%) 24 (19%)
Diabetes 18 (14%) 5 (4%)
Hypercholesterolemia 78 (63%) 84 (67%)
oral contraceptives 11 (19%) 8 (14%)
Positive family history for cardiovascular disease 75 (61%) 56 (45%)
Previous DVt 6 (5%) 0 (0%)
Table 2. Division of stroke subtypes in cases according to the TOAST criteria
toASt n (%)
Large vessel disease 11 (9%)
Cardiac embolism 4 (3%)
Small vessel disease 46 (37%)
other etiology 0 (0%)
Undetermined etiology 61 (49%)
Incomplete evaluation 2 (2%)
thirty four (27%) patients and 41 (33%) controls were heterozygous for –148 C/t fibrinogen 
gene polymorphism and 6 (5%) patients and 5 (4%) controls were homzygous for the t allele. 
the genotype frequencies in controls were in a Hardy-weinberg equilibrium. the odds ratio 
(oR) of ischemic stroke associated with the -148C/t genotype was 0.8 (95% CI:0.4-1.3) and with 
the –148 t/t genotype 1.1 (95% CI: 0.5-1.4, table 3). 
we also estimated the relative risk of stroke associated with the -148 C/t fibrinogen gene 
polymorphism in several subgroups of patients. there were no indications that the polymorphism 
was a risk factor in patients who smoked or had hypertension or diabetes. Furthermore, there 
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were no differences in stroke risk for the fibrinogen gene polymorphism in patients with small 
vessel disease, cardiac embolism or large vessel disease. there was no relationship between 
stroke severity and genotype (data not shown).
Table 3. Genotype frequencies of the –148C/T polymorphism among patients and controls and the odds ratio (with 95% confidence interval) of 
ischemic stroke associated with the CC homozygotes versus T-allele carriers 
Cases (n=123) Controls (n=123) oR (95%CI)
CC 83 (67%) 77 (62%) --
Ct / tt 40 (33%) 46 (37%) 0.8 (0.5-1.4)
In the stroke patients, the highest fibrinogen levels were found in combination with the tt 
genotype and the lowest in combination with the CC genotype (table 4). In controls, there were 
no differences in fibrinogen level according to genotype.
the mean fibrinogen level was higher in patients than in controls (3.7 g/l vs. 3.4 g/l, p<0.02 
student’s t). the blood sample could be repeated at least three months after the ischemic stroke 
in 64 patients. At that time, the mean fibrinogen level had decreased to 3.3 g/l, which did not 
significantly differ from the level in controls. 
Table 4. Mean fibrinogen levels (g/l) and standard deviation (g/l) according to genotype in controls and in patients one week after the stroke(1st 
blood sample) and three months after the stroke (2nd blood sample) n=number of patients or controls, sd=standard deviation
Controls Patients 1st sample Patients 2nd sample
Genotype mean sd n mean sd n mean sd n
CC 3.45 0.6 70 3.62 1.1 81 3.25 0.8 42
Ct 3.34 0.5 38 3.82 0.9 34 3.43 0.6 19
tt 3.38 0.4 4 3.75 0.6 6 4.07 0.7 3
we divided the fibrinogen levels in quartiles and estimated the oR for ischemic stroke per 
quartile fibrinogen (table 5). the odds ratio for ischemic stroke in the highest quartile versus the 
lower three quartiles was 3.9 (95% CI: 1.9-8.5). After adjustment for smoking and hypertension 
the oR was 3.5 (95% CI:1.7-7.2). the oR based on fibrinogen levels in the second blood samples, 
taken three months after the index event, dropped to 1.4 (95% CI: 0.6-3.3).
Table 5. Odds ratio (OR) for ischemic stroke per quartile of fibrinogen level (g/l) 1st blood sample was taken at 1-2 weeks after stroke, 2nd blood 
sample was taken at 3 months after stroke.
1 week after stroke 3 months after stroke
Quartile (fibrinogen range) oR (95% CI) oR (95% CI)
1 (1.9-3.0) Ref ref
2 (3.1-3.5) 0.5 (0.2-1.1) 0.5 (0.2-1.3)
3 (3.6-3.9) 0.6 (0.3-1.4) 0.7 (0.3-1.7)
4 (>3.9) 2.6 (1.1-6.5) 1.01 (0.4-2.7)
4 vs 1-3 3.9 (1.9-8.5) 1.4 (0.6-3.3)
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the mean CRP level was 16 mg/l (median 5mg/l, range 1-215 mg/l) in patients and 4 mg/l 
(median 3 mg/l, range 1-21 mg/l) in controls one week after the stroke. After three months the 
CRP values were equal in both groups and lower than during the first blood examination. CRP 
level was strongly related to fibrinogen early after the stroke (r=0.56).
DISCUSSIon
we studied the association of the -148 C/t fibrinogen gene polymorphism and first-ever ischemic 
stroke in a case-control study among Caucasian subjects. our results showed no association 
between ischemic stroke and the –148 C/t fibrinogen promoter gene polymorphism.
Internal validity
Cases were prospectively and consecutively included. All patients underwent neuro-imaging 
to rule out hemorrhage. we were able to include population controls, thus avoiding the 
biases induced by “hospital controls”. we collected detailed information about cardiovascular 
risk factors, medical history and family history from patients as well as controls. All subjects 
participating were of the Caucasian race and allele frequencies of the polymorphism in the 
control group were in Hardy-weinberg equilibrium, indicating that we studied a representative 
group. 
Because the primary aim of the study was to investigate the influence of a genetic feature, the 
t allele of the fibrinogen polymorphism, on the risk of stroke, bias does not play a role. Although 
the phenotypic expression, i.e. fibrinogen level, may vary, we can assume that genotypes are 
not changed by the occurrence of ischemic stroke. As a consequence of its design our study 
is limited to nonfatal cases of stroke. If the t allele was associated with fatal cases of stroke, we 
would underestimate the true risk for ischemic stroke associated with the presence of the t 
allele. 
External validity
one could argue that our study is not large enough to exclude an association between ischemic 
stroke and the –148 C/t fibrinogen gene polymorphism. the oR in our study was 0.8 with a 
narrow 95% confidence interval of 0.5 to 1.4. Although we did not reach statistical significance 
for the risk, we think we can conclude that the 95% confidence interval indicates that even if 
the polymorphism is a risk factor, it cannot be a strong one. one other (nested case-control) 
study confirms our findings in that it did not find evidence for an increased stroke risk in the 
presence of the polymorphism.20 
we found a statistically significant difference between fibrinogen levels in patients and 
controls one week after the stroke. this finding confirms the already accepted association 
between fibrinogen level and cardiovascular events.1-4 In several nested case-controls studies 
higher fibrinogen levels at baseline were found among patients who developed a stroke during 
the follow-up time with oR’s varying between 1.3 and 2.6 in the highest quartile.2,9,27,28 our oR 
of 1.4 (95%CI: 0.6-3.3) for the highest quartile three months after the stroke is compatible with 
previous studies.
the fibrinogen level in controls was not related to genotype in our study. two other cross-
sectional cohort studies did not find increased fibrinogen levels in individuals with a Ct or tt 
genotype at –148 position of the fibrinogen promoter gene as well.15,29 
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Discussion
there are several explanations for the differences in fibrinogen levels between stroke patients 
and controls that were highly significant shortly after the event but had mostly disappeared 
after 3 months.
Fibrinogen levels are subject to biologic variation, with elevated circulating levels as a 
consequence of an acute phase reaction. this might explain the elevated fibrinogen levels in 
patients one week after the stroke. this is supported by concomitant changes in CRP level, 
an established acute phase glycoprotein. Secondly, other cardiovascular risk factors such as 
hypertension, smoking and diabetes, are associated with higher fibrinogen levels and advanced 
atherosclerosis.30 the lower fibrinogen levels at three months after the stroke could in theory 
have resulted from rigorous treatment of these risk factors, particularly smoking. However, only 
5 patients (4 %) stopped smoking. this could therefore only partly explain our observations.
Apart from the cardiovascular risk factors, Il-6 elevates the fibrinogen level and also the 
CRP level.2,28,31 In one case-control study, the –174 G/C polymorphism of the IL-6 gene was 
associated with higher IL-6 and fibrinogen levels but not with cardiovascular disease.32 In 
contrast, in a recent case-control study the polymorphism was associated with lacunar stroke.33 
It may be that this or another polymorphism of the IL-6 gene, rather than the known fibrinogen 
promoter gene polymorphisms, are associated with the occurrence of ischemic stroke. Since 
the -148 C/t polymorphism lies close to the putative IL-6 responsive element in the fibrinogen 
gene, one could hypothesize that this polymorphism is also within the IL-6 responsive region, 
and therefore its intrinsic effect on the fibrinogen levels, determined by the presence of a C or 
t allele, is additionally modulated by IL-6. this could explain why the fibrinogen levels were 
associated with the -148C/t fibrinogen promoter polymorphic alleles only in patients, but not 
in the group of controls.
In conclusion, the –148 C/t fibrinogen gene polymorphism is not associated with an 
increased risk of ischemic stroke in Caucasian patients. the high fibrinogen levels shortly after 
the stroke most likely represent a nonspecific acute phase response, although a causative or 
prognostic role cannot be excluded. Future studies should focus on other polymorphisms, and 
their phenotypic expression, that may be related to increased acute phase proteins. 
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ABStRACt
Background: Protein Z (PZ) is a vitamin k-dependent plasma protein that plays a role in 
dampening coagulation. It acts as a cofactor in the inhibition of factor Xa by PZ-dependent 
protease inhibitor. the exact role of PZ in arterial thrombosis and ischemic stroke is still 
unknown. the risk of ischemic stroke may be under genetic influence, through modulation of 
plasma levels of PZ. the aim of this study was to determine the association between the intron 
F G79A PZ gene polymorphism, PZ level and ischemic stroke. 
Methods: we performed a case-control study in 124 Caucasian patients with first ever ischemic 
stroke confirmed by Ct, and 125 age-and sex-matched controls the population controls 
were unrelated to the patients and did not have a history of stroke. Patients with a definite 
non-atherosclerotic cause of the stroke, use of oral anticoagulants or age over 75 years were 
excluded. Venous blood samples for PZ level were collected one week and 3 months after 
the ischemic stroke. the G79A PZ gene polymorphism was determined by polymerase chain 
direction and restriction enzyme digestion and PZ levels were determined using a commercially 
available enzyme-linked immunosorbent assay. 
Results: Mean age was 56 years (range 18 to 75). the relative risk of ischemic stroke associated 
with PZ levels in the lowest quartile was 1.9 (95% CI: 1.0 to 3.8) at one week, but it increased to 2.9 
(95% CI: 1.3 to 6.7) at 3 months after the stroke. thirty-nine patients (33%) and 32 (28%) controls 
were heterozygous for the G79A PZ gene polymorphism and 4 (3%) patients and 4 (4%) controls 
had the AA-genotype. the PZ levels were significantly lower in subjects with the AA-genotype 
and intermediate in heterozygote subjects. the odds ratio of ischemic stroke associated with A-
allele carriers versus GG-homozygotes was 1.2 (95% CI: 0.7 to 2.1). All associations were adjusted 
for differences in frequency of cardiovascular risk factors between cases and controls.
Conclusion: Low PZ levels are independently associated with an increased stroke risk. However, 
the G79A PZ gene polymorphism is not a strong risk factor for ischemic stroke. we suggest that 
previous studies were confounded by acute phase reactions. 
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IntRoDUCtIon 
Protein Z (PZ) is a vitamin k dependent single-chain glycoprotein of 62 kDa synthesized in the 
liver. Its amino-terminal sequence is highly homologous to the vitamin k-dependent coagulation 
factors II, VII, IX, X and protein C.1, 2 Although PZ was already purified from bovine plasma in 19773 
and later found in human plasma1, its precise physiological function remains unclear.
Although initial data suggested that PZ deficiency was associated with a bleeding tendency,4 
subsequent clinical studies and a PZ null mice model failed to confirm these observations.5-7 
More recently, PZ was found to act as a cofactor in the inhibition of factor Xa by a plasma protein 
called Z-dependent protease inihibitor (ZPI).2 It therefore seems more likely that low PZ levels 
are associated with a procoagulant rather than an anticoagulant state. Vasse et al8 were the first 
to report a significant association between PZ deficiency and arterial (ischemic stroke) rather 
than venous thrombosis. Further support for a role of low PZ levels and arterial thrombosis 
comes from two additional studies in patients with ischemic stroke and acute coronary 
syndromes9,10 Several other clinical case-control studies, mainly among younger patients, have 
yielded contradictory results (table 1). two studies reported a significant association between 
high (instead of low) PZ levels and the risk of ischemic stroke11,12, whereas other authors found 
no differences in PZ level between patients and controls.13 two studies have investigated the 
PZ levels in the acute as well as the convalescent phase, with conflicting results.10,12 whereas 
the first10 found lower PZ levels in cases, the second12 reported a strong association between 
elevated PZ levels and ischemic stroke in the acute phase, that was no longer present 3 months 
after the stroke.
Table 1. Results of previous case-control studies on protein Z level, PZ gene polymorphism and ischemic stroke
Author year n cases/controls timing of sample PZ levels oR (95%CI) for IS and PM
Protein Z level
Vasse8 2001 169 / 88 convalescent ↓ nA
kobelt11 2001 157 / 192 convalescent ↑ nA
wuillemin14 2001 157 / 192 convalescent ↑ nA
Lopaciuk13 2002 99 / 100 convalescent = nA
Heeb10 2002 154 / 206 convalescent ↓ nA
McQuillan12 2003 173 / 186 acute & convalescent ↑ nA
Intron F G79A PZ gene polymorphism
Lichy17 2004 200 / 199 convalescent nA 0.58 (0.39-0.86)
↑ increased in patients compared to controls; ↓ decreased in patients compared to controls; = no difference between patients and controls. 
the gene encoding for PZ has been characterized and several common single nucleotide 
polymorphisms in the gene have been reported.15,16 Recently, the A allele of the intron F 
polymorphism G79A in the PZ gene was described to be protective for ischemic stroke in the 
young.17 In this study the PZ level was determined only in controls and not in patients. 
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to further clarify the role of PZ level in ischemic stroke and to determine in howfar this 
role is genetically determined, it is necessary to study the polymorphism and PZ plasma level 
simultaneously, as well as a sequential measurement of the PZ level. we therefore studied the 
association between the PZ G79A promoter gene polymorphism, PZ level and ischemic stroke 
among first ever ischemic stroke patients and population controls of the same genetic area. 
MetHoDS
Study design 
we performed a case-control study with prospective inclusion of the participants. Cases 
were consecutively recruited patients with first ever acute ischemic stroke, admitted to the 
department of neurology of a university hospital, between January 1999 and December 2001. 
this hospital is an urban area hospital without specific selection criteria for the admission of 
stroke patients. However, young stroke patients are referred more frequently to this center 
than to the non-academic centers in the region. Fifty percent of the urban population consists 
of Caribbean or Mediterranean habitants. we used population controls, i.e partners, friends 
or neighbours of the patients. they were age-and sex matched, of the same race, without a 
history of stroke and not related to the patient. the local ethics board approved the study and 
informed consent was obtained form all subjects.
Inclusion and exclusion criteria
Patients, controls and their parents were born in northern europe and of the Caucasian race, 
because substantial differences in the prevalence of genetically determined coagulation 
disorders between people from different geographical regions or race have been reported.16 
Patients with a definite non-atherosclerotic cause for the stroke like mechanical heart valve, 
endocarditis or carotid dissection were excluded. other exclusion criteria were age above 75 
years and the use of oral anticoagulants. 
Definitions and measurements
Ischemic stroke was defined as the acute onset of focal cerebral dysfunction due to cerebral 
ischemia with symptoms lasting more than 24 hours. Patients with tIA (symptoms lasting less 
than 24 hours) were included only if the neurological deficit in the acute phase was observed by 
a neurologist. In all patients a Ct scan of the brain was made within three days after the onset of 
symptoms to confirm the diagnosis of ischemic stroke and to rule out hemorrhagic stroke. 
Clinical stroke subtypes were classified according to the oCSP criteria, adjusted for Ct 
findings.18 etiologic stroke type was classified according to the toASt criteria.19 we defined 
large artery atherosclerosis as a stenosis of presumed atherosclerotic origin in the symptomatic 
extracranial carotid or in the basilar artery of more than 50%. Stroke severity was assessed with 
the Barthel index at inclusion.20
Hypertension was defined as systolic blood pressure above 160 mm Hg or diastolic blood 
pressure above 90 mmHg 5 days after the event, or the use of antihypertensive medication. 
Hyperlipidemia was defined as fasting cholesterol level above 5.0 mmol/l or use of lipid lowering 
drugs. Diabetes mellitus was defined as the use of antidiabetic medication or glycosylated 
hemoglobin level over 6.5%. Myocardial infarction was defined as typical chest pain with 
documented elevated cardiac enzymes or confirmation by eCG. Deep venous thrombosis had 
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to be confirmed by compression ultrasonography or phlebology and pulmonary embolism by 
ventilation-perfusion scan or computed tomography of the chest. 
Blood samples and procedures
one week and 3 months after the stroke, venous blood samples were taken under strictly 
standardized conditions as the patients were in fasting condition, with no exposure to cigarette 
smoking or alcohol for at least the preceding 8 hours. Venapuncture was performed after 15 
minutes of rest. we measured PZ levels, cholesterol, glyco-Hb, and CRP levels. CRP was used as a 
control parameter of the acute phase response. PZ was measured using a commercially available 
elisa (Asserachrom® protein Z, Roche Diagnostics, Almere, the netherlands). the interassay-
and intra-assay variation were 6.6% and 2.9% respectively. Genomic DnA was isolated from 
the white cell fraction of citrated blood, using a standard salting out procedure.21 the PZ gene 
polymorphism was detected by amplification of a 320 bp sequence. each 30 μl PCR reaction 
contained 20ng genomic DnA, 12.5 pmol of each primer (5’-tAA CAC CAt AGA CAG AGt CCG 
AtA ttC GC-3’ and 5’-AtG AAC tCG GCA ttA GAA CAt GGt tGG AA-3’.), 150 nmol of each dntP, 
0.75 U taq polymerase (Amersham) en PCR buffer (Amersham). the reaction components were 
incubated at 94ºC for 4 min, followed by 32 cycles of 94ºC for 1 min, 57ºC for 1 min and 74ºC 
for 1 min. Digestion for at least 1 hour at 37ºC with Hpal yielded 2 products of 221 and 99bp 
in length in the presence of the A allele, whereas the G allele was not digestible. the digestion 
products were separated by electrophoresis through a 2% agarose gel and visualized under 
UV-light.17
In both patients and controls, we collected detailed information about cardiovascular 
risk factors, such as smoking habit, hyperlipidemia, hypertension, diabetes, use of oral 
contraceptives, and about medical history and family medical history. Patients were screened 
for cardiac abnormalities by means of standard twelve lead eCG examination. A cardiologist 
was consulted in female patients aged 55 years or less, in male patients aged 45 years or less, 
and in patients with eCG abnormalities or a history of cardiac disease. In these patients, 24 hours 
eCG monitoring, transthoracic and/or transesophageal echocardiography was performed. 
Screening for large vessel disease included duplex ultrasound or, if indicated, angiography of 
the carotid or vertebral arteries. 
Statistical aspects
For the PZ gene G79A polymorphism with an expected prevalence of the A allele of about 
20% in the controlgroup16 with a power of 80% and a significance level of 5%, the minimal 
detectable odds ratio would be 2.3 
the relationship between the G79A PZ gene polymorphism and ischemic stroke was analysed 
using logistic regression analysis and expressed as an odds ratio with a 95% confidence interval. 
the PZ levels were divided into quartiles and the relationship between PZ level and ischemic 
stroke was estimated as odds ratio of each quartile against the lowest quartile, and for the 
lowest quartile versus the higher three quartiles. the logistic regression analysis was used to 
adjust for possible confounders, such as smoking, hypertension, diabetes and oral contraceptive 
use, as these vascular risk-factors are known to affect PZ level as well as cardiovascular risk. 
Furthermore, the relationship between genotype and stroke severity was explored by relating 
genotype to a dichotomized Barthel score (0-19 vs. 20 pts). 
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ReSULtS
During the study period 1034 patients with acute stroke were admitted to our hospital. twenty 
percent of the patients had an intracerebral hemorrhage, 13% died within a few days, 28% had a 
recurrent ischemic stroke. of the remaining patients, 38% were of Caribbean or Mediterranean 
origin and were therefore excluded. one patient was excluded later, after she was found to 
have diffuse intravascular coagulation, induced by a pancreatic malignancy. the final study 
population consisted of 124 patients and 125 controls. Because in several participants some 
blood samples were not collected for logistical reasons, blood samples were available in 118 
patients and 113 controls for detection of the PZ gene polymorphism and in 102 patients and 
107 controls for the PZ level. In about half of the patients the blood sample could be repeated 
more than three months after the index event. In the other half the blood sample could not be 
repeated because patients stayed in a nursing-home outside the area of our hospital, used oral 
anticoagulants or had died. none of the subjects had a significant vitamin k deficiency or liver 
dysfunction, since the FX levels varied between 75% and 164% of normal values. 
table 2 shows the baseline demographics and vascular risk factors in patients and controls. 
Patients were more often smokers and more often had hypertension, diabetes or were known 
to have cardiovascular disease compared with controls. 
In half of the cases no cause was found according to the toASt classification. eleven patients 
(9%) suffered from large vessel disease and 46 (37%) from small vessel disease. In four patients 
(3%) a probable source of cardio embolism was detected. In two young patients (2%) the 
evaluation was not complete because both refused echocardiography. 
Table 2. Baseline characteristics
Cases (n=124) Controls (n=125)
Demographics
Age, yr (sd) 56 (±12) 56 (±12)
Female sex 58 (47%) 59 (47%)
Index event
Stroke: tIA 115: 9 nA
Risk factors
Smoking 61 (49%) 37 (30%)
Hypertension 60 (48%) 24 (19%)
Diabetes 18 (14%) 5 (4%)
Hypercholesterolemia 78 (63%) 84 (67%)
oral contraceptive 11 (19%) 8 (14%)
Family history of cardiovascular disease 75 (61%) 56 (45%)
Previous DVt 6 (5%) 0 (0%)
TIA=transient ischemic attack, DVT=deep venous thrombosis
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In the acute phase the mean PZ level in patients and controls was almost equal (1.64 ± 0.6 μg/
ml ±vs. 1.77 ± 0.6 µg/ml respectively, p=0.11 student’s t). In the convalescent phase the mean 
PZ level in patients dropped to 1.47 ± 0.6 µg/ml, which was significantly lower than during 
the acute phase (p<0.008, student’s t), and significantly lower than in controls as well (p<0.005, 
student’s t) (figure 1).
we divided the PZ levels in quartiles and estimated the relative risk for ischemic stroke 
in the lowest quartile versus the higher three quartiles. During the acute phase, the oR for 
ischemic stroke associated with low PZ level was 1.7 (95% CI: 0.9-3.2). After adjustment for 
smoking, hypertension, diabetes and oral contraceptives the oR changed to 1.9 (95% CI: 1.0-
3.8). exclusion of patients who did not have a second sample did not affect the relationship of 
PZ levels in the acute phase with stroke occurrence. In the convalescent phase, three months 
later, the oR for lowest quartile of PZ level versus the higher three was 3.4 (95% CI: 1.6-7.3) 
and remained highly significant after adjustment, i.e. 2.9 (95% CI: 1.3-6.7) (table 3). odds ratio’s 
increased monotonously with each quartile of protein Z level (p for trend = 0.006)
Table 3. Adjusted odds ratio (OR) for ischemic stroke per quartile and for lowest quartile versus higher three quartiles during the acute and 
convalescent phase. 95% CI=95% confidence interval; #p for trend=0.12; +p for trend=0.006
1st blood sample 2nd blood sample
Quartile oR (95% CI)# oR (95% CI)+
4 Ref Ref
3 1.8 (0.8-3.3) 2.6 (1.0-6.7)
2 1.1 (0.5-2.5) 3.5 (1.3-9.9)
1 2.5 (1.2-5.2) 5.0 (1.8-12.5)
1 vs. 2-4 1.9 (1.0-3.8) 2.9 (1.3-6.7)
H 4.3 figure 1 
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Figure 1. Protein Z levels in controls and patients 1 week and 
3 months after the ischemic stroke
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In patients as well as controls, those with diabetes mellitus had higher PZ levels (p<0.05, 
student’s t). In patients older than 45 years, the PZ levels in the acute phase as well as in the 
convalescent phase were significantly lower than in age-matched controls (1.82 μg/ml vs. 1.61 
μg/ml, p<0.02, student’s t, and 1.82 μg/ml vs 1.53 μg/ml, p<0.02, student’s t, respectively)
the mean CRP level was 16 mg/l (median 5mg/l, range 1-215 mg/l) in patients and 4 mg/l 
(median 3 mg/l, range 1-21 mg/l) in controls one week after the stroke. After three months the 
mean CRP values were equal in both groups and lower than during the first blood examination. 
there was no correlation between CRP levels and PZ levels in both blood samples (Spearman’ 
rho 0.02, p=0.83).
In controls, the highest PZ levels were found in combination with the GG genotype and the 
lowest in combination with the AA genotype. In patients also the highest levels were found in 
the GG genotype in the acute phase as well as in the convalescent phase. the presence of the 
A-allele was associated with lower levels, but there were no statistically significant differences 
between the heterozygous and homozygous A-genotype in patients (table 4).
Table 4. Mean protein Z levels (g/l) and standard deviation (g/l) according to genotype in controls and in patients one week after the stroke(1st 
blood sample) and three months after the stroke (2nd blood sample) n=number of patients or controls, sd=standard deviation
Controls Patients 1st sample Patients 2nd sample
Genotype mean sd n mean sd n mean sd n
GG 1.90 0.61 68 1.79 0.51 65 1.6 0.65 27
GA 1.56 0.46 28 1.43 0.64 30 1.2 0.49 18
AA 0.81 0.04 3 1.61 0.49 3 - - 0
total 1.77 0.61 107 1.64 0.59 102 1.46 0.62 47
thirty nine (33%) patients and 32 (28%) controls were heterozygous for G79A PZ gene 
polymorphism and 4 (3%) patients and 4 (4%) controls were homozygous for the A-allele. the 
genotype frequencies in controls were in Hardy-weinberg equilibrium. the odds ratio (oR) 
of ischemic stroke associated with A-allele carriers versus GG-homozygotes was 1.2 (0.7-2.1). 
After exclusion of patients who did not have a second blood sample, the association between 
genotype and the occurrence of ischemic stroke was not different from that of the group as a 
whole. 
we also estimated the relative risk of stroke associated with the PZ gene polymorphism in 
several subgroups of patients. there were no indications that the polymorphism was a risk factor 
in patients who smoked or had hypertension or diabetes. Furthermore, no differences in stroke 
risk for the PZ gene polymorphism in patients with small vessel disease, cardiac embolism or 
large vessel disease was found. neither was there a relationship between stroke severity and 
genotype (data not shown).
88
Ch
ap
te
r 4
.3
DISCUSSIon
we studied the association between PZ gene polymorphism and PZ levels with ischemic stroke 
in a case-control study among Caucasian subjects. we found a trend towards lower levels of PZ 
in patients compared with controls shortly after the stroke. three months after stroke onset, 
the PZ levels in patients were significantly lower than in controls. Furthermore, we observed a 
strong correlation between genotype and PZ levels. the genotype, however, was not associated 
with the occurrence of ischemic stroke. 
Internal validity
A strength of this study is that cases were prospectively and consecutively included and that all 
patients underwent a detailed assessment, including neuro-imaging to rule out hemorrhage. 
we were able to include population controls, thus avoiding the biases induced by “hospital 
controls”. we collected detailed information about cardiovascular risk factors, medical history 
and family history from patients as well as controls. All participating subjects were of the 
Caucasian race and the allele frequencies of the polymorphism in the control group were in 
Hardy-weinberg equilibrium, indicating that we studied an unselected group. 
A limitation of this study is the inclusion of mainly nonfatal cases of stroke. If the A-allele 
would be associated with fatal stroke, we underestimate the true risk for ischemic stroke 
associated with the presence of the A-allele. 
A further limitation was the small number of patients in whom we were able to obtain a 
blood sample 3 months after the onset of stroke, which raises the possibility of selection bias. 
However, the similar age, sex and genotype distribution does not support that. Moreover, our 
results did not change after exclusion of patients with only one blood sample. 
we did find a relationship of protein Z level with presence of the A allele in controls, and 
a relationship between decreased protein Z level and stroke. one would therefore expect 
therefore that more stroke patients would have the A allele than controls, but this was not the 
case. the most likely explanation is in our view the existence of a yet unknown polymorphism 
that is alsoassociated with decreased protein Z levels. A systematic laboratory error that could 
explain differences in prot Z level is excluded, because all samples were assessed in one batch, 
by one laboratory assistant, who was not aware of the status of the samples.
Other studies
our findings are in accordance with two other case-controls studies8,10 that reported an 
increased risk of stroke in subjects with low PZ levels. Furthermore, our results are in agreement 
with recent pathophysiological studies that described a much higher relevance of PZ in 
humans as a mediator of factor X inhibition than as a procoagulant agent.2,5 our results are 
in discordance with two previously reported studies, investigating PZ level in the acute phase 
and the convalescent phase together.12 one study10 found no differences in PZ levels measured 
within 4 days and 2 months after the stroke. the other study12 reported significantly higher 
PZ levels in the acute phase, whereas that difference had disappeared three months later. In 
our study, during the first sample the PZ levels were slightly lower in patients than in controls 
and significantly higher than in the convalescent phase. the different findings of PZ can be 
possibly explained by the moment the blood samples were taken. we measured the PZ level 7 
to 14 days after the event, whereas McQuillan et al12 took blood samples within the first week, 
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when the acute phase response is more pronounced. the presence of an acute phase response 
in our study was supported by concomitant changes in CRP level, an established acute phase 
glycoprotein. the difference between the two studies in PZ levels in the convalescent phase 
cannot be explained by influence of a mild vitamin k deficiency as FX antigen level were 
normal in cases as well as controls. the use of oral anticoagulant therapy does not provide an 
explanation as this was an exclusion criterion for our study. Another reason for the difference 
could be that we included by chance only patients with the AA-genotype, which is associated 
with low PZ levels, during the convalescent phase. However, the distribution of the genotype 
frequencies was not different from that during the acute phase. Moreover, the oR for low PZ 
levels and ischemic stroke did not change when only the patients in whom blood samples were 
taken during both phases were considered. Furthermore, our results during the convalescent 
phase disagree with those from two case-controls studies11-13, but are supported by the majority 
of the pathophysiological1,2,5 and clinical studies.8-10, 13
one could argue that our study is not large enough to exclude an association between 
ischemic stroke and the G79A PZ gene polymorphism. the oR in our study was 1.2 with a narrow 
95% confidence interval of 0.7 to 2.1, which indicates that even if the polymorphism is a risk 
factor, it cannot be a strong one. one other study that addressed the relationship between PZ 
gene and stroke reported a protective role of genetically determined low PZ levels in juvenile 
cerebral ischemia.17 In our population, there were no differences in the genotype distibution 
of the PZ G79A gene polymorphism in the study as a whole or in the young participants. 
we cannot explain this difference since the allele frequencies in controls in both studies were 
in Hardy-weinberg equilibrium, and the participants in both studies represented a genetically 
homogeneous group. In the same study17, the PZ level was determined only in a part of the 
control group. the authors inferred that high PZ levels could be a risk factor for ischemic stroke 
because the A-allele, that is associated with lower PZ levels, was more frequent in the control 
group. As the PZ levels in patients were not determined, we think it is premature to conclude 
that high PZ levels are associated with ischemic stroke, particularly since our results and those 
of three other studies suggest the opposite.8,10,11
the first aim of our study was not to unravel the pathophysiological mechanism of PZ in 
ischemic stroke. However, as low PZ levels in the convalescent phase were independently 
associated with an increased risk of ischemic stroke, a causative role for PZ in ischemic stroke 
seems likely. this is supported by our finding that the lowest PZ levels were measured in 
patients older than 45 years, in whom also other cardiovascular risk factors were more prevalent. 
It may be that an (atherosclerotic) vascular lesion is necessary for PZ deficiency to affect the 
risk of stroke. this view is supported by one study that showed that PZ is present in human 
atherosclerotic lesions, suggesting involvement of PZ in the process of atherogenesis.22 the 
exact role of PZ in the pathogenesis of atherothrombosis clearly needs further study.
our study demonstrates an independent association between low blood plasma levels of PZ 
and an increased risk of ischemic stroke in Caucasian patients. Further studies are necessary 
to confirm this association and to elucidate the possible causal nature of this association. 
Such studies should focus on PZ gene polymorphisms and PZ level simultaneously in stroke 
populations of different ethnicity and age.
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ABStRACt
Background: High levels of plasminogen activator inhibitor type 1 (PAI-1) have been implicated 
as a risk factor for cardiovascular disease, but its precise role remains controversial. the 4G allele 
of the PAI-1 4G/5G promoter polymorphism is associated with higher levels of PAI-1. we studied 
the relationship between ischemic stroke and the PAI-1 4G/5G polymorphism and PAI-1 antigen 
levels. 
Methods: we performed a case-control study among patients aged 18-75 years with first 
ischemic stroke, confirmed by Ct. All patients were screened for cardiovascular risk factors, 
cardiac disorders and large vessel disease. we excluded patients with a definite non-
atherosclerotic cause of the stroke and patients using oral anticoagulants. Population-controls 
were age -and sex-matched, without a history of stroke, and of the Caucasian race. the PAI-1 
4G/5G polymorphism was detected by allele-specific PCR amplification. Venous blood samples 
were taken for PAI-1 level one week after the stroke, under strictly standardized conditions. 
Results: we included 124 patients and 125 controls. Mean age was 56 yrs (range 18 to 75 
yrs). Sixty one patients (50%) and 58 (47%) controls were heterozygous for the PAI-1 4G/5G 
polymorphism. the homozygous 4G/4G genotype was found in 33 patients (27%) and also in 
36 controls (29%). the odds ratio of ischemic stroke associated with 4G-carriers versus 5G/5G 
homozygotes was 1.0 (95% CI: 0.6-1.8). the relative risk of ischemic stroke associated with the 
level of PAI-1 in the upper quartile was 0.73 (95%CI: 0.4 to 1.4). 
Conclusion: neither the PAI-1 4G/5G polymorphism nor the PAI-1 antigen level is a strong risk 
factor for ischemic stroke.
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IntRoDUCtIon 
Increased levels of the plasminogen activator inhibitor-1 (PAI-1) have been reported in patients 
with myocardial infarction and stroke.1-3 whether these increased levels are a result of a genetic 
variation of the PAI-1 gene, and whether they increase the risk of ischemic stroke is not yet 
clear. 
PAI-1 is a glycoprotein with a molecular weight of approximately 50 kD that serves as the 
major physiological inhibitor of tissue plasminogen activator (t-PA), thereby attenuating 
fibrinolysis.4,5 the human PAI-1 gene is located on chromosome 7 and several polymorphisms 
within this gene are associated with PAI-1 level in plasma.6,7 A common polymorphism, located 
in the promoter region, consists of a single guanosine insertion/deletion variation (4G or 5G), 
resulting in two alleles containing either 4 or 5 guanosines in a row. In the general population, 
an association has been found between the 4G/5G polymorphism and the PAI-1 level, with 
individuals homozygous for the 4G allele having a significantly higher PAI-1 concentration in 
plasma.7 thus, the 4G allele could increase the risk of ischemic stroke through its association 
with high PAI-1 levels, that inhibit endogenous fibrinolysis.
the association of PAI-1 level and the 4G/5G polymorphism has been more extensively 
studied in myocardial infarction than in stroke. A recent meta-analysis of nine studies showed 
a significant 20% increased risk of myocardial infarction for the 4G/4G genotype.8 In stroke 
patients, studies have yielded conflicting results. Several case-control studies failed to find an 
association, but they often considered selected patients, such as women, patients with tIA and 
minor stroke or even hemorrhagic stroke.2,9,10 Furthermore, most studies reported on genotype 
only instead of genotype and phenotype simultaneously. Recently, the 4G allele was reported 
to be protective for ischemic stroke in the elderly.11 In the same age group in women, the allele 
has been associated with a reduced mortality from stroke.12 In contrast, in another case-control 
study, the 4G/4G genotype was found to be an independent risk factor for atherothrombotic 
stroke.13 Finally, a recent and large prospective follow-up study could not support an association 
between the PAI-1 polymorphism and stroke in the elderly.14
to clarify whether a higher risk of stroke as a result of elevated PAI-1 levels is genetically 
determined, it would be of interest to study the PAI-1 polymorphism and its phenotypic 
expression simultaneously in a well defined population.
we therefore designed a case-control to investigate the possible association between 4G/5G 
PAI-1 gene promoter polymorphism and the occurrence of ischemic stroke and secondly, to 
study the role of PAI-1 level.
MetHoDS
Study design 
the design of the study has been described extensively in chapter 3 of this thesis. In short, 
CoCoS is a case-control study with prospective inclusion of Caucasian participants with first 
ever ischemic stroke, confirmed by Ct. Controls are population based, age-and sex-matched, of 
the Caucasian race and not related to the patients. Blood samples for genotype and phenotype 
were drawn under strictly standardised conditions one week after the event and in almost half 
of the patients also after three months. 
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Blood samples and procedures
Blood for the detection of PAI-1 concentration was drawn using the vacutainer system and 
collected in CtAD- tubes, containing citrate and platelet stabilizing agents (Beckton Dickenson, 
Plymoth,Uk). Blood was centrifuged for 20 min at 4ºC and plasma was stored using small aliquots 
at -80ºC until use. PAI-1 level, cholesterol and glyco-Hb were determined in the blood samples. 
PAI-1 antigen levels were measured using a commercially available eLISA (tintelize®PAI-1, 
Biopool, Umea, Sweden) and were expressed in ng/ml. Genomic DnA was isolated from the white 
cell fraction of citrated blood, according to the high-salt concentration standard procedure.15 
the PAI-1 4G/5G gene polymorphism was detected by allele-specific PCR amplification.16
Statistical aspects
the relationship between the 4G/5G PAI-1 gene polymorphism and ischemic stroke was 
expressed as an odds ratio with a 95% confidence interval. the PAI-1 levels were divided into 
quartiles and the relationship between PAI-1 level and ischemic stroke was estimated by odds 
ratio for the highest quartile versus the lower three quartiles. Multiple logistic regression analysis 
was used to adjust for possible confounders, such as smoking, hypertension, as these vascular 
risk-factors are known to affect PAI-1 level as well. Furthermore, we assessed the relationship 
between genotype and stroke severity by relating genotype to a dichotomized Barthel score 
(0-19 vs. 20 points).17 
ReSULtS
During the study period 1034 patients with acute stroke were admitted to our hospital. 
twenty percent of the patients had an intracerebral hemorrhage, 13% died within a few days 
as a result of the stroke, 28% had a recurrent ischemic stroke. of the remaining patients, 38% 
were of Caribbean or Mediterranean origin and were therefore not included. one patient was 
excluded later, after she was found to have DIC, induced by a pancreatic malignancy. the final 
study population consisted therefore of 124 patients and 125 controls. In 123 patients and 
123 controls, blood samples were available for detection of the PAI-1 polymorphism and PAI-1 
level. 
Population characteristics
table 1 shows the baseline demographics and vascular risk factors in patients and controls. 
Patients were more often smokers and more often had hypertension, diabetes or previous 
cardiovascular disease than controls. 
In half of the cases no cause for the stroke was found according to the toASt classification. 
eleven patients (9%) suffered from large vessel disease and 46 (37%) from small vessel disease. 
Four patients (3%) had a probable cardiac source of embolism. In two young patients (2%) the 
evaluation was not complete because both refused echocardiography.
Genotype distribution
the distribution of PAI-1 genotypes in patients was: 4G/4G, 33 (27%), 4G/5G, 61 (49%) and 5G/5G 
29 (24%). when compared with the matched controls, whose genotype distribution was, 4G/4G, 
36 (29%), 4G/5G, 58 (47%) and 5G/5G 29 (24%), there were no significant differences. the allele 
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frequencies in patients were 0.52 for 4G and 0.48 for 5G, compared with 0.53 for 4G and 0.47 
for 5G in controls. the genotype frequencies in controls were in Hardy-weinberg equilibrium. 
the odds ratio (oR) of ischemic stroke associated with the 4G-allele versus 5G/5G-homozygotes 
was 1.0 (95% CI: 0.6-1.8). there was no difference in relative risk of ischemic stroke between 
heterozygous and homozygous 4G-genotype (table 2).
Table 1. Baseline characteristics
Cases (n=124) Controls (n=125)
Demographics
Age, yrs (sd) 56 (12) 56 (12)
Female sex 58 (47%) 59 (47%)
Index event
Stroke: tIA 115: 9 nA
Risk factors
Smoking 61 (49%) 37 (30%)
Hypertension 60 (48%) 24 (19%)
Diabetes 18 (14%) 5 (4%)
Hypercholesterolemia 78 (63%) 84 (67%)
oral contraceptives 11 (19%) 8 (14%)
Family history of cardiovascular disease 75 (61%) 56 (45%)
Previous DVt 6 (5%) 0 (0%)
Table 2. Frequencies of 4G/5G PAI-1 gene polymorphism among patients and controls and the odds ratio (with 95% confidence interval) of 
ischemic stroke associated with the PAI-1 gene polymorphism 
Cases (n=123) Controls (n=123) oR (95%CI)
5G/5G 29 29 reference
4G/5G 61 58 1.1 (0.6-2.0)
4G/4G 33 36 0.9 (0.5-1.8)
Frequency of 5G allele 0.48 0.47
Frequency of 4G allele 0.52 0.53
PAI-1 levels
the mean PAI-1 level was lower in patients than in controls, 22.9 ng/ml vs. 25.1 ng/ml respectively, 
but this difference was not statistically significant (student’s t p>0.22). we divided the PAI-1 
level in quartiles and the relative risk for stroke in the highest quartile versus the lower three 
quartiles was 0.74 (95% CI: 0.4-1.4). In patients as well as in controls, the highest PAI-1 levels 
were associated with the 4G/4G genotype (table 3).
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Table 3. Mean PAI-1 level (ng/ml) and standard deviation (ng/ml) according to genotype in controls and in patients one week after the stroke 
n=number of patients or controls, sd=standard deviation
Controls Patients 
Genotype mean sd n mean sd n
4G/4G 28.3 16.8 35 25.3 17.5 31
4G/5G 25.6 14.6 57 21.5 12.5 58
5G/5G 20.3 12.7 28 22.7 10.4 28
Subgroups
we estimated the relative risk of stroke associated with the PAI-1 promoter gene polymorphism 
in several subgroups of patients. there were no statistically significant differences in the 
distribution of genotypes according to gender, smoking habits, hypertension, diabetes or stroke 
type. there was no relationship between stroke severity and genotype (data not shown). 
In controls, the mean PAI-1 level was higher in subjects with diabetes (38.1 vs. 24.5, p<0.04). In 
patients, we found no differences in PAI-1 level in those with or without diabetes (24.5 vs.22.6, 
p>0.59). Similarly, the mean PAI-1 level was significantly higher in controls with hyperlipidemia 
(27.3 vs.20.7, p<0.02) than in those without, whereas in patients no differences were found in 
PAI-1 levels in those with or without hyperlipidemia (24,6 vs. 20.1, p=0.08).
DISCUSSIon
Internal validity
the strength of our study is the prospective and consecutive inclusion of patients by a neurologist. 
Furthermore, all patients underwent neuro-imaging to rule out hemorrhage. we were able to 
include population controls, thus avoiding the biases induced by “hospital controls”. we collected 
detailed information about cardiovascular risk factors, medical history and family history from 
patients as well as controls. All subjects participating were of the Caucasian race and allele 
frequencies of the polymorphism in the control group were in Hardy-weinberg equilibrium, 
indicating that we studied a representative group. 
Because the primary aim of the study was to investigate the influence of a genetic feature, 
the 4G allele of the PAI-1 polymorphism, on the risk of stroke, confounding by other variables is 
unlikely. Although the phenotypic expression, i.e. PAI-1 level, may vary, it is unlikely that genotype 
is affected by confounding variables or by the occurrence of ischemic stroke. As a consequence 
of its design our study is limited to nonfatal cases of stroke. If the 4G allele was associated with 
fatal cases of stroke, we would underestimate the true risk for ischemic stroke associated with the 
4G allele. 
PAI-1 levels in patients were not increased in comparison with controls. the blood samples in 
patients and controls were collected according to eCAt procedures18 and taken under strictly 
standardized conditions, i.e. in fasting condition, with no exposure to alcohol or nicotine and after 
15 minutes of rest. By doing so, we were able to exclude the confounding influence on the PAI-1 
level by smoking, diabetes or physical exercise. therefore, we think that the measurements of the 
PAI-1 level and the lack of difference in PAI-1 level between patients and controls are valid. these 
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results are in agreement with one other case-control study.19 In some other studies that reported 
on PAI-1 level and stroke, non-fasting blood samples were taken.1,2,11 this might explain the higher 
PAI-1 levels in patients, especially since cardiovascular risk factors that increase the PAI-1 activity 
like smoking, diabetes and hyperlipidemia were more prevalent in the patient group. Furthermore, 
in these studies tubes containing citrate were used instead of CtAD-tubes containing platelet 
stabilizing agents. this might further explain the differences in PAI-1 level.
External validity
A limitation of our study is its small size. one could argue that our study is not large enough to 
exclude an association between ischemic stroke and the PAI-1 4G/5G polymorphism. the oR in 
our study was 1.0 with a narrow 95% confidence interval of 0.6 to 1.8. our study indicates that even 
if the polymorphism is a risk factor, it cannot be a strong one. this observation is in agreement 
with several other case-controls studies that also found no evidence for an increased stroke risk in 
the presence of the polymorphism.2,14,19,20 our results are not consistent with a recent prospective 
study that described a protective effect against stroke for the 4G allele in the elderly.11 In that 
study the population was not in Hardy-weinberg equilibrium, which may suggest selection bias. 
other studies that reported the 4G allele to be protective for stroke also concerned subgroups of 
patients, like young women10 or patients with minor stroke.9 on the other hand, one other case-
control study concluded that the 4G allele is a significant risk factor in a selected patient group of 
atherothrombotic stroke.13 Selection of patients might partly explain the heterogeneous results 
of the studies concerning the 4G/5G polymorphism of the PAI-1 gene and stroke.
In our study, the highest PAI-1 levels were associated with 4G allele in patients as well as controls, 
which is in agreement with the accepted relation between PAI-1 level and the 4G allele.16,21 elevated 
plasma PAI-1 level is a core feature in the insulin resistance syndrome (IRS). this syndrome is defined 
as a cluster of abnormalities, which includes obesity, glucose intolerance and dyslipidemia and 
which is strongly related with low grade inflammation.22 In our control population, PAI-1 levels 
were higher in those having diabetes and hyperlipidemia. An explanation for this might be that 
these cardiovascular risk factors are better treated in the patient group. However, only a small 
percentage of the patients suffered from diabetes and there was no difference in the prevalence 
of hyperlipidemia between patients and controls. this does not provide enough explanation why 
the PAI-1 level was not increased in our patients. 
the relationship between elevated PAI-1 levels and myocardial infarction (MI) seems to be more 
straightforward than the relationship between PAI–1 and ischemic stroke. An explanation for 
this could be the difference in pathophysiological mechanism between MI and ischemic stroke. 
In MI patients, rupture of atherosclerotic plaques is considered the most important underlying 
mechanism. Atherosclerotic plaques are associated with elevated PAI-1 levels.23 In stroke patients, 
small vessel disease and thromboembolism without significant large vessel disease are more 
common causes of cerebral ischemia than carotid and aortic arch atherosclerosis.24 this may, at 
least partially, explain the lack of association. 
In conclusion, our results indicate that PAI-1 promoter gene polymorphism is not a risk factor 
for ischemic stroke. Although our results confirm the association between plasma PAI-1 level and 
genotype, they do not support the hypothesis that increased PAI-1 levels are an important risk 
factor for ischemic stroke. 
Future studies should focus on other promoter gene polymorphisms and their phenotypic 
expression, to further examine to which extent genetically determined coagulation disorders 
contribute to the occurrence of ischemic stroke.
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ABStRACt
Background: the -1C/t polymorphism of the annexin A5 (AnxA5) gene has been associated 
with myocardial infarction. whether this polymorphism is also a risk factor for ischemic stroke 
is unknown. 
Methods: we performed a case-control study among patients with first ischemic stroke, 
confirmed by Ct. Population-controls were age-and sex-matched, and did not have a history 
of stroke. the -1C/t AnxA5 polymorphism was detected by PCR of exon 2 of the AnxA5 gene, 
followed by restriction fragment length polymorphism (RFLP) analysis using the restriction 
enzyme.
Results: we included 124 patients and 125 controls. Mean age was 56 yrs (range 18 to 75 yrs). 
thirty (25%) patients and 23 (24%) were heterozygous for the -1C/t AnxA5 gene polymorphism 
and 1 (1%) patient and 1(1%) control were homozygous for the t-allele. the odds ratio of 
ischemic stroke associated with t-allele carriers versus CC-homozygotes was 1.1 (95%CI: 0.6-
2.0).
Conclusion: the -1C/t AnxA5 gene polymorphism is not a strong risk factor for ischemic 
stroke.
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IntRoDUCtIon 
It has been suggested that annexin A5 (AnxA5) has a regulatory role in hemostasis, by regulating 
the exposure of negatively charged phospholipids ions and prolonging the phospholipid-
dependent coagulation reactions.1 AnxA5 has various antithrombotic properties. It prevents 
formation of prothrombinase and tenase complexes and inhibits platelet aggregation and 
thrombus formation both in vitro as in vivo.2,3
the AnxA5 gene has been described in 19944, followed by the discovery of a polymorphism 
(-1C/t) in the kozak sequence of the gene.5 the -1C/t polymorphism has been shown to play 
a protective role against myocardial infarction in young patients and it has been suggested 
that this is due to an increased translation efficiency resulting in increased levels of AnxA5.6 
In the same study, no association was found in other groups of patients such as patients with 
spontaneous intracranial hemorrhage, deep venous thrombosis or coronary heart disease.6 on 
the other hand, a recent case-control study reported a slight non significant increase in the risk 
of myocardial infarction in men in the presence of the -1C/t polymorphism.7 Furthermore, in a 
control population the levels of AnxA5 were not affected by the –C/t polymorphism.8 
to our knowledge, the association between the AnxA5 kozak sequence (-1C/t) polymorphism 
and ischemic stroke has not been studied before. the aim of this study was to investigate 
the role of the -1C/t polymorphism of the AnxA5 gene in ischemic stroke in a well-defined 
Caucasian population. 
MetHoDS
Study design
the design of the study has been described extensively in chapter 3 of this thesis. In short, 
CoCoS is a case-control study with prospective inclusion of Caucasian participants with first 
ever ischemic stroke, confirmed by Ct. Controls are population based, age-and sex-matched, of 
the Caucasian race and not related to the patients. Blood samples for genotype and phenotype 
were drawn under strictly standardised conditions one week after the event and in almost half 
of the patients also after three months. 
Blood samples and procedures
one week after the stroke, venous blood samples were taken. Genomic DnA was isolated from 
the white cell fraction of citrated blood, according to the high-salt concentration standard 
procedure.9 the –1C/t AnxA5 polymorphism was detected by PCR of exon 2 of the AnxA5 gene, 
followed by restriction fragment length polymorphism (RLPF) analysis using the restriction 
enzyme ncol.8
Statistical aspects
For the -1 C/t mutation with an expected prevalence of the t allele of about 12% in the control 
group6, the minimal detectable odds ratio would be 2.7 (β=20%, α=5%). the relationship 
between the AnxA5 –1 C/t polymorphism and ischemic stroke was expressed as an odds ratio 
with a 95% confidence interval. Furthermore, the relationship between genotype and stroke 
severity was assessed, by relating genotype to a dichotomized Barthel score (0-19 vs. 20 pts). 
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ReSULtS AnD DISCUSSIon
our study population consisted of 124 patients and 125 controls. In 118 patients and 97 controls, 
blood samples were available for detection of the AnxA5 gene polymorphism. 
table 1 shows the baseline demographics and vascular risk factors in patients and controls. 
Patients were more often smokers and more often had hypertension, diabetes or were known 
to have cardiovascular disease compared with controls. 
In half of the cases no cause was found according to the toASt classification. eleven patients 
(9%) suffered from large vessel disease and 46 (37%) from small vessel disease. In four patients 
(3%) a probable source of cardio embolism was detected. In two young patients (2%) the 
evaluation was not complete because both refused echocardiography.
Table 1. Baseline characteristics
Cases (n=124) Controls (n=125)
Demographics
Age, yr (sd) 56 (±12) 56 (±12)
Female sex 58 (47%) 59 (47%)
Index event
Stroke: tIA 115: 9 nA
Risk factors
Smoking 61 (49%) 37 (30%)
Hypertension 60 (48%) 24 (19%)
Diabetes 18 (14%) 5 (4%)
Hypercholesterolemia 78 (63%) 84 (67%)
oral contraceptives 11 (19%) 8 (14%)
Family history of cardiovascular disease 75 (61%) 56 (45%)
Previous DVt 6 (5%) 0 (0%)
thirty (25%) patients and 23 (24%) controls were heterozygous for –1 C/t AnxA5 gene 
polymorphism and 1 (0.9%) patient and 1 (1.0%) control were homozygous for the t allele. 
the genotype frequencies in controls were in Hardy-weinberg equilibrium. the odds ratio (oR) 
of ischemic stroke associated with the CC-homozygotes versus t-allele carriers was 1.1 (95% 
CI: 0.6-2.0). the allelic frequencies are comparable to the results published in other control 
populations and patients with myocardial infarction.6,7,10 
we estimated the relative risk of stroke associated with the -1C/t AnxA5 gene polymorphism 
in several subgroups of patients. there were no statistically significant differences in the 
distribution of genotypes according to gender, smoking habits, hypertension, diabetes or stroke 
subtype according to toASt. Furthermore, there was no relationship between stroke severity 
and genotype (data not shown). 
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A strength of our study is that cases were prospectively and consecutively included by a 
neurologist. Furthermore, all patients underwent neuro-imaging to rule out hemorrhage. we 
were able to include population controls, thus avoiding the biases induced by “hospital controls”. 
we collected detailed information about cardiovascular risk factors, medical history and family 
history from patients as well as controls. All subjects participating were of the Caucasian race 
and allele frequencies of the polymorphism in the control group were in Hardy-weinberg 
equilibrium, indicating that we studied a representative group. 
Table 2. Genotype frequencies of the AnxA5 –1C/T gene polymorphism among patients and controls and the odds ratio (with 95% confidence 
interval) of ischemic stroke associated with the CC homozygotes versus T-allele carriers 
Cases (n=118) Controls (n=97) oR (95%CI)
CC 87 (74%) 73 (75%) reference
Ct/ tt 31 (26%) 24 (25%) 1.1 (0.6-2.0)
A limitation of this study is the inclusion of mainly nonfatal cases of stroke. If the t-allele 
would be associated with fatal cases of stroke, we underestimate the true risk for ischemic 
stroke associated with the presence of the t allele. Because the primary aim of this study 
was to investigate the influence of a genetic feature, the t allele of the AnxA5 –1C/t gene 
polymorphism, on the risk of stroke, bias does not play a role here. 
this is the first study on the association between ischemic stroke and the AnxA5 -1C/t gene 
polymorphism. we conclude that the polymorphism is not a strong risk for ischemic stroke. 
Although the t-allele has been associated with myocardial infarction, this study does not 
provide evidence for an important role of the AnxA5 -1C/t gene polymorphism in ischemic 
stroke. 
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ABStRACt 
Background: thrombin-activatable fibrinolysis inhibitor (tAFI) is a recently described 
fibrinolysis inhibitor that attenuates fibrinolysis by cleaving the C-terminal lysines of partially 
degraded fibrin, thereby reducing plasminogen activation. Increased levels of tAFI have been 
associated with an increased risk of venous thrombosis. A role in the pathogenesis of arterial 
thrombosis, such as acute myocardial infarction, has been suggested in several studies, but 
results have been contradictory. 
Methods: we studied tAFI antigen levels, functional tAFI levels using a new clot lysis based 
assay, and three tAFI gene polymorphisms in 125 patients with a recent ischemic stroke, and 
compared this with an age- and sex- matched control group.
Results: Clot lysis times were significantly increased in patients compared to controls (clot lysis 
time 47.3 ± 3.8 min vs. 44.1 ± 3.7 min, p<0.00001). Functional tAFI levels, defined as tAFI-related 
retardation, the difference in clot lysis time in the absence or presence of a specific tAFI inhibitor 
potato carboxypeptidase inhibitor (PCI), were significantly higher in patients than controls 
(19.5 ± 4.2 min vs. 17.7 ± 3.7 min, p <0.005). Individuals with clot lysis times and tAFI-related 
retardation in the highest quartile had a markedly increased risk of ischemic stroke compared 
with the lowest quartile (oR 8.2, CI 3.2-21.3, and 4.0, CI 1.6-9.8 respectively). no difference was 
found between patients and controls with respect to tAFI antigen levels and tAFI –438A/G, 
505G/A and 1040C/t genotype.
Conclusion: we conclude that an increase of functional tAFI levels, resulting in a decreased 
fibrinolysis, is associated with a marked increased risk of ischemic stroke.
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IntRoDUCtIon
Several studies have indicated that reduced fibrinolysis, for instance due to increased PAI-1 levels, 
may be associated with the risk of acute ischemic stroke.1-4 thrombin-activatable fibrinolysis 
inhibitor (tAFI) is a more recently described fibrinolysis inhibitor of which the role in the 
pathogenesis of ischemic stroke is not yet clear. the known physiological role of activated tAFI 
is the inhibition of fibrinolysis by removing C-terminal lysine and arginine residues of partially 
degraded fibrin, thereby slowing the rate of tissue plasminogen activator-induced plasminogen 
activation.5-7 tAFI also inhibits plasminogen activation induced by other plasminogen activators.8 
A role of tAFI in arterial thrombosis, including unstable angina pectoris and myocardial infarction, 
has been suggested, but is still controversial.9-13 In patients with symptomatic coronary heart 
disease (CHD) contradictory results concerning tAFI antigen levels have been reported, some 
studies showing elevated levels in CHD9-11, whereas others found decreased levels.12,13 this may be 
caused by a difference in study populations, but also due to a difference in assay characteristics, 
for instance antibody specificity.14,15 
one recent study found increased tAFI activity levels in patients with a history of ischemic 
stroke.16 In addition, one other small study showed increased tAFI antigen levels shortly after 
the occurrence of ischemic stroke.17 So far at least 14 polymorphisms in the tAFI gene have 
been identified, and some of these are strongly associated with plasma tAFI antigen levels.18-20 
therefore, it is of interest to study the allele frequencies of tAFI gene polymorphisms also in 
patients with ischemic stroke.
we determined tAFI gene polymorphisms, as well as functional tAFI levels and tAFI antigen 
levels in patients with a recent acute ischemic stroke to further explore the possible association 
between tAFI and ischemic stroke.
MetHoDS
Study design 
we performed a case-control study with prospective inclusion of the participants. Cases 
were consecutively recruited patients with first ever acute ischemic stroke, admitted to the 
department of neurology of a university hospital, between January 1999 and December 2002. 
we used population controls, i.e partners, friends or neighbours of the patients. they were age- 
and sex matched, did not have a history of stroke and were not related to the patient. 
Inclusion and exclusion criteria
Patients, controls and their parents should be born in northern europe and be of the Caucasian 
race, because substantial differences in the prevalence of genetically determined coagulation 
disorders have been reported between people from different geographical regions or race. 
Patients with a definite non-atherosclerotic cause of the stroke, such as a mechanical heart 
valve, endocarditis or carotid dissection were excluded. other exclusion criteria were age above 
75 years and the use of oral anticoagulants. 
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Definitions and measurements
Ischemic stroke was defined as the acute onset of focal cerebral dysfunction due to cerebral 
ischemia with symptoms lasting more than 24 hours. Patients with tIA (symptoms lasting less 
than 24 hours) were included only if the neurological deficit in the acute phase was witnessed 
by a neurologist. In all patients a Ct of the brain was made within three days from the onset of 
symptoms to confirm the diagnosis of ischemic stroke and to rule out hemorrhagic stroke. Clinical 
stroke subtypes were classified according to the oCSP criteria, modified by Ct.21 etiologic stroke 
type was classified according to the toASt criteria.22 we defined large artery atherosclerosis as 
a stenosis of presumed atherosclerotic origin in the symptomatic cervical artery of more than 
50%. Stroke severity was assessed with the Barthel index.23 Hypertension was defined as systolic 
blood pressure above 160 mm Hg or diastolic blood pressure above 90 mm Hg 5 days after the 
event, or the use of antihypertensive medication. Hypercholesterolemia was defined as fasting 
cholesterol level above 5.0 mmol/l or use of lipid lowering drugs. Diabetes mellitus was defined 
as the use of antidiabetic medication or glyco-Hb >6.5%. Myocardial infarction was defined as 
typical chest pain with documented elevated cardiac enzymes, or confirmation by eCG. Deep 
venous thrombosis had to be confirmed by compression ultrasonography or phlebology and 
pulmonary embolism by ventilation-perfusion scan or spiral computed tomography of the 
chest. 
In patients as well as in controls, we collected detailed information about cardiovascular 
risk factors, such as smoking habit, hyperlipidemia, hypertension, diabetes, use of oral 
contraceptives, and about medical history and family medical history. Patients were screened 
for cardiac abnormalities by means of standard twelve-lead eCG examination. A cardiologist 
was consulted in female patients aged 55 years or less, in male patients aged 45 years or less 
and in patients with eCG abnormalities or a history of cardiac disease. In these patients, 24 
hours eCG monitoring, transthoracic and/or transesophageal echocardiography was carried 
out. Screening for large vessel disease included duplex ultrasound or, if indicated, angiography 
of the carotid or vertebral arteries.
Blood samples and procedures
Between 7-14 days after the stroke, venous blood samples were taken under strictly standardized 
conditions. the patients were in fasting condition, with no exposure to cigarette smoking or 
alcohol for at least the preceding 8 hours and the drawing of blood took place after 15 minutes 
of rest. Blood was collected in citrate (0.105 M) using a Vacutainer system (Beckton Dickinson, 
Plymouth, Uk). the blood was centrifuged (2000x g for 30 min at 4°C) and the collected plasma 
was stored in aliquots at -70°C until use. Genomic DnA was isolated from the white cell fraction 
of citrated blood, according to the high-salt concentration standard procedure.24 
Analysis of TAFI gene polymorphisms
Determination of the -438A/G, 505A/G (Ala147thr) and 1040 C/t (thr325Ile) genotype was 
performed using polymerase chain reaction (PCR) and subsequent restriction analysis. the 
-438A/G and 1040 C/t (thr325Ile) polymorphism were analyzed by duplex PCR and digestion 
analysis. the PCR conditions have been previously described.12 the end volume of the PCR 
mixture was 25 µl and contained: 50 ng genomic DnA, 37.5 pM of each primer, 1.5 mM of each 
dntP (Pharmacia), 2.5 µL buffer (15 mM MgCl2, 500 mM kCl, 100 mM tris-HCl, pH 8.3) and 1.25 
U taq DnA polymerase (Boehringer Mannheim). the PCR conditions used for all PCR reactions 
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were: 4 min 95° C of initial denaturation, followed by 32 cycles of 1 min of denaturation at 94° 
C, 1 min annealing at 58° and 62° C resp and 2 min of elongation at 72° C. the PCR products 
were digested with their specific restriction enzymes for 180 min at 37°C and analyzed on a 
2.5% agarose gel.
TAFI Functional Assay 
tAFI functional assay based on clot lysis was performed as described elsewhere (Guimarães 
et al., manuscript in preparation). Briefly, 100 µl of diluted plasma samples (20-fold dilution 
of individual plasmas in tAFI-depleted plasma) were added to the wells of a microtitre plate 
containing 25 µl of a reaction mix composed of thrombin, thrombomodulin, CaCl2 and r-tPA 
(concentrations in the final mixture: 3.3 nIH units/ml, 0.6 units/ml, 20 mM, and 0.10 µg/ml 
respectively), after which clots were formed. A control with addition of potato carboxypeptidase 
inhibitor (PCI) was tested for each sample (concentration in the final mixture 30 µg/ml). the 
wells were immediately covered with paraffin oil and the plate was placed in a pre-warmed 
incubation chamber (37oC, teCAn Sunrise Microplate-reader). the optical density at 405 nm 
was monitored for 150 min. Lysis time (Lt) was defined as the time point corresponding to a 50% 
decrease in optical density. Functional tAFI levels were calculated as tAFI-related retardation 
(Rt), defined as the difference between the lysis time in the absence and in the presence of PCI, 
(Lt(-PCI) - Lt(+PCI)). 
Recombinant tPA (Actilyse) was kindly supplied by Boehringer Ingelheim (Ingelheim, 
Germany). Human thrombin and PCI were purchased from Sigma (St Louis, Mo, USA) and 
Calbiochem (La Jolla, CA, USA), respectively. Rabbit lung thrombomodulin, with a specific activity 
towards thrombin of 1.2 units/μg, was acquired from American Diagnostica Inc (Greenwich, Ct, 
USA).
Plasma TAFI Antigen level determination
Plasma tAFI Ag levels were determined by means of a sandwich eLISA consisting of an affinity-
purified sheep anti-tAFI IgG raised against tAFI purified from plasma as a capture antibody, and 
HRP-conjugated affinity-purified sheep anti-tAFI IgG for detection (Affinity Biologicals, kordia, 
Leiden, the netherlands). this assay measures total tAFI antigen, including tAFI, activated tAFI 
(tAFIa) and inactivated tAFIa. All the necessary buffers and reagents were prepared according 
to the manufacturer’s instructions. normal plasma from Chromogenix was used as reference 
material arbitrarily defined to contain 100% tAFI antigen.
Statistical aspects
For the tAFI 1040C/t (thr325Ile) polymorphism with an expected prevalence of the tt genotype 
of 10% in the control group, the minimal detectable odds ratio associated with the tt genotype 
would be 2.8 (with an α=0.05, β=0.80). the relationship between the tAFI gene polymorphisms 
and ischemic stroke was expressed as an odds ratio (oR) with a 95% confidence interval (CI). 
the clot lysis times (Lt), tAFI-related retardation (Rt), and tAFI antigen levels were divided into 
quartiles, based on the measurements in both cases and controls. the relationship between Lt, 
Rt, and tAFI antigen levels and ischemic stroke was estimated by odds ratio per quartile. Multiple 
logistic regression analysis was used to adjust for possible confounders, such as smoking, 
hypertension, age, as these vascular risk-factors may be associated with variations in tAFI levels. 
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ReSULtS
Patient population
the baseline characteristics of patients and controls are given in table 1. Stroke subtypes were 
classified according to the toASt criteria and are also given in table 1. Smoking, hypertension 
and diabetes occurred more frequently in the patients compared to controls. 
Table 1. Baseline characteristics
Patients (n=124) Controls (n=125)
Demographics
Age, yr (sd) 56 (±12) 56 (±12)
Female sex 58 (47%) 59 (47%)
Index event 
Stroke: tIA 115: 9
Stoke subtypes (toASt criteria)
Large vessel disease 11 (9%) nA
Cardiac embolism 4 (3%)
Small vessel disease 46 (37%)
Undetermined etiology 61 (49%)
Incomplete evaluation 2 (2%)
Risk factors
Smoking 61 (49%) 37 (30%)
Hypertension 60 (48%) 24 (19%)
Diabetes 18 (14%) 5 (4%)
Hypercholesterolemia 78 (63%) 84 (67%)
oral contraceptives 11 (19%) 8 (14%)
Previous DVt 6 (5%) 0 (0%)
TAFI activity and antigen levels in ischemic stroke
Functional tAFI levels were measured by means of a clot lysis assay in tAFI-depleted plasma. 
Clot lysis time (Lt (-PCI) ) was significantly increased in patients with ischemic stroke compared 
with controls 47.3 ± 3.8 min vs. 44.1 ± 3.7 min (p<0.00001, table 2), which indicates less efficient 
fibrinolysis in patients with ischemic stroke compared to controls. Clot lysis times were also 
determined in the presence of a specific tAFI inhibitor, potato carboxypeptidase inhibitor 
(PCI). tAFI-related retardation (Rt), defined as the difference in clot lysis time (Lt) measured 
in the absence (Lt (-PCI) ) and presence (Lt(+PCI)) of PCI (Lt (-PCI) – Lt(+PCI )), was increased in patients 
compared with controls, which reflects higher functional tAFI levels in ischemic stroke (table 2). 
the results of Lt (-PCI) and Rt of the individual patients and controls are shown in figure 1.
we subdivided the individuals according to quartiles of clot lysis time (Lt(-PCI) ) and Rt, of 
which the results are given in figure 2. A significant association between Lt(-PCI) and Rt and 
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the risk of ischemic stroke was found. Individuals with the highest Lt(-PCI) (4
th quartile) had a 
markedly increased risk of ischemic stroke: odds ratio (oR) of 8.2, confidence interval (CI) 3.2-
21.3 compared to the lowest quartile (figure 2). this was also found when the highest quartile 
was compared with the lower three quartiles (oR 5.0, CI 2.1-11.0). this finding reflects the 
relative increase of the number of patients compared with controls in the upper quartile of 
Lt(-PCI) (43 patients in the 4
th quartile vs 13 controls). Similar findings were obtained when the 
tAFI-related retardation (Rt) were divided into quartiles (oR 4.0, CI 1.6-9.8, highest quartile vs 
lowest quartile, Figure 2).
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Figure 2. Risk of ischemic stroke expressed in 
odds ratio’s for every quartile of both clot lysis 
time (LT-PCI) (upper figure) and TAFI related 
retardation (RT= LT-PCI-LT+PCI) (lower figure). 
Odds ratios are given above the bars. 
Figure 1. Clot lysis times (LT-PCI) (left figure) and TAFI-related retardation (RT= LT-PCI-LT+PCI) (right figure) in patients with ischemic stroke and 
controls. The horizontal lines indicate mean value. 
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tAFI antigen levels were not significantly different between patients and controls, with mean 
values of 103 % and 101.5 % respectively (oR 1.0) (table 2). After dividing tAFI antigen levels 
into quartiles no increased risk of stroke was seen in individuals with the highest tAFI antigen 
levels (highest quartile vs. lowest quartile, oR 1.3, CI 0.6-3.0). 
Table 2: TAFI antigen levels and functional TAFI in patients and controls
Patients
(n=124)
Controls
(n=125)
P value*
odds Ratio
(95% CI)
tAFI ag (%) 103.0± 31.3 101.5 ± 34.5 0.74; ns 1.00 (0.99-1.01)
Lt-PCI (min) 47.3 ± 3.8 44.1± 3.7 <0.00001 1.25 (1.15-1.36)
Lt+PCI (min) 27.8 ± 2.5 26.4 ± 2.5 <0.0001 1.25 (1.11-1.41)
Rt (min) 19.5 ± 4.2 17.7 ± 3.7 0.0012 1.12 (1.04-1.20)
Data are given as mean ± SD; ag = antigen; LT –PCI = clot lysis time in the absence of potato carboxypeptidase inhibitor (PCI); LT+PCI = clot 
lysis time in the presence of PCI; RT = TAFI-related retardation (LT-PCI – LT+PCI); *two-sample t-test with equal variance
Stroke severity and TAFI levels.
we did not detect a difference between tAFI antigen levels or clot lysis times in different types 
of stroke, subdivided as presented in table 1 (data not shown).
TAFI gene polymorphisms in relation to ischemic stroke.
we could not detect an association between the three studied polymorphisms in the tAFI gene 
and the risk of ischemic stroke. the 1040C/t polymorphism, which codes for the Ile325thr is 
especially important, since this is a functional polymorphism resulting in a difference in half-
life and activity. Also this polymorphism in the tAFI gene was not associated with functional 
tAFI levels: oR Ct + tt vs. CC (reference) is 0.9 (CI 0.6-1.5).the results of all three studied 
polymorphisms are shown in table 3.
TAFI gene polymorphisms in relation to functional TAFI and TAFI antigen levels.
tAFI antigen levels were strongly correlated with all three studied polymorphisms (table 4). this 
was found for both the control group and the patient group. Functional tAFI levels, as measured 
by the tAFI related retardation (Rt), were not associated with the three polymorphisms studied 
(table 5). In our population tAFI antigen levels were not correlated with functional tAFI levels 
(tAFI ag vs Rt: r = 0.09, ns).
120
Ch
ap
te
r 5
.3
Table 3: Associations between TAFI genotype and risk of ischemic stroke 
Genotype Genotype numbers and
allele frequencies
patients (n=124)
Genotype numbers and
allele frequencies
controls (n=125)
oR (95% CI)
1040 C/t
CC
Ct
tt
Ct+tt
C
t
55 (44%)
51 (41%)
18 (15%)
69 (56%)
0.65
0.35
51 (42%)
58 (48%)
12 (10%)
70 (58%)
0.66
0.34
reference
0.82 (0.48-1.39)
1.39 (0.62-3.13)
0.91 (0.55-1.51)
505 G/A
GG
GA
AA
GA+AA
G
A
54 (45%)
53 (44%)
13 (11%)
66 (55%)
0.67
0.33
48 (41%)
51 (44%)
18 (15%)
69 (59%)
0.63
0.37
reference
0.93 (0.54-1.59)
0.64 (0.29-1.43)
0.85 (0.51-1.42)
-438A/G
GG
GA
AA
GA+AA
G
A
61 (49%)
48 (38%)
16 (13%)
64 (51%)
0.68
0.32
61 (50%)
50 (41%)
10 (8%)
60 (49%)
0.71
0.29
reference
0.96 (0.56-1.63)
1.60 (0.67-3.80)
1.07 (0.64-1.75)
Table 4: Association between TAFI antigen levels and TAFI gene polymorphisms
 tAFI antigen levels (%)
Patients n Controls n
tAFI 1040 CC 124.8 ± 22.5 46 123.8 ± 27.1 44
Ct 89.6 ± 18.2 43 92.6 ± 29 52
tt 76.5 ± 40.2 16 52.5 ± 15 10
tAFI 505 GG 95.1 ± 34.4 47 89.1 ± 34.1 42
GA 108.7 ± 23.6 45 105.4 ± 30.5 45
AA 122.6 ± 31.6 9 132.5 ± 23.2 16
tAFI –438 GG 122.0 ± 22.7 51 123.1 ± 26.7 50
AG 90.0 ± 26.0 41 86.9 ± 29.3 47
AA 70.2 ± 26.5 14 60.5 ± 22.0 9
Data given as mean ± SD. TAFI antigen levels were not significantly different between patients and controls for each genotype.
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Functional TAFI levels and base line characteristics
we also studied the association between various baseline characteristics and functional tAFI 
levels in the total study group. tAFI related retardation was not different between males and 
females, individuals with and without diabetes and smokers and non-smokers. Individuals with 
hypertension, hypercholesterolemia and of higher age (>45 years) had increased functional 
tAFI levels (table 6). the results of clot lysis times, Lt(+pci), Lt(-pci), and tAFI-related retardation 
(Rt), shown in table 2 were similar after adjustment for these confounding variables including 
hypertension, diabetes, smoking, age and hypercholesterolemia (data not shown).
Table 5: Association between clot lysis time (LT –PCI) and TAFI-related retardation (LT –PCI – LT+PCI) and TAFI gene polymorphisms 
Clot lysis time (Lt –PCI)
 (minutes)
tAFI-related retardation 
 (minutes)
Patients n Controls n Patients n Controls n
tAFI 1040 CC 47.1 ± 4.2 46 43.6 ± 4.0 43 18.7 ± 4.3 46 16.9 ± 4.1 43
Ct 47.8 ± 3.3 43 44.6 ± 3.2 52 20.8 ± 4.1 43 18.3 ± 3.0 52
tt 46.5 ± 3.8 16 43.2 ± 4.9 10 18.5 ± 4.0 16 16.9 ± 4.6 10
tAFI 505 GG 46.8 ± 4.0 46 43.4 ± 3.7 41 18.8 ± 4.2 46 17.1 ± 3.7 41
AG 47.9 ± 3.6 45 44.0 ± 3.9 45 20.8 ± 4.3 45 17.9 ± 3.4 45
AA 46.3 ± 4.0 10 46.0 ± 3.2 16 17.1 ± 3.9 10 18.3 ± 4.4 16
tAFI –438 GG 47.4 ± 4.4 51 44.1 ± 3.9 49 19.2 ± 4.6 51 17.4 ± 4.2 49
AG 47.4 ± 2.9 41 44.4 ± 3.1 46 20.1 ± 3.8 41 18.0 ± 2.9 46
AA 46.5 ± 4.0 14 42.3 ± 5.4 9 18.8 ± 4.3 14 16.9 ± 4.8 9
Data given as mean ± SD
Table 6: Effects of metabolic and environmental variables on functional TAFI levels (expressed as TAFI-related retardation LT (-PCI) – LT(-PCI) in 
minutes) in the total study group.
Variable Yes (n) no (n) P value
Smoking 18.6 ± 4.3 (85) 18.6 ± 4.0 (117) 0.92
Hypercholesterolemia 19.2 ± 3.7 (136) 17.6 ± 4.5 (76) 0.0058
Age >45 years 19.1 ± 4.0 (170) 16.7 ± 4.0 (42) 0.0005
Diabetes 18.1 ± 4.2 (21) 18.7 ± 4.1 (191) 0.563
Hypertension 20.0 ± 3.8 (66) 18.0 ± 4.1 (146) 0.0007
Male sex 19.0 ± 4.0 (114) 18.2 ± 4.2 (98) 0.18
Data are given as mean ± SD
122
Ch
ap
te
r 5
.3
DISCUSSIon
In this study, we found increased clot lysis times, indicative of impaired fibrinolysis in patients 
with a recent ischemic stroke compared with healthy controls. the risk of ischemic stroke was 
strongly associated with fibrinolysis, as was demonstrated by the odds ratio of 8.2 for individuals 
within the highest quartile of clot lysis times compared to the lowest quartile. this was also 
seen, though to a lesser extent, for functional tAFI levels, defined as tAFI-related retardation 
(Rt, Lt (-PCI) – Lt(-PCI) ). this indicates that increased functional levels of tAFI are associated with an 
increased risk of ischemic stroke. 
only two previous studies on tAFI levels in stroke patients have been reported so far. 
Montaner et al. showed in a small study including 30 patients that tAFI antigen levels were 
increased in patients with ischemic stroke.17 Plasma samples were taken within 24 hours of 
onset of the symptoms. therefore the high tAFI antigen levels may be caused by an acute 
phase response, and may not reflect a causative role of tAFI in the development of ischemic 
stroke.9,25 Santamaria et al. performed a case-control study, comparable with our study design.16 
the patients were included at least one month after the event, thereby excluding the influence 
of a potential acute phase response. they measured functional tAFI levels using a synthetic 
substrate based assay. they found that increased functional tAFI levels were associated with 
a 6-fold increased risk of ischemic stroke. the study population consisted of patients with at 
least one previous ischemic event, which may result in a selection of patients with recurrent 
thrombotic events, whereas our patients had a recent first episode of ischemic stroke. Despite 
these differences in patient population our study confirms the finding that increased functional 
tAFI levels are associated with an increased risk of ischemic stroke.
 the mechanism by which increased functional tAFI levels may result in ischemic stroke is 
still unknown. A decreased fibrinolytic potential may result in more stable thrombi, that are 
less prone to lysis. our findings are in concordance with previous studies on other fibrinolysis 
inhibitors, such as plasminogen activator inhibitor type I (PAI-1), of which increased levels are 
also suggested to predispose to arterial thrombosis.2,4
earlier studies have shown that elevated tAFI antigen levels are associated with venous 
thrombosis.18,26 Patients with tAFI antigen levels above the 90th percentile had a two-fold 
increased risk of deep venous thrombosis.26 Also tAFI gene polymorphisms that are related to 
high tAFI antigen levels are associated with an increased risk of deep venous thrombosis.18 the 
role of tAFI in arterial thrombosis is, however, still unresolved. Several studies have shown that 
reduced tAFI antigen levels are found in patients with a history of acute myocardial infarction or 
unstable angina pectoris (UAP).12,13 we have previously shown in patients with UAP that lower 
tAFI antigen levels were present in patients who were refractory to medical treatment (more 
severe cases) compared to non-refractory patients.12 In contrast, other studies found increased 
levels of tAFI antigen in patients with arterial thrombosis.9-11 A major difference between the 
above mentioned studies was the method of determination of tAFI antigen levels. It has become 
evident that some antigen assays have a variable antibody reactivity towards the different 
isoforms of tAFI.14,15 the discrepancy between the studies may therefore in part be attributed 
to the various assays that have been used in the past. In our study we measured tAFI antigen 
levels by means of an eLISA that is more specific for the 325thr isoform (1040C/C genotype).15 
It would be interesting to use tAFI antigen assays, which are not sensitive to tAFI genotypes, 
to measure tAFI antigen levels in new prospective studies in arterial thrombotic disorders. In 
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our study no difference was observed in tAFI levels of patients with ischemic stroke compared 
with a population based control group. Because of the problems arising with tAFI antigen 
level measurement, and the difficulties of interpretation of the various results, measurement of 
functional tAFI levels seems to be of utmost importance, as is also shown in our study.
Relatively few studies have been performed on tAFI activity levels in arterial thrombosis.17,27 
the tests used in these studies were based on synthetic substrates. A clot lysis based assay is a 
more physiological method to study the impact of tAFI on fibrinolysis. In addition, this assay has 
to be specific for tAFI. In the clot lysis based assay used in this study, patient plasma was diluted 
20-fold in tAFI deficient plasma. the clot lysis time (Lt) was also measured in the presence 
of a specific tAFI inhibitor PCI. tAFI-related retardation, defined as Lt (-PCI) – Lt (+PCI), is a specific 
parameter for functional tAFI. Several tAFI activity assays have been developed.28,29 Also activity 
assays based on clot lysis times that are tAFI dependent have previously been described28, 
however this assay may be influenced by other plasma components.30 the method that we 
have used to study functional tAFI levels is used for the first time in a patient population. the 
finding that both the clot lysis time without addition of PCI, and the tAFI-related retardation 
are significantly higher in patients compared to controls, indicates that functional tAFI levels 
are an important risk factor for ischemic stroke. However, also clot lysis times in the presence 
of PCI are significantly higher in patients with ischemic stroke (table 2). this indicates that 
other variables that influence clot lysis time probably also contribute to the increased risk of 
ischemic stroke. we adjusted for other potential confounders in our study population, such as 
hypercholesterolemia, age, and smoking, but these did not influence the association of clot 
lysis times with the risk of ischemic stroke. In the total study group, tAFI-related retardation was 
higher in individuals with hypercholesterolemia, higher age and hypertension. we did not find a 
good correlation between tAFI antigen levels and tAFI-related retardation. this may be caused 
by the eLISA antigen assay used in our study, of which the results are strongly dependent upon 
tAFI isoforms in plasma.15 therefore the measured differences in tAFI antigen levels between 
the various genotypes may be exaggerated.15 tAFI antigen levels and functional tAFI levels or 
clot lysis times may correlate better using different antigen assays15,31, some of which are known 
to be less sensitive for tAFI isoforms.15 our findings are consistent with a recent study in young 
patients with acute myocardial infarction, in which tAFI activity was significantly higher in 
patients with AMI compared to controls.27 In that study a discrepancy was found between tAFI 
activity and antigen levels, without a correlation in both patients and controls 
It is well known that tAFI genotype is correlated with tAFI antigen levels. we confirmed that 
three polymorphisms (-438A/G, 505G/A and 1040C/t) are associated with tAFI antigen levels, 
both in patients and controls. we could not demonstrate a difference in the risk of ischemic stroke 
between the various genotypes. Previous studies showed that the 505G/A SnP (Ala147thr) in 
the tAFI gene is associated with the risk of acute myocardial infarction.13 Individual carrying 
the “tAFI antigen decreasing allele” (505G, Ala147) had an increased risk of acute myocardial 
infarction in a combined analysis of three case-control studies.13 In our study we could not find 
this association between the tAFI 505G/A gene polymorphism and the risk of ischemic stroke. 
we also could not detect an association between the 1040 C/t polymorphism (Ile325thr) and 
the risk of ischemic stroke, in agreement with two previous studies on the risk of AMI.27,32 
one of the limitations of our study is the size of the study population, especially, as already 
mentioned above, in assessing the association between tAFI gene polymorphisms and ischemic 
stroke. Based on the confidence intervals, however, tAFI gene variations will probably not be a 
strong risk factor for ischemic stroke.
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we conclude that reduced fibrinolysis, as shown by a prolongation of clot lysis times in 
patients with a first ischemic stroke, results in a significantly increased risk of ischemic stroke. 
this is mainly due to an increase of functional tAFI, but also other factors influencing the 
fibrinolytic system may be involved. Additional studies involving larger patients groups are 
necessary to study both functional levels and non-genotype dependent antigen levels as well 
as tAFI genotype.
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Chapter 6
the number of inherited coagulation 
disorders and the association with ischemic 
stroke: is there a synergistic effect?
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IntRoDUCtIon 
Ischemic stroke is the third cause of death and the first cause of disability in the western 
world. In the majority of ischemic stroke patients rather weak risk factors such as age, male sex, 
hypertension and smoking can be found. In young patients often no risk factors are found at all. 
As the chance of recurrence of cardiovascular events is an important issue for the patient as well 
as for the clinician, identification of new and stronger risk factors is needed. Inherited coagulation 
disorders are important risk factors for venous thrombosis and are thereforeobvious targets for 
investigation in arterial thrombosis, including ischemic stroke. the difficulty in clinical practice 
is generally not making the diagnosis of underlying thrombophilia, as it is often revealed by 
routine blood tests, but in assessing whether the thrombophilia is a risk factor for the ischemic 
stroke. Chapter 4 and 5 of this thesis address this issue. we studied the role of several inherited 
coagulation disorders in the occurrence of ischemic stroke. In conclusion, none of the studied 
coagulation disorders was associated with the occurrence of ischemic stroke. this finding is in 
agreement with other larger case-control studies.1-5
As our results provide no evidence for a higher risk for ischemic stroke in the presence of 
a single genetically determined coagulation disorder, it seems obvious to investigate the 
influence of clustered coagulation disorders on stroke risk. we hypothesized that there could 
be a synergistic effect on stroke risk in the presence of more than one inherited coagulation 
disorder. we used our case-control study to investigate if the number of genetically determined 
coagulation disorders was associated with the occurrence of ischemic stroke.
MetHoDS
the design of the study has been extensively described in chapter 3. In short, CoCoS is a case-
control study with prospective inclusion of Caucasian participants with first ever ischemic 
stroke, confirmed by Ct. Controls are population based, age-and sex-matched, of the Caucasian 
race and not related to the patients. Blood samples for genotype were drawn under strictly 
standardised conditions one week after the event. the studied coagulation disorders were 
FVL mutation, G20210A prothrombin gene variant and polymorphisms of the -148 C/t 
fibrinogen gene, 4G/5G PAI-1 gene, -1C/t AnxA5 gene, G79A PZ gene and 1040C/t, 505G/A, -
438A/G tAFI gene. the methods for isolating DnA and detection of the separate mutations and 
polymorphisms have been described in chapters 4 and 5. In order to test the hypothesis that 
the number of genetically determined coagulation disorders is associated with the occurrence 
of ischemic stroke, additional statistical analyses within the CoCoS population were performed. 
we estimated the odds ratio (oR) associated with ischemic stroke in the presence of more than 
one inherited coagulation disorder for each number of disorders separately. the oR for the 
presence of any coagulation disorder was also estimated. In second instance, the coagulation 
disorders were divided in two groups. one consisted of coagulation disorders that mainly 
relate to fibrinolytic part of the clotting cascade, i.e. PAI-1 gene polymorphism, 1040 C/t tAFI 
gene polymorphism, 505 G/A tAFI gene polymorphism, -438 A/G tAFI gene polymorphism and 
the -1C/t AnxA5 gene polymorphism. the second group consisted of coagulation disorders 
that mainly relate to the prothrombotic part of the clotting cascade, i.e. the FVL mutation, the 
G20210A prothrombin gene variant, the -148 C/t fibrinogen gene polymorphism and the G79A 
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PZ gene polymorphism. For both groups the oR associated with ischemic stroke in the presence 
of more than 1 coagulation disorder of that group was estimated. Multiple logistic regression 
analysis was used to adjust for possible confounding variables, such as smoking, hypertension 
and use of oral contraceptives.
ReSULtS
the study population consisted of 124 patients and 125 controls. the mean age was 56 years 
(range 18-75 years). Forty-seven percent of the participants were female. Patients were more 
often smokers and more often had hypertension, diabetes or were known to have cardiovascular 
disease compared with controls. the determination of the PZ gene polymorphism and the 
AnxA5 gene polymorphism was performed in second instance. At that time, in only 83% of the 
patients and controls DnA was available for genotyping. In the other participants, there was no 
remainder of the blood sample for technical reasons. table 1 summarizes the distribution of 
the genotypes in patients and controls and the relative risk associated with the occurrence of 
ischemic stroke in the presence of each individual coagulation disorder. 
Table 1 Prevalences of inherited thrombophilia in patients and controls and associated odds ratio with 95% confidence interval (95%CI). 
PM=polymorphism
Coagulation disorder Genotype Cases (n=124) Controls (n=125) oR (95% CI)
FVL mutation GGGA+AA
115 
5 + 0
119 
4 + 0 1.3 (0.4-4.6)
PtII gene variant GGGA+AA
118 
2 + 0 
118 
5 + 0 0.4 (0.1-1.8)
-148C/tFibrinogen gene PM CCCt+tt
83 
34 + 6 
77 
41 + 5 0.8 (0.5-1.4)
4G/5G PAI-1gene PM 5G/5G4G/5G+4G/4G
29 
61 + 33 
29 
58 +36 1.0 (0.6-1.8)
-1C/t AnxA5 gene PM CCCt+tt
87 
30 + 1 
73 
23 + 1 1.1 (0.6-2.0)
tAFI -1040 gene PM CCCt+tt
55 
51 + 18 
51 
58 + 12 0.9 (0.6-1.5)
tAFI 505 gene PM GGGA+AA
54 
53 + 13 
48 
51 + 18 0.9 (0.5-1.4)
tAFI -438 gene PM AAAG+GG
61 
48 + 16
61 
50 + 10 1.1 (0.6-.8)
G79A PZ gene PM GGGA+AA
75 
39 + 4 
77 
32 + 4 1.2 (0.7– 2.1)
Any inherited disorder absentpresent
 3
121
5
119 1.7 (0.4-6.6)
Synergistic effect of coagulation disorders in stroke 131
none of these genetically determined coagulation disorders were individually associated with 
an increased risk of ischemic stroke. the oR for ischemic stroke in the presence of more than 1 
coagulation disorder was 1.2 (95% CI: 0.5-2.7) and the oR for the presence of any coagulation 
disorders was 1.7 (95% CI: 0.4-6.6). table 2 shows that the relative risk was not different for the 
groups with a fixed number of genetic variants. After separating the coagulations disorders 
in procoagulant and fibrinolysis related disorders, again no convincing association was found 
(table 3 and 4). the oR for ischemic stroke in the presence of any fibrinolysis related coagulation 
disorder was 0.9 (95% CI: 0.5-1.5). For the group of disorders related to the procoagulant part of 
the clotting cascade the oR was 1.0 (95% CI: 0.3-3.0). After adjustment for smoking, hypertension 
and use of oral contraceptives the results remained the same in all groups.
Table 2 Distribution of the number of coagulation disorders in patients and controls with associated odds ratio and 95% confidence interval 
(95% CI); NA=not applicable
number of coagulation disorders Cases (n=124) Controls (n=125) oR (95%CI)
0 3 5 0.6 (0.1-2.5)
1 8 8 1.0 (0.4-2.6)
2 26 20 1.3 (0.7-2.3)
3 33 37 0.9 (0.6-1.4)
4 28 31 0.9 (0.5-1.5)
5 22 19 1.2 (0.6-2.1)
6 3 4 0.8 (0.2-3.4)
7 1 0 nA
Table 3. Distribution of the number of fibrinolysis related coagulation disorders in patients and controls with associated odds ratios and 95% 
confidence interval (95% CI); NA=not applicable
number of coagulation disorders Cases (n=124) Controls (n=125) oR (95%CI)
0 6 7 0.9 (0.3-2.6)
1 15 21 0.7 (0.4-1.4)
2 38 30 1.3 (0.8-2.0)
3 39 40 1.0 (0.6-1.5)
4 22 25 0.9 (0.5-1.6)
5 4 2 2.0 (0.4-10.9)
Table 4. Distribution of the number of coagulation disorders related to the procoagulant part of the clotting cascade in patients and controls 
with associated odds ratios and 95% confidence interval (95% CI); NA=not applicable
number of coagulation disorders Cases (n=124) Controls (n=125) oR (95%CI)
0 53 50 1.1 (0.7-1.6)
1 51 57 0.9 (0.6-1.3)
2 18 17 1.1 (0.5-2.1)
3 1 0 nA
132
Ch
ap
te
r 6
DISCUSSIon
Internal validity
A strength of this study is the well defined population as we collected detailed information 
about cardiovascular risk factors, medical history and family history in consecutively included 
patients as well as in controls. the ischemic nature of the stroke was determined by Ct scan of 
the brain and patients with tIA were only included if the neurological deficit was observed by a 
neurologist. the insurance of a well defined ischemic stroke group is important as the studied 
prothrombotic coagulation disorders are not likely to cause hemorrhagic stroke. All participants 
were of the Caucasian race and the allele frequencies of the polymorphism in the control 
group were in Hardy-weinberg equilibrium, indicating that we studied a representative group. 
Because we only studied survivors, we cannot exclude that the presence of the variant allele of 
one of the studied coagulation disorders is associated with fatal ischemic stroke. However, an 
association with fatal stroke is not very likely, since genotype was not related to stroke severity 
in our population. Furthermore, the majority of deaths within a few days after stroke is caused 
by pneumonia or other (non-hematological) complications.
External validity
our results show that inherited coagulation disorders are a frequent finding in ischemic stroke 
patients, but that it is unlikely that they are relevant in the pathogenesis of the stroke. this is 
in agreement with three similar studies6-8 that failed to find an association between ischemic 
stroke and the presence of any genetically determined coagulation disorder. In the same 
studies also no association was reported for pathogenic subgroups of patients such as those 
with large or small vessel disease or cardio-embolic stroke6 or younger stroke patients.7 on the 
other hand, an increased stroke risk in patients with patent foramen ovale in combination with 
the FVL mutation or prothrombin gene variant was reported by several case-control studies.9-
11 the prothrombin gene variant has also been associated with an increased stroke risk in 
selected population of Mediterranean origin.12,13 In our population we were not able to perform 
subgroup analysis because of the small sample size and the low prevalence of especially the 
FVL mutation and the prothrombin gene variant.
In conclusion, in our study of Caucasian individuals the number of genetically determined 
coagulation disorders was not associated with an increased risk of ischemic stroke. A synergistic 
effect of combinations of coagulation disorders is also not likely. therefore, in Caucasian patients 
with ischemic stroke, routinely performed coagulation tests to screen for an inherited coagulation 
disorder are not indicated. these findings have also implications for ischemic stroke patients 
with coincidently found genetic thrombophilia. these patients are often treated empirically 
with oral anticoagulants, based on the assumptions that the association between stroke and 
the coagulation disorder is likely to be causal and that anticoagulants are the most effective 
therapy. However, neither of these assumptions is evidence-based and the most appropriate 
treatment for secondary prevention in these patients is still antiplatelet therapy. Further studies 
are needed to investigate the role of genetically determined coagulation disorders in selected 
stroke populations such as patients with PFo or patients of Mediterranean origin.
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the objective of this thesis was to gain more insight in the association between genetically 
determined coagulation disorders and the occurrence of ischemic stroke. the CoCoS study 
was performed as a co-operation between the departments of neurology and Hematology 
of the erasmus Medical Center. Detailed clinical information about the participants, as well as 
the remainder of the blood samples was stored in a database. this provides an easy accessible 
database of DnA and blood plasma of a well-defined case-control population. In case new 
polymorphisms, a possible association with ischemic stroke can be studied rapidly.
we have studied potent risk factors for venous thrombosis but also some more recently 
described polymorphisms of the genes encoding for coagulation factors. In this chapter the 
main findings will be summarized and some methodological aspects will be considered. the 
clinical implications will be discussed and finally suggestions for further research will be made. 
MAIn FInDInGS
the main negative associations of this thesis are:
•	 the FVL mutation and the G20210A prothrombin gene variant were not associated with an 
increased risk of ischemic stroke in the Caucasian
•	 the -148C/t fibrinogen gene polymorphism, the 4G/5G PAI-1 gene polymorphism, nor the 
PLA1/PLA2 polymorphism were associated with an higher risk of ischemic stroke in the 
Caucasian
•	 the more recent described polymorphism in the PZ gene, AnxA5 gene and the tAFI gene 
were not associated with an increased risk of ischemic stroke in the Caucasian
•	 the number of genetically determined coagulation disorders is not related to the 
occurrence of ischemic stroke. therefore, a synergistic effect is not likely
the main positive associations of this thesis are:
•	 the phenotypic expression of the polymorphism, i.e. the protein plasma level was clearly 
related to genotype
•	 High fibrinogen levels in stroke patients shortly after the event are mainly the result of an 
acute phase response
•	 Low PZ levels and high prothrombin levels may be associated with the occurrence of 
ischemic stroke in the Caucasian
•	 High functional level of tAFI are associated with an increased risk of ischemic stroke in the 
Caucasian
the comparison of these findings with those of other studies is described in the previous 
chapters and will not be repeated here.
MetHoDoLoGICAL ISSUeS
In this section, I will discuss some general issues, which pertain to all studies performed within 
the CoCoS population.
Study design
the CoCoS study was a case-control study among Caucasian patients with first ever ischemic 
stroke. In 125 patients and 125 controls blood sample were taken to determine genotype 
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concerning 9 different coagulation factor genes and their corresponding phenotypic expression 
one week after the event. In 68 patients the blood sample for plasma protein level was repeated 
in the convalescent phase, more than 3 months later. the design of the study provides fast 
inclusion of the participants as well as detailed information about the participants concerning 
cardiovascular risk factors, medical history and family history. Hemorrhagic stroke was excluded 
by Ct scan of the brain and patients with tIA were only included if the neurological deficit was 
observed by a neurologist. this ensures a well defined ischemic stroke group. this is necessary 
as we were studying prothrombotic risk factors, which are unlikely to cause hemorrhagic stroke. 
As the blood extraction was standardized, different findings in plasma protein levels between 
participants as a result of food intake, smoking, physical exercise or circadian rhythm, were ruled 
out. 
the design of the study has three important disadvantages. the first is that the exposure, i.e. 
the plasma protein level, was determined after the occurrence of the index event. we partly 
dealt with this issue by repeating the measurements of the protein levels in the convalescent 
phase. However, this could be performed in only about 50% of the patients. Secondly, we 
cannot exclude that the studied mutations or polymorphisms are associated with fatal stroke, 
as we included only survivors of ischemic stroke. Again, for answering this question population 
based prospective studies are more suitable than clinical case-control studies. However, 
an association with fatal stroke is not very likely, since genotype was not related to stroke 
severity in our population. Furthermore, the majority of deaths within a few days after stroke 
is caused by pneumonia or other (non-hematological) complications. Finally, as a result of the 
study design we were not able to further unravel the pathophysiological mechanism of the 
occurrence of ischemic stroke. In our patients, we found elevated levels of fibrinogen during 
the acute phase. whether these increased levels are a cause or consequence of ischemic stroke 
is not yet clarified. nested case-control studies can only partly contribute to this question as 
the risk factor is determined long before the occurrence of ischemic stroke, comparable with 
the repeated measurement after three months in our study. Animal studies with continuous 
measurements of the protein levels can give more information about the pathophysiological 
mechanism of stroke occurrence.
Ethnicity
In order to create a genetic homogenous group, only participants of the “Caucasian race” were 
included. Caucasian was defined as “the participant and his or her parents has to be born in 
northern europe with the river Rhône as Southern border for northern europe”. Such division 
was needed as in Rotterdam about 50% of the urban population is foreign and originates 
from Caribbean or Mediterranean areas. However, the assumption that ethnicity is an isolated 
epidemiological variable delineating clinically distinct disease groups is controversial.1 ethnic 
classification may vary from one community to another, as the perception of an ethnic group 
may be different across countries. ethnicity as a variable may be greatly influenced by cultural 
attitude. As Caldwell and Popenoe2 put it, “what is black to someone from the United States 
may be white to a Brazilian or a Caribbean islander”. ethnicity is not a dichotomous variable, 
such as gender. How black is black or how white is white? Defining disease on the basis of 
ethnicity might perhaps hide socioeconomic differences that are the real cause of disease in 
some ethnic groups.1 within CoCoS, I think we have adequately dealt with the issue of ethnicity. 
Because of the sample size of 125 and the aim to study genetically determined coagulation 
disorders, it is necessary to choose participants of the same genetic area. keeping this in mind, 
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the group of blacks seems to be more heterogeneous than the group of whites. Furthermore, 
the FVL mutation and G20210A prothrombin gene variant were almost exclusively found in 
whites.3;4 we used population based controls of the same genetic area as the patients in order 
to generate a control group of comparable socioeconomic status. Finally, we did not compare 
between groups of presumed different origin. 
Generalizability
when studying the association between a genetically determined coagulation disorder and 
the occurrence of ischemic stroke, two underlying mechanisms can be assumed. First, the 
coagulation disorder itself can be an isolated risk factor for ischemic stroke and its presence 
is enough to cause the ischemic event. In that case, the study population is limited to patients 
in whom no other cause for the stroke is found. on the other hand, the presence of the 
coagulation disorder could increase the risk of ischemic stroke in combination with other 
cardiovascular risk factors. we have chosen to include all consecutive patients with first ever 
ischemic stroke, either with or without an established cause. the relationship between the 
coagulation disorder and ischemic stroke could hence be studied for the group as a whole as 
well as for subgroups. this enabled us to test both hypotheses. the baseline characteristics of 
our study were comparable with other stroke populations.5 Patients were more often smokers 
and more often had hypertension, diabetes and were more often known to have cardiovascular 
disease. In 49% of the cases no cause for the ischemic stroke was found according to the toASt 
classification.5 nine percent suffered from large vessel disease, 37% from small vessel disease 
and in 3 % of the patients a probable source of cardiac embolism was detected. this breakdown 
of possible causes is comparable with previous studies, except for the lower rate of cardiac 
embolism in our study. In general, in ischemic stroke populations in 15-20% a cardiac cause 
for the ischemic event is found. there are several explanations for the difference in prevalence 
of cardiac disorders. we classified only the probable and not the possible causes of the toASt 
classification as positive cardiac embolism. Furthermore, only in the young patients (47%) 
transthoracal echocardiography was performed. In 44% of them this investigation was followed 
by transesopageal echocardiography, which is more sensitive in detecting small cardiac 
abnormalities or abnormalities in the left atrial appendage. A final explanation may be the use 
of oral anticoagulants. In general stroke populations, about 50% of the patients with cardiac 
embolism were already known to suffer from atrial fibrillation at the time of the ischemic stroke 
and therefore treated with oral anticoagulants. As this therapy was an exclusion criterion in our 
study, this might also contribute to the lower prevalence of cardiac embolism in the CoCoS 
study. 
PAtHoGeneSIS
Hypercoagulability: Venous thrombosis versus arterial thrombosis
the studied coagulation disorders in CoCoS, especially the FVL mutation and the G20210A 
prothrombin gene variant, are strong risk factors for venous thrombosis.6-8 new treatment 
strategies by means of anticoagulant therapy have lead to prognostic improvement of patients 
with venous thrombosis, but also to improvement of primary and secondary prevention.9 
However, in arterial thrombosis, the role of the genetically determined coagulation disorders 
appears to be less rectilinear and more complicated. In the studies presented in this thesis, 
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none of the studied genetically determined coagulation disorders appeared to be a risk factor 
for ischemic stroke, which is supported by several other (nested) case-control studies. the 
explanation for the different influence of coagulation disorders between venous and arterial 
thrombosis can only be explained by different underlying pathogenetic mechanisms. In 
venous thrombosis three factors are important, i.e. blood stasis, hypercoagulability and vessel 
damage, collectively known as the Virchow ‘s triad. there is no need for all these components 
to be present in order for thrombosis to occur. As a matter of fact, venous thrombosis may even 
occur in the presence of only one of these conditions, wherein clotting changes and blood 
flow are seen to play the major role. In recent years, remarkable advances in the understanding 
of the concept of hypercoagulability have been made, with special emphasis to genetically 
determined thrombophilic abnormalities.10-12 these give rise to disturbances of the balanced 
clotting cascade, leading to increased activation of the procoagulant factors of hemostasis, 
leading to increased thrombus formation. Venous thrombi are mainly composed of fibrin and 
red blood cells and usually are formed in areas of stasis. In arterial thrombosis the underlying 
mechanism is based on atherosclerosis. Atherosclerosis is increasingly viewed as a chronic 
inflammatory disease that, over many years leads to the development of atherosclerotic plaques. 
Rupture of local vulnerable plaques is considered the most important underlying mechanism 
of myocardial infarction.13-16 In ischemic stroke small vessel disease and thromboembolism 
without significant large vessel disease are more common causes. Arterial thrombi are primarily 
composed of platelets and are formed in areas of rapid blood flow. Formation of local thrombus 
as a result of a hypercoagulable state like in venous thrombosis is, because of higher flow of 
blood in the larger arteries, not very likely. the pathogenesis of arterial thrombosis is a complex 
process in which environmental and genetic factors seem to interact.16-19 
CLInICAL IMPLICAtIonS
In none of the studies described in this thesis we found support for an important causal role for 
genetically determined coagulation disorders. Hence, we face the paradox that polymorphisms 
within certain genes do correlate with plasma levels of the respective proteins, and that certain 
laboratory parameters correlate consistently with ischemic stroke, but that positive associations 
between genotype and ischemic stroke are absent. therefore, there is no indication to routinely 
determine the presence of these coagulation disorders in patients with ischemic stroke.20 Also, 
there is no need to treat ischemic stroke patients with coincidently detected genetic coagulation 
disorders, differently from ischemic stroke patients without these disorders. Increased plasma 
levels of procoagulant factors are most likely the result of an acute phase response, leading to 
a similar approach of treatment as for the genotype. Decreased protein Z levels might be an 
exception as these were in our population almost similar in patients and controls in the acute 
phase, but significantly lower in patients in the reconvalescent phase. Protein Z has been reported 
to act as cofactor in the inhibition of FXa, leading to a more procoagulant than anticoagulant 
state in case of low protein Z levels. However, the exact role of protein Z in ischemic stroke 
needs to be clarified. As yet, decreased protein Z levels have no clinical consequences. 
In childhood stroke, genetically determined coagulation disorders are a well known risk 
factor.21-24 therefore, the only category of ischemic stroke patients with an indication for 
coagulation screening are children with ischemic stroke. Another group of interest is that of 
patients with suspected antiphospholipid syndrome. Antiphospholipid syndrome is defined as 
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recurrent arterial or venous thromboses, sometimes combined with miscarriage, in the presence 
of antiphospholipid antibodies (anticardiolipin IgG or IgM and/or lupus anticoagulant).25 It is 
obviously indicated to perform coagulation tests in these patients because of their high risk 
of recurrent thrombotic events. In case of presence of lupus anticoagulant (LA) or elevated 
anticardiolipin IgG or IgM (ACL), oral anticoagulant therapy is often started. However, there is no 
evidence for an effect of this treatment on recurrent thrombotic events in stroke patients with 
positive APL. we performed a follow-up study among 128 young ischemic stroke patients, of 
whom 17% had positive aPL.26 the relative risk of any thrombotic event in patients with aPL was 
0.9 (95% CI: 0.3-2.4) and for recurrent ischemic stroke or tIA 0.7 (95% CI: 0.3-2.2). these findings 
were in agreement with the recent results of wARRS/APASS27, a large prospective cohort study, 
that not indicated an effect of treatment with low intensity (InR 1.4-2.8) oral anticoagulants in 
patients with aPL. two further remarks on this subject need to be made. APL, especially ACL, are 
liable to changes, for instance as a result of medication use or acute phase reactions. Repeated 
measurements are absolutely mandatory to show consistency of the findings and to minimize 
the possibility that increased ACL levels occurred by chance. Second, the studies that reported 
an increased thrombotic risk in patients with aPL mostly concerned very high ACL levels, i.e 
above 100 U.28-31 In patients with mildly elevated ACL the relationship is less clear. therefore, 
only in patients with very high ACL the measurements must be repeated. In these patients 
systemic lupus erythomatodes (SLe) is frequently detected. 
FUtURe StUDIeS
the CoCoS population is a well designed database for future research concerning coagulation 
disorders in ischemic stroke patients. In my opinion, it is unlikely that a genetically determined 
coagulation disorder in itself plays a causative role in the occurrence of ischemic stroke. Future 
studies should focus on the subgroups of patients in whom interaction of a coagulation disorder 
and another minor cause such as patent foramen ovale (PFo) can be studied. PFo has been 
associated with cryptogenic stroke32-34 and several studies showed a further increase of stroke 
risk in patients with PFo combined with FVL mutation or G20210A prothrombin gene variant.35-
37 Although defining ethnicity is controversial, future studies should be performed in stroke 
patients of different ethnic regions. the prothrombin gene variant has been repeatedly reported 
as a significant risk factor for cryptogenic ischemic stroke in Mediterranean populations38,39 and 
recently PFo was reported to be significantly more frequent in whites compared with blacks.40
For the FXIII Val34Leu polymorphism, a protective effect on the development of venous 
thrombosis and MI has been shown in several studies 41-44. the results in ischemic stroke are 
contradictory42,45,46 and need further investigation.
Finally, the exact role of protein Z and tAFI in ischemic stroke needs to be further clarified. 
For tAFI a new study has already started, the AttACk study, a co-operation between the 
departments of Hematology, neurology, Cardiology and Vascular Surgery of the erasmus MC. 
Patients with ischemic stroke, myocardial infarction and peripheral vascular diseases will be 
included. Again genotype and phenotype will be studied in relation to the disease. when 
this reveals an association of protein levels in the convalescent phase and the occurrence of 
ischemic stroke, searching for a responsible genotype will be of renewed interest.
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SUMMARY
Stroke is the main cause of disability and the third cause of death in the western world. the 
known cardiovascular risk factors as smoking, hypertension and diabetes are often weak and 
not clustered. A search for new risk factors is necessary, as it is important to identify patients 
with high risk for (recurrent) vascular events. Genetically determined coagulation disorders are 
strong risk factor for venous thrombosis. their role in arterial thrombosis, like ischemic stroke, 
is less clear.
In this thesis, I describe our research concerning the role of genetically determined coagulation 
disorders in the occurrence of ischemic stroke. we studied the relationship between ischemic 
stroke and various mutations and polymorphisms of coagulation related genes as well as their 
phenotypic expressions in order to identify a genetic mutation as an important risk factor for 
ischemic stroke. For this purpose, we performed two case-control studies in patients with recent 
ischemic stroke.
In chapter 2, the results of a retrospective case-control study in 49 young patients with ischemic 
stroke and 87 healthy controls are described. Chapter 2.1 adresses the association between the 
G20210A prothrombin gene variant, the prothrombin level and ischemic stroke. Although the 
prothrombin gene variant was only a weak risk factor for ischemic stroke, increased prothrombin 
activity, which was more frequent than the mutation, appeared to be more strongly related to 
cerebral ischemia. Chapter 2.2 shows the association between ischemic stroke and the PLA1/A2 
gene polymorphism in the same study population. the polymorphism was not associated with 
an increased risk of stroke. 
Chapter 3 covers the rationale, background and design of the Controlled study of genetically 
determined Coagulation disorders in ischemic Stroke (CoCoS). the CoCoS study was a case-
control study with prospective inclusion of 125 patients with first ever ischemic stroke. Controls 
were population based, age-and sex-matched and not related to the patients. All participants 
were of the Caucasian race. Blood samples were taken one week after the ischemic stroke and 
repeated after three months in about half of the patients. Genotype and phenotype of several 
genetically determined coagulation disorders were determined. Because of the repeated 
measurements, we were able to compare protein levels in the acute phase and the convalescent 
phase. 
Chapter 4 concerns the association in the CoCoS population between ischemic stroke and 
the presence of a prothrombotic genetically determined coagulation disorder. Chapter 4.1 
provides a review of the literature concerning the Factor V Leiden mutation and the G20210A 
prothrombin gene variant as risk factors for ischemic stroke combined with the results of 
these coagulation disorders within the CoCoS study. Based on our own results and those in 
the literature, an association between one of these mutations and the occurrence of ischemic 
stroke is highly unlikely. Consequently, there is no indication for routinely performing these 
coagulation studies in ischemic stroke patients. the influence of both mutations in subgroups, 
such as patients with patent foramen ovale of patients of Mediterranean origin, is not clear 
yet and needs further investigation. elevated protrombin levels, however, were associated with 
an increased risk of ischemic stroke. this finding is comparable to our results in young stroke 
patients described in chapter 2.1. Chapter 4.2 describes the role of the -148C/t fibrinogen gene 
polymorphism and fibrinogen level in ischemic stroke. the polymorphism was not associated 
with an increased stroke risk. Fibrinogen levels were significantly higher in patients compared 
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with controls one week after the stroke, but this difference had mostly disappeared after three 
months. High fibrinogen levels most likely represent an acute phase response. In Chapter 4.3 
the association between G79A protein Z gene polymorphism and protein Z levels is studied. 
Again, the studied polymorphism was not associated with the occurrence of ischemic stroke. 
Protein Z levels, however, were inversely related to ischemic stroke. the relative risk of ischemic 
stroke associated with protein Z levels in the lowest quartile was 3.4 (95% CI: 1.3-7.3) during 
the convalescent phase. therefore, a causative role for protein Z in the occurrence of ischemic 
stroke seems likely.
Chapter 5 focuses on the association between fibrinolysis related genetically determined 
coagulation disorders in the CoCoS population. In chapter 5.1 and chapter 5.2 the association 
between 4G/5G PAI-1 gene polymorphism and PAI-1 levels and the annexin A5 kozak sequence 
(-1C/t) polymorphism and ischemic stroke is studied. neither the polymorphisms nor the PAI-
1 level were associated with the occurrence of ischemic stroke. Chapter 5.3 addresses three 
recently identified polymorphisms of the tAFI gene, tAFI antigen levels and functional tAFI 
levels in relation to ischemic stroke. none of the tAFI gene polymorphisms were associated with 
a higher stroke risk. However, an increase of functional tAFI levels, which results in a decreased 
fibrinolysis, was associated with an increased risk of ischemic stroke.
In Chapter 6 all genetically determined coagulation disorders of the CoCoS study are 
combined to assess whether the risk of ischemic stroke changes with the presence of more 
than one coagulation disorder in comparison with an isolated mutation. the number of genetic 
mutations was not associated with the occurrence of ischemic stroke and we found no evidence 
for a synergistic effect of certain combination of coagulation disorders.
In chapter 7, our findings are discussed and reviewed in a broader context. Furthermore, this 
chapter contains methodological issues and describes suggestions for further research.
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SAMenVAttInG
Het herseninfarct is de belangrijkste oorzaak van invaliditeit en de derde doodsoorzaak in de 
westerse wereld. Bekende cardiovasculaire risicofactoren, zoals roken, hypertensie en diabetes, 
zijn niet geclusterd en hun afzonderlijke invloed is vaak relatief klein. Het identificeren van 
nieuwe risicofactoren voor het optreden van een herseninfarct is van belang om patiënten 
met een hoog (recidief ) risico op te sporen. Genetisch bepaalde stollingstoornissen zijn een 
belangrijke risicofactor voor het optreden van veneuze trombose. Hun rol in het ontstaan van 
arteriële trombose, zoals het herseninfarct, is minder duidelijk.
In dit proefschrift beschrijf ik de resultaten betreffende de rol van genetisch bepaalde 
stollingsstoornissen bij het optreden van een herseninfarct. De relatie tussen het herseninfarct 
en verschillende mutaties en polymorfismen in de stollingsgenen en hun fenotypische 
expressies wordt bestudeerd met als mogelijk doel een van de onderzochte stollingsstoornissen 
als risicofactor voor het herseninfarct te identificeren. Hiervoor werden 2 case-control studies 
onder patiënten met een recent doorgemaakt herseninfarct verricht.
In hoofdstuk 2 beschrijf ik de resultaten van een retrospectieve case-control studie onder 49 
jonge patiënten met een doorgemaakt herseninfarct en 87 gezonde controles. Hoofdstuk 2.1 
bestudeert de associatie tussen de G20210A protrombine gen variant, het protrombine level 
en het herseninfarct. Hoewel de protrombine gen variant hooguit een zwakke risicofactor was, 
bleek een verhoogd protrombine level, dat frequenter was dan de mutatie, sterker gerelateerd 
aan het optreden van het herseninfarct. Hoofdstuk 2.2 laat het verband zien tussen het 
herseninfarct en het PLA1/A2 gen polymorfisme in dezelfde studie populatie. Het polymorfisme 
was niet geassocieerd met een verhoogd risico op het optreden van een herseninfarct.
Hoofdstuk 3 bevat de rationale, achtergrond en design van de “Controlled study of genetically 
determined Coagulation disorders in ischemic Stroke” (CoCoS). De CoCoS studie is een case-
control studie met prospectieve inclusie van 125 patienten met een eerste doorgemaakt 
herseninfarct. Controles zijn afkomstig uit de normale bevolking, zijn gematched voor leeftijd 
en geslacht en niet verwand aan de patienten. Alle deelnemers zijn van het caucasische ras. De 
bloedmonsters werden afgenomen 1 week na het herseninfarct en herhaald na 3 maanden bij 
ongeveer de helft van de patiënten. Het genotype en het fenotype van verschillende genetisch 
bepaalde stollingsstoornissen werden bepaald. Door de bloedafname te herhalen, was het 
mogelijk de eiwit concentraties in de acute fase en de herstelfase te vergelijken.
In Hoofdstuk 4 beschrijf ik de associatie in de CoCoS populatie tussen het optreden 
van een herseninfarct in aanwezigheid van een meer protrombotisch genetisch bepaalde 
stollingsstoornis. Hoofdstuk 4.1 toont de resultaten van een review van de literatuur betreffende 
de Factor V Leiden mutatie en de G20210A protrombine gen variant als risicofactor voor het 
herseninfarct, gevolgd door de resultaten van deze mutaties binnen de CoCoS studie. een 
associatie tussen een van deze mutaties en het optreden van een herseninfarct is op grond van 
onze resultaten en die in de literatuur erg onwaarschijnlijk. Daarom is er geen indicatie voor het 
routinematig uitvoeren van dit stollingsonderzoek bij patiënten met een eerste herseninfarct. De 
invloed van beide mutaties in subgroepen van patiënten, zoals patiënten met een persisterend 
foramen ovale of patiënten van mediterrane afkomst, is nog niet goed duidelijk en dient verder 
onderzocht te worden. Verhoogde protrombine levels, daarentegen, waren geassocieerd met 
een verhoogd risico of een herseninfarct. Deze bevinding is vergelijkbaar met onze resultaten 
in jonge patiënten met een herseninfarct beschreven in hoofdstuk 2.1. Hoofdstuk 4.2 beschrijft 
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de rol van het -148C/t fibrinogeen gen polymorfisme en fibrinogeen level in het optreden 
van een herseninfarct. Het polymorfisme was niet geassocieerd met een verhoogd risico op 
een herseninfarct. Fibrinogeen levels waren significant hoger in patiënten dan in controles 
1 week na het herseninfarct, maar 3 maanden later was dit verschil grotendeels verdwenen. 
Hoge fibrinogeen levels zijn meest waarschijnlijk het gevolg van een acute fase reactie. In 
hoofdstuk 4.3 wordt de associatie tussen het G79A proteïne Z gen polymorfisme en proteïne 
Z levels bestudeerd. Het polymorfisme was opnieuw niet geassocieerd met het optreden van 
een herseninfarct. Proteine Z levels, echter, waren omgekeerd evenredig geassocieerd met 
het herseninfarct. Gedurende de convalescente fase was het relatieve risico op het optreden 
van een herseninfarct geassocieerd met proteine Z levels in het laagste quartiel 3.4 (95% CI: 
1.3-7.3). Daarom lijkt een causale rol voor proteine Z in het ontstaan van het herseninfarct 
waarschijnlijk.
Hoofdstuk 5 betreft de associatie tussen meer fibrinolyse gerelateerde genetisch bepaalde 
stollingsstoornissen binnen de CoCoS populatie en het optreden van een herseninfarct. 
In hoofdstuk 5.1 en hoofdstuk 5.2 bestudeerden wij de associatie tussen het 4G/5G PAI-1 gen 
polymorfisme en PAI-1 levels en het annexin A5 kozak sequence (-1C/t) polymorfisme en het 
herseninfarct. noch de polymorfismen noch het PAI-1 level waren geassocieerd met het optreden 
van een herseninfarct. Hoofdstuk 5.3 betreft drie recent geïdentificeerde polymorfismen van 
het tAFI gen, tAFI antigeen levels en functionele tAFI levels in relatie tot het herseninfarct. Geen 
van de tAFI gen polymorfismen was geassocieerd met een hoger risico op een herseninfarct. 
een toename van functionele tAFI levels, welke resulteren in een afgenomen fibrinolyse, is 
daarentegen wel geassocieerd met een verhoogd risico op een herseninfarct.
In hoofdstuk 6 worden alle genetisch bepaalde stollingsstoornissen binnen CoCoS 
gecombineerd om te zien of het risico op een herseninfarct verandert in aanwezigheid 
van meer dan één stollingsstoornis in vergelijking met 1 geïsoleerde mutatie. Het aantal 
stollingsstoornissen was niet geassocieerd met het optreden van het herseninfarct en we 
vonden geen aanwijzingen voor de aanwezigheid van een synergistisch effect van bepaalde 
combinaties van stollingsstoornissen.
In hoofdstuk 7 worden onze bevindingen besproken en in een bredere context geplaatst. 
tevens komen in dit hoofdstuk de methodologische aspecten aan de orde en doe ik suggesties 
voor verder onderzoek.
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De afgelopen jaren hebben velen geholpen bij de tot standkoming van dit proefschrift. een 
aantal wil ik met naam noemen.
Allereerst mijn promotor, Professor P.J. koudstaal. Beste Peter, jouw vermogen om in korte 
tijd dingen goed te overzien en je enthousiasme waarmee je werkt, hebben op mij een 
positieve uitwerking gehad. Het feit dat jij oog hebt voor de sfeer binnen de afdeling en de 
onderzoeksgroep is een benadering die ik erg waardeer. Dank voor de ruimte die ik gekregen 
heb. Je supersnelle commentaar op manuscripten is al meerdere malen geroemd. Mede 
daardoor kon ik het strakke schema van de afgelopen maanden handhaven.
Mijn co-promotor, Dr. D.w.J. Dippel. Beste Diederik, onze samenwerking vond ik erg plezierig 
en ik heb heel veel van je geleerd. Ik bewonder het enthousiasme waarmee je de AGIko’s (ik 
citeer: “die wel hard werken, maar helaas ook zwanger kunnen worden”) begeleidt. Jij verdient 
absoluut de titel van co-promotor en ik weet zeker dat deze rol je de komende jaren nog vaker 
ten deel zal vallen. Voorlopig ben ik erg vereerd dat het bij mij de eerste keer is. Dank voor 
alles. 
Dr. F.w.G. Leebeek, beste Frank, we hebben voor het eerst samengewerkt op de longafdeling, 
waar jij het verplichte deel van je interne opleiding afrondde en ik co-assistent was. toen al vielen 
me je nauwkeurigheid en gedrevenheid op. Deze eigenschappen hebben zeker bijgedragen 
aan een goede samenwerking tussen onze afdelingen voor het CoCoS project. Dat je altijd wel 
even tijd had om naar uitslagen te kijken of mooie plaatjes van de stollingscascade te zoeken 
heb ik zeer gewaardeerd. Bij mij is de stolling in ieder geval geen ondergeschoven kindje 
meer.
De leden van de kleine commisie, Prof. dr. H. van Urk, Prof. dr. L.J. kappelle en Prof. dr. B. 
Löwenberg, dank ik voor het kritisch bestuderen van m’n proefschrift. Daarnaast dank ik hun 
samen met de overige leden van de commissie, Prof. dr. P.A.e. Sillevis Smitt, Prof. dr. C.M. van 
Duijn, voor het plaatsnemen in de grote promotie commissie. 
encarna Gómez García en Geert-Jan Brouwers, hoewel onze samenwerking voor het afronden 
van CoCoS eindigde, hebben we in ieder geval een aantal stukken samen geschreven. Veel 
succes in jullie nieuwe werkomgeving. Mijn andere co-auteurs Moniek de Maat, Dick Rijken, 
Asiong Jie, Ana Guimaraes, waander van Heerde en Selene Schoormans dank ik voor hun 
kritische commentaar op m’n stukken. Moniek, hoewel we elkaar pas kort kennen, zijn jouw 
opmerkingen altijd erg waardevol.
Marjolein Grooteboer, zonder jou was er geen controlegroep geweest. naziha el Ghannouti 
en Hanneke Hilkemeijer, dank voor de hulp bij de 2e bloedafname. De verpleging op de poli 
neurologie en de laboranten op het hemostase lab dank ik voor de bloedafnames en de 
verwerking van de bloedmonsters.
Annemarie, bedankt voor je eindeloze hulp wanneer ik na een half jaar kliniek niet eens meer 
wist hoe de computer aan moest. Die voorsprong heb je op mij, dus het moet jou ook zeker 
lukken, weg met de rode stoplichten!
eric van Breda, dank voor diezelfde hulp als Annemarie er niet was. 
M’n collega’s van de neurologie dank ik voor hun interesse en medeleven. In het bijzonder 
Desirée, Annemieke, Rinske en Sonia, dank voor de nuttige tips bij het schrijven van dit 
proefschrift. Rinske, als jij de pedel niet gebeld had stond ik hier nu ook niet.
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Mijn collega’s op de knF dank ik voor het af en toe inspringen, maar met name voor hun 
geduld om steeds maar weer m’n promotieperikelen aan te horen. 
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Lisette, we konden het al goed vinden samen en op de knF leer je elkaar nog beter kennen. Je 
hebt altijd een luisterend oor of een relativerende opmerking, je zorgt voor een kruis op het 
goede moment, maar bovenal hebben we veel lol. Ik zie uit naar de resultaten van CoStA en 
jouw boekje. Monique, het klikte 14 jaar geleden meteen in de collegezaal. toen wisten we niet 
dat we nu in diezelfde zaal zo naast elkaar zouden staan. Anno nu is het niet meer dan logisch. 
Ik zal onze vriendschap altijd blijven koesteren ondanks de afstand en drukke bezigheden. 
Fred, Sonja, Sandra en Stefan, dank voor jullie interesse en aanmoediging. Sonja, ‘de 
maandagavond’ werkte zo goed, omdat ik wist dat eline in goede handen was. Heel veel dank 
daarvoor.
René, jij hebt vanaf heel in het begin meegeleefd en meegedacht, wat ik erg gewaardeerd 
heb. Helaas weet ik nog steeds niet waarom mensen gapen. Misschien iets voor jou. Dank voor 
de figuren.
Pap en mam, dank voor jullie onvoorwaardelijke steun en vertrouwen de afgelopen (30) 
jaren. niet alleen voor jullie maar vooral door jullie sta ik hier nu. Ik heb alleen maar m’n best 
gedaan, zoals ik dat van jullie geleerd heb. Daar ben ik ontzettend trots op. en voor nu, oma en 
opa aan de top!
Lieve eric, zonder jou was dit echt niet gelukt. Jij was m’n grootste supporter die het altijd 
zag zitten (of wellicht goed deed alsof ). Lou aan een schema, wie had dat gedacht, ik zag je 
genieten. Hoewel het me echt goed geholpen heeft, denk ik dat het bij dit schema blijft. Dan 
zijn we weer op alle fronten ‘a perfect match’. 
Lieve eline, hoe dubbel dit ook klinkt, maar zonder jou had ik niet zo hard kunnen werken. 
Mama is nu echt klaar met typen. Lieverds, ik hou van jullie. we zijn weer met z’n drietjes!
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CURRICULUM VItAe
De schrijfster van dit proefschrift werd in 1972 geboren in Swalmen. na een middelbare 
schoolopleiding Gymnasium B, verliet zij het mooie Limburgse land om Geneeskunde te gaan 
studeren aan de erasmus Universiteit in Rotterdam. In 1995 werd het doctoraal examen met 
goed gevolg afgelegd en 2 jaar later het arts-examen. Aansluitend begon zij haar medische 
carrière als AGnIo neurologie op de afdeling neurologie van het erasmus MC te Rotterdam. 
Daar startte zij in augustus 1998 met haar opleiding tot neuroloog (opleiders: Prof. dr. F.G.M. 
van der Meche, Prof. dr. P.J. koudstaal, Prof. dr. P.A.e. Sillevis Smitt). Gedurende deze opleiding 
kreeg zij door middel van een AGIko constructie ruimte voor het verrichten van klinisch 
wetenschappelijk onderzoek. Dit onderzoek, dat een samenwerkingsverband met de afdeling 
hematologie van het erasmus MC betrof, was de basis voor dit proefschrift. Momenteel is zij nog 
steeds werkzaam als AGIo ter voltooiing van haar opleiding tot neuroloog. Ze is getrouwd en 
heeft een prachtige dochter van 2 jaar.
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